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« La connaissance des maladies infectieuses enseigne aux hommes 
qu’ils sont frères et solidaires. Nous sommes frères parce 
que le même danger nous menace, solidaires parce que 
la contagion nous vient le plus souvent de nos semblables » 
(Charles Nicolle) 
 
« Les moyens à dédier peuvent sembler énormes. Ils sont dérisoires 
en regard du coût d’une épidémie, voire d’une pandémie. 
La recherche est le meilleur investissement que nous puissions proposer » 
(Philippe Sansonetti) 
  





Brucellae are alpha-proteobacteria which induce brucellosis, a worldwild zoonotic disease 
infecting mammals, including humans. B. melitensis and B. abortus are the species the most 
often isolated in human brucellosis. Inhalation of airborne agents, ingestion of contaminated 
products and contact between a contaminated fluid or organ with a cutaneous lesion constitute 
the main natural routes of transmission. Up to now, no fully efficient prophylactic or therapeutic 
treatments are available, leading to serious economic losses and public health problems. 
Despite recent progress in mouse models of brucellosis, very little is known about the first steps 
of Brucella infection in vivo. Here we studied the Brucella melitensis 16M strain, that infects 
goat and sheep, and we investigated the immune response of mice following intraperitoneal 
(i.p.), intranasal (i.n.) or intradermal (i.d.) infection. The main objectives were to compare (i) 
the dissemination of bacteria after a primary infection, (2) the immunity required to control a 
primary infection, (3) the virulence gene essentiality, and (4) the lymphocyte populations 
indispensable for a secondary infection control. Our results showed that these four parameters 
are strongly influenced by the route of infection. For example, the dissemination from the local 
site of infection to the systemic organs is dependent on the amount and the rapidity of bacteria 
that enter in blood at the same time. The protective immune response after a primary and 
secondary infections seems dependent on the localization of bacteria (inter- or extra-cellular), 
the amount of bacteria, and the infected organs. The control of secondary i.p. infection in spleen 
requires B cells and CD4 T cells, while CD4 T cells or CD8 T cells are sufficient to control a 
secondary i.n. infection in the same organ. Finally, we showed that virB, a virulence gene 
defined as essential in in vitro Brucella model, can be partially dispensable, or even deleterious 
after i.p or i.d. infections, respectively.  
The intranasal model mimics one of the most physiological route of infection. Thus, we chose 
to deeply study this model. Following intra-nasal infection, the alveolar macrophages are the 
main (> 95 %) infected cells during the first 48 hours post infection. We used a without a priori 
approach (RNA sequencing) in order to find new potential genes involved in the early response 
in alveolar macrophages after Brucella infection. Among the 466 genes upregulated in alveolar 
macrophages, Acod1 was one of the most interesting candidate. Indeed, itaconate, a Krebs cycle 
derivate, produced by aconitate decarboxylase1 gene (Acod1, also known as Irg1), is emerging 
as a potential immunoregulatory metabolite since few years. This compound, produced mainly 




in mitochondria of myeloid cells, is known to have two main roles: an anti-inflammatory one 
and an anti-bacterial one. In our model of intranasal Brucella infection, we observed that the 
deficiency of Acod1 does not trigger any inflammation signs in comparison to wild type mice. 
In contrast, we observed that itaconate inhibits the in vitro Brucella growth and that Acod1 
deficiency increase the number of bacteria in the lungs of infected mice. These effects seem 
Brucella isocitrate lyase-dependent in both conditions. The understanding of how itaconate 
impacts the growth of Brucella could allow the development of new therapeutic drug against 
brucellosis. 
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I. General introduction 
 
 Symbiotic relations 
 The different relationships 
Since the apparition of life on Earth, individuals have learned to live together, or at least to 
survive for some ones. Indeed, the co-habitation, and the co-evolution inter- or intra-species are 
the consequences of many years of biological interactions. The symbiosis refers to close and 
prolonged associations between organisms of distinct species. These interactions can be 
mutualist, commensalist, or parasitic. In the mutualism, all partners benefit from the relation. 
A remarkable example of mutualism is the interaction between tubeworms (a long marine 
invertebrate in the phylum of Annelida, living near the hydrothermal vent sites) and different 
intracellular chemosynthetic bacteria living in their trophosome1. Some carbon isotope 
experiments showed that the worms are dependent on bacteria carbon compounds synthesis for 
their nutrition. Bacteria use chemosynthesis to gain energy from a chemical reaction and to 
capture carbon dioxide from seawater. This leads to the synthesis of molecules used by the 
worms from the carbon dioxide present in vents. In this relation, through the well-adapted body 
of tubeworms, bacteria found an oasis in this hydrothermal extreme environment (Dimijian 
2000). Another example is the presence of bacteria in our digestive system. The intestinal flora 
benefits of an environment rich in nutrients, favorable to a high rate of proliferation. In 
exchange, these bacteria help our digestive system to digest some elements such as fibers. 
In the commensalism relationship, only one partner benefits of the relation, but this is not to the 
detriment of the other ones that are unharmed. An example of this relationship is the barnacles, 
a type of crustacean, which fixe to the whale or turtles body conferring to barnacles a mean of 
transport, without consequences (either positive or negative) for the whales or turtles. 
Another type of biological interaction is the parasitism. In the case where an organism 
associates to another one to take advantage of its resources (endoparasitism), we will talk about 
an infection. This relation, most of the time unbalanced, is composed of a “pathogenic agent” 
 
1 A highly vascularized organ found in some organisms which do not possess digestive system. This organ 
houses bacteria providing food to their host. 




(coming from “pathos” meaning “suffering” and “gēnes” meaning “producer of”) and a “host”. 
The first one will “use” the host to reproduce, and/or to eat, and/or to hide, etc. All of this will 
be, in a certain way, detrimental to the host, which will adapt to defend and to survive. But in 
another hand, the host also can find some advantages to this relation as it will allow him to 
increase its robustness and to control, at long term, the population demography. In terms of 
evolution, it is more advantageous for the pathogenic agent to do not kill its host. The host-
pathogen relationship is a very precise balance between survival of both host and pathogenic 
agent.   
These three types of relationship are not frozen. Indeed, a relation can shift rapidly or gradually 
in another type of relation. Many pathogens colonize for example their host for all the host’s 
lifetime. But if the disease is asymptomatic, the relationship between the host and the pathogen 
can somehow be considered as a commensal relationship for at least a certain period of time. 
At the contrary, commensal bacteria can become pathogenic for immunocompromised people. 
 Host-pathogen relationship 
Pathogenic agents can be classified into two categories: the facultative ones, and the obligate 
ones. These latter are fully dependent on the machinery of their host to reproduce. It is the case 
of all viruses, but also some bacteria such as Chlamydia. Some pathogenic agents are able to 
infect different host species while other have a very small range of hosts (Balloux and van Dorp 
2017). Currently, few is known about the genetic changes necessary for a “host jump”. 
Sometimes, only one mutation is sufficient (Viana, Comos et al. 2016). It was the case for 
example of the human-adapted Staphylococcus aureus strain to adapt to rabbit (Viana, Comos 
et al. 2016). The intracellular pathogenic agents are well adapted to their host: they can 
manipulate it, defend against it, use its resources, etc. For that, they acquired virulence factors 
that are often encoded by clusters of genes named pathogenicity islands. As mentioned above, 
there is no advantage, in the long term, for a microorganism to kill its host. Even if they are 
able to produce damages to it with toxins for example (tetanus, anthrax, etc), the host damages 
are often self-inflicted via a too strong or chronic immune response (Balloux and van Dorp 
2017).  
In a spirit of “co-evolution” and “relationship”, how did the host adapt to the pathogenic agents? 
In the case of humans, even if they co-evolve with certain microbes and suffer of selection 
pressures since years, few genetic variants are known (Hill 2012). Today, even if some 




devastating agents are eradicated or under control, the recent outbreaks of Zika, Ebola, SARS-
CoV-2 viruses, and the drug resistance selection highlight the importance to continue research 
of new vaccines or therapeutic molecules discovery.  
 Anthropozoonosis, when the infection comes from animals 
A study of 2005 identified more than 1,400 human pathogenic agents, of which 58 % have an 
animal origin (Woolhouse and Gowtage-Sequeria 2005). When the transmission of these 
pathogenic agents occurs from animals to humans, the term “anthropozoonosis” is used, coming 
from greek ánthrôpos (human), zoo (life), and nose (disease). Some anthropozoonoses are 
dramatically famous all around the world and the pathogenic agent can be either a helminth, a 
protozoan, a virus or a bacterium. The Plague disease is one historically but terrible famous 
example of bacterial anthropozoonoses. This pandemic made up to 50 million of victims just in 
Europe and Mediterranean area, representing around 35-60 % of the European population 
(Alfani and Murphy 2017). The Malaria is another example of zoonosis in which Plasmodium, 
the parasite responsible for the disease, is transmitted from mosquito to humans. The typical 
symptoms of Malaria are fever, vomiting, tiredness. In 2018, more than 200 million of cases 
were reported by the WHO (WHO 2019) resulting in more than 400,000 deaths in the world, 
mainly children. Finally, the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), 
known as “Covid19”, considerably modified the human behaviors in 2020. The worldwide 
pandemic started in December 2019, with probably an animal origin as genetic analyses 
revealed high homology between SARS-CoV-2 and bat or pangolin Coronaviruses. Up to now, 
the pandemic made up more than 66 million of infection cases, with more than 1.5 million of 
death, exclusively people of > 60 years old (WHO 2020). 
The number of the different reservoirs, of the intermediated hosts, of the different vectors, etc. 
are some factors leading to a complex understanding of these zoonoses.  
 Host and pathogen defense strategies 
 The host side: immunity in brief 
 From innate immunity … 
The innate immunity is more and more seen as an essential partner of the adaptive immunity, 
both working together with close associations to fight infections. But this is only true for 
vertebrates, as the adaptive immune system appeared only 500 million years ago (more 




precisely in jawed fish) (Martin and Kasahara 2010). This late apparition of the adaptive 
immune system highlights the efficiency of the innate immunity, alone, to protect all non-
vertebrate organisms against infections. The innate immune system is composed of several 
components: physical/chemical and cellular ones. Indeed, before to meet the cellular 
components, pathogenic agents have to face the epithelia, mucus, cilia, pH, etc. Then, the 
cellular components: the granulocytes (neutrophils, eosinophils, mast cells, basophils), the 
phagocytic cells (monocytes, macrophages, dendritic cells (DCs)), and the Natural Killer cells 
(NK), each one having a specific role (see Table 1). NK are part of the Innate Lymphoid Cells 
(ILC) that are cells from innate immunity, even if they derived from a common lymphoid 
progenitor. These cells secrete signal molecules and are able to activate both innate and adaptive 
cells. They are mainly located in mucosal environment and play a key role in the homeostasis 
of tissue. Following lungs infection by viruses or bacteria, ILC, whose NK, secrete IFN-J and 
IL-17. After skin damages, ILC are recruited to the injured site, secrete mainly IL-17 to recruit 
effector cells (Artis and Spits 2015). 
The activation of the innate response is based on (1) the recognition of pathogenic agents 
molecules and (2) an intracellular signaling cascade leading to the triggering of an early 
response.  
(1) The repertoire of invariant receptors to detect microorganisms is quite limited, as the 
immune receptors are encoded in the germline in order to produce an immediate 
response (Akira, Uematsu et al. 2006). The cells mainly expressing these receptors are 
the Antigen-presenting cells (APC), such as DCs and macrophages. This limited 
repertoire is counterbalanced by the fact that these receptors (Pattern recognition 
receptors – PRRs) target pathogenic agent’s components that are very widespread and 
Table 1: Summary of the different functions of the innate immune system cells 




conserved such as lipopolysaccharide (LPS), lipoproteins, cytosine-phosphate-guanine 
(CpG) deoxyribonucleic acid (DNA), flagellum’s components, etc, called PAMPs 
(Pathogenic-Associated Molecular Patterns) (Akira, Uematsu et al. 2006). One of the 
most studied family of PRRs are the TLRs, for Toll-like receptors. Each PAMPs is 
recognized by specific receptors: LPS by TLR4, lipoproteins by TLR1/2, CpG DNA by 
TLR9, porins and peptidoglycans by TLR2/6, and flagellin by TLR5 for examples (see 
Figure 1) (Akira, Uematsu et al. 2006). In total, there are 12 different TLRs that have 
been identified in mammals (Akira, Uematsu et al. 2006). Adaptor proteins such as 
Myeloid differentiation primary response 88 (MYD88) and Toll-interleukin 1 receptor 
(TIR) domain containing adaptor protein (TIRAP) allow the signal transduction after 
PAMPs detection by TLRs and allow the activation of proteins that control the pro-
inflammatory genes transcription such as Nuclear factor κ-light-chain-enhancer of 
activated B cells (NF-κβ) or Interferon Regulatory Factor 3 (IRF3) (Figure 1) (Kawai 
and Akira 2007). 
 
Moreover, the innate immune system can also recognize danger signals (Damage-
associated molecular patterns – DAMPs) that are molecules released outside the cell 
during tissue damages (Rubartelli and Lotze 2007). Some examples of DAMPs are Heat 
Shock Proteins, fibrinogen, oxidative stress, ATP, or uric acid crystal. These DAMPs 
Figure 1: Recognition of bacteria PAMPs by PRRs. Different TLRs can recognized specific PAMPs of bacteria. For 
examples, TLR9 recognizes DNA, TLR2 is specific for peptidoglycans and porins, TLR4 for LPS, and TLR5 recognizes 
flagellin. (Made with BioRender). 




are recognized by TLR2, TLR4, P2X/P2Y receptors, or TLRs 2 and 4, respectively 
(Frevert, Felgenhauer et al. 2018) 
 
(2) Once the PAMPs/DAMPs detected, signals are presented to the host, triggering pro-
inflammatory and anti-microbial responses by activating kinases, transcription factors 
and other molecules of intracellular signaling pathways (Akira and Takeda 2004). This 
will be followed by changes in the expression of genes of different proteins such as 
chemokines, cytokines, receptors, etc that will be involved in the early immune 
response, such as type I interferon (IFN) for examples. Also, these molecules allow to 
link innate and adaptive immune responses (see below) (Akira, Uematsu et al. 2006).  
The main essential effector mechanisms of the innate immune system are the 
phagocytosis and the inflammation. The phagocytosis is a mechanism that allows the 
elimination of pathogenic agents or cellular debris by internalizing and digesting them 
(Rosales and Uribe-Querol 2017). Once internalized, they will be destroyed by different 
mechanisms such as acid hydrolases from lysosomes, reactive oxygen intermediates 
(ROI), and reactive nitrogen intermediates (RNI) (Kaufmann and Dorhoi 2016). The 
macrophages, DCs and neutrophils are cells able to do that. The inflammation is 
induced either after a pathogenic agent invasion or in response to tissue damages. The 
inflammation has to be a perfect balance between the defense mechanisms and the 
restoration of the impacted tissue. The inflammation process is mediated by a lot of 
signals such as chemokines, cytokines, prostaglandins, etc. secreted by the injured cells 
(Medzhitov 2010).  
In addition to this, other elements/mechanisms contribute to the innate mechanisms such as 
antimicrobial peptides, complement system, autophagy, degranulation (by granulocytes) 
(Mogensen 2009).  
In addition to their role in the innate response, macrophages and DCs, belonging to the APCs, 
make the link between innate and adaptive immune responses. Indeed, APC and T cells will 
interact via different receptor-ligand complexes: major histocompatibility complexes (MHC), 
and CD80/86 of APCs will interact with T cell receptor (TCR), and CD28 of T cells, 
respectively. This allows to activate, but also to differentiate the T cells (see below) (Ni and 
O'Neill 1997). 




 … to adaptive immunity 
The apparition of the adaptive system dates of 500 million years ago, but the reason of its 
selection is debated. In one hand, it is highlighted that the immune system had to adapt to 
pathogenic agents more and more virulent and furtive. But this would imply that the evolution 
pressure of microbes would be so strong that no host without adaptive immune system would 
have survived. On the other hand, it would be possible that the adaptive immune system 
appeared to reduce the tissue damages made during the chronic infections (Usharauli 2010). 
Following the first hypothesis, the adaptive response provides another level of protection 
against pathogenic agents and is in close association with the innate immune response. Indeed, 
the efficiency of the adaptive immune response will partially depend on the ability of the innate 
immune system to detect pathogenic agents and to transmit the signals to the adaptive system 
(Usharauli 2010). 
The adaptive immune cells (T and B cells) are composed of two types of receptors: the TCR 
(for T cells) and the BCR (for B cells). A huge repertoire of these antigen receptors is randomly 
generated by somatic DNA recombination events during lymphocytes maturation (Schatz, 
Oettinger et al. 1992). Other mechanisms such as somatic hypermutations (for BCR only) allow 
to generate a highly diverse repertoire of receptors, with a huge potential to recognize 
specifically almost every antigenic determinants (Medzhitov 2007). This specificity has a cost: 
it makes several days to develop. The activation of B and T cells is not only dependent on the 
antigenic recognition, but also on other signals, termed costimulatory signals, delivered by the 
innate immune system. 
2.1.2.1 The T lymphocytes 
The maturation of T cells occurs in thymus. The activation of these cells is dependent on the 
interactions with APCs that will present, via their MHC, the antigens. The T cells possess two 
main functions, associated to two different phenotypes: one lineage expresses the γδ-CD3 TCR 
(γδ T cells) and the other one the αβ-CD3 TCR (αβ T cells) (Ciofani and Zuniga-Pflucker 2010). 
The γδ T cells are unconventional T cells. Ideally located in epithelia, they act rapidly upon an 
infection. They secrete cytokines such as IFN-γ, or interleukin (IL)-17, leading to inflammation. 
They express TLRs and other receptors close to the ones of NK, making them close to innate 
immune cells. Their activation seems independent on the antigen processing and MHC 




presentation of peptide epitopes. Their ligands are today unidentified (Ciofani and Zuniga-
Pflucker 2010, Lawand, Dechanet-Merville et al. 2017). 
Once differentiated into CD4 or CD8 T cells, expressing the CD4 or CD8 costimulatory 
molecule (a glycoprotein), respectively, the αβ T cells migrate from the thymus to the secondary 
lymphoid organs. 
1) The CD8 T cells are cytotoxic cells. They recognize the infected cells via the presented 
antigens (Figure 2) and destruct them via the perforin/granzymes axis, leading to the 
apoptosis (Henkart 1994). The CD8 T cells are activated by cytosolic antigens presented 
by the MHC-I of DCs. For that, the proteins of intracellular pathogenic agents are 
degraded by the proteasome in peptides that then enter in the endoplasmic reticulum 
(ER) via the transporter associated with antigen processing, TAP1. The ER is also the 
place where MHC-I is formed. The pathogenic peptides bind the MHC-I and are 
relocated to the cell surface to be presented to the receptor of CD8 T cells (Figure 2) 
(Kobayashi and van den Elsen 2012). The CD8 T cells are able to secrete cytokines such 
as IFN-γ and tumor-necrosis factor (TNF)-α, allowing to activate macrophages to kill 
the infected cells (Tau, Cowan et al. 2001).  
 
2) The CD4 T cells activation is dependent on the antigen presentation by APC. Once 
phagocytosed, the extracellular pathogenic agent is degraded by lysosomal proteases 
activity. The vesicles containing the new formed peptides fuse with the vesicle 
containing the MCH-II molecule. The peptides are then presented, via the MHC-II 
relocated at the APC surface, to T cells (Figure 4) (Kobayashi and van den Elsen 2012). 
In addition to this first signal of activation, two other signals are required to fully 
activate and differentiate CD4 T cells: CD80/CD28 interaction (the costimulatory 
signal) and a cytokine-dependent signal. In function of the cytokines secreted by APCs, 
the CD4 T cells will differentiate into distinct CD4 T cells subsets, including T Helper 
(TH) 1, 2, 17, and T regulator (Treg), each one being specialized for particular infections 
(Zhu, Yamane et al. 2010).  







Briefly, the TH1 response is adapted to eliminate intracellular pathogenic agents. IFN-γ and IL-
12 (composed of p40 and p35 proteins) are cytokines produced by DCs and macrophages to 
differentiate CD4 T cells into TH1 (Figure 3). These cells then secrete mainly IFN-γ via the 
Signal Transducer and Activators of Transcription (STAT)4/transcription factor T-box 
expressed in T cells (T-bet) pathway. When IFN-γ binds its receptor (composed of IFN-γR1 
and IFN-γR2 sub-units) on macrophages, the signalization is transmitted by Janus Kinases 
(JAK)/STAT1 pathway, leading to IRF1 expression, a transcriptional factor involved in 
immune responses and inducible Nitric Oxide Synthase (iNOS) expression. These expressions 
induce an oxidative burst and the activation of effector cells such as macrophages, leading to a 
cytolytic activity (Honda, Takaoka et al. 2006, Thieu, Yu et al. 2008).  
The TH17 response is induced by IL-6, IL-1β, IL-23, and Transforming Growth Factor (TGF)-
β cytokines (Figure 3), and acts against extracellular pathogenic agents and fungi mainly. 
Figure 2: Antigenic presentation. An intracellular pathogen is presented by MHC-I to CD8 T cells: the proteins of the 
pathogen are degraded into peptides by the proteasome. Peptides enter in the ER via TAP1 and bind MHC-I. They are 
presented to CD8 T cells. An extracellular pathogen is presented by MHC-II to CD4 T cells: the proteins of the pathogen are 
degraded by proteases in endosomes. This vesicle fuses with a vesicle that contains the MHC-II coming from the endoplasmic 
reticulum where the peptide site was blocked by the invariant (li) chain and Corticotropin-like intermediate peptide, CLIP. 
Once removed, peptides bind the MHCII and are presented to CD4 T cells. (Made with BioRender). 




Sometimes, the TH17 response, via the IL-21, can also lead to auto-immune diseases. The 
activated TH17 CD4 T cells secrete IL-17, IL-21, IL-22, and IL-23 (Figure 3), but also 
chemokines such as the C-X-C motif ligand (CXCL)1 and CXCL2 to recruit neutrophils. The 
pro-inflammatory role of these cells is mediated by the stimulation of antimicrobial peptides 
and pro-inflammatory cytokines production by neutrophils, but also by epithelial cells. Indeed, 
these latter express IL-17 receptors and TLRs, leading to the production of antimicrobial 
peptides after stimulation by IL-17 and PAMPs, respectively (Kolls, McCray et al. 2010). The 
IL-17 cytokines also allow the stimulation of some Immunoglobulin (Ig) production by B cells  
(Ouyang, Kolls et al. 2008, Perez-Lopez, Behnsen et al. 2016). 
Finally, the Tregs have a role of suppressor of the immune response by direct cell-to-cell 
contact, but also through the release of regulatory cytokines such as IL-10 and TGF-E. IL-10 is 
for example able to negatively impact the TH1 response, modulating TNF-D, IFN-J, and IL-12 
cytokines production (Corsetti, de Almeida et al. 2013). 
Figure 3: Resume of the different T cells and T Helper subpopulations. Each T cells possess a CD3-T receptor. But this 
receptor can be composed of αβ chains or γδ chains. Among the αβ-CD3 T cells, some have a CD8 co-receptor (cytotoxic T 
cells), other have a CD4 co-receptor (Helper T cells). Those Helper T cells will differentiate into different T subsets in function 
of the cytokinic signal they will receive. (Made with BioRender). 




2.1.2.2 The B lymphocytes 
The maturation of B cells occurs in the bone marrow, but their activation occurs in secondary 
lymphoid organs.  There, naive B cells scan the environment to the research of microorganism 
antigens. Once encountered, the antigens activate B cells via their BCR, resulting in B cells 
proliferation and differentiation. B cells activation requires a second signal, which is dependent 
or independent of T cells.   
1) In the case of T cells-dependent activation of B cells (most of the time), two main 
signals are required: (1) the binding of CD40L (T cells) to CD40 (B cells), and (2) the 
antigenic peptide presentation from B to T cells. For that, B cells do endocytosis of 
antigens and degrade them into peptides via the lysosomal proteases. The peptides are 
then presented at the B cells surface by the MHCII, allowing to activate T cells. Once 
activated, T cells secrete cytokines to activate B cells, leading to their proliferation. B 
cells differentiate into “germinal center B cells” and into “short-lived plasma cells” 
secreting low-affinity IgM and IgG antibodies (MacLennan, Gulbranson-Judge et al. 
1997, Bonilla and Oettgen 2010, Takemori 2015, Gaudino 2019). The germinal center 
B cells form the germinal center and proliferate during the second phase of primary 
response (Akkaya, Kwak et al. 2020). The germinal center B cells differentiate into 
memory B cells, and long-lived plasma cells. During its maturation, BCR undergoes 
somatic hypermutations leading to a better adaptation of BCR to the antigens. Then, 
they change of phenotype to better adapt to the pathogenic agent via the class-switching, 
a rearrangement of the heavy chains of antibodies. This process is dependent on 
cytokines such as IL-4, IL-13, IFN-γ, IL-10 or TGF-β (MacLennan, Gulbranson-Judge 
et al. 1997, Bonilla and Oettgen 2010).  
 
2) In the T cells-independent activation of B cells, the development of active B cells is 
faster, but the antibodies generated have a lower affinity and are less specific than the 
ones generated by the T cells-dependent activation. In one case, antigens such as LPS 
activate B cells via their TLR expressed at their surface. This leads to the production of 
polyclonal antibodies. The second type of antigens are repetitive structures of bacteria, 
which will bind and activate a lot of different BCRs, leading to the proliferation, 
differentiation of B cells, and antibodies production (Mond, Lees et al. 1995, Vos, Lees 
et al. 2000).  




 Until immune memory 
In 430 before Christ (BC), the immune memory was for the first time briefly mentioned by 
Thucydides who described that “the same man was never attacked twice - never at least 
fatally », talking about the plague (Tangye 2015). One characteristic of our immune system is 
to “remember” previously encountered pathogenic agents. It can come from natural infection, 
but also from vaccination. The secondary response will be faster and more efficient than the 
first one. Although it was associated for years with the adaptive immune system, it seems more 
and more clear that the innate immune system could be also able to “memorize” certain stimuli 
(Kurtz 2005, Boraschi and Italiani 2018).  
B cells develop into memory cells after their activation in a T cells-dependent manner (see 
above). They will be reactivated following a new contact with the same antigen, and will secrete 
specific antibodies. In the same way, T cells can also develop in memory T cells upon a first 
contact with an antigen. Indeed, after a first activation, 90-95 % of activated T cells undergo 
apoptosis while 5-10 % of T cells differentiate into memory T cells (Valbon, Condotta et al. 
2016). Different memory T cells can be distinguished: the tissue effector memory, the central 
memory and the resident memory T cells (Ratajczak 2018). 
- The central memory T cells colonize the secondary lymphoid organs such as lymph 
nodes. These cells are able to proliferate rapidly upon an antigenic stimulation and to 
activate DCs. However, they do not possess effector functions. The central memory T 
cells could also regenerate the pool of effector memory T cells (Walzer, Arpin et al. 
2001, Ratajczak 2018). 
- The effector memory T cells are located in the non-lymphoid organs such as lungs, 
liver, intestine, etc. They circulate between blood and tissues and secrete IL-4, IL-5, 
IFN, perforin and granzym B, conferring cytotoxic properties to these cells. After a 
second infection with the same pathogenic agent, the effector memory T cells activate 
the immune mechanisms, help DCs to migrate to the lymph nodes, and help the CD8 T 
cells at the infection site. The CD4 effector T cells proliferate less than the CD8 effector 
T cells (Ratajczak 2018).  
- The resident memory T cells constitute the first line of defense as they are located in 
tissues, potentially a “becoming-infectious site” (lungs, brain, skin, reproductive tract, 
etc). Following a second infection with the same pathogenic agent, their response is the 




faster as they are already at the site of infection. The role of the CD4 resident memory 
T cells is not well known. They secrete IFN-γ, IL-17 and help to the recruitment of cells 
towards the infectious site. The CD8 resident memory T cells have different roles once 
activated: they initiate the antimicrobial defenses, help APCs in their functions, rapidly 
secrete IFN-γ, activate NK, mature DCs, help to recruit T and B cells, etc (Ratajczak 
2018). 
 The pathogenic agent side: how to escape the immune system? 
With years of co-evolution with their hosts, pathogenic agents have acquired different strategies 
to escape the host immune system. The defense strategies of bacteria can be subdivided in three 
levels, but with the same objective: avoid or inactivate the immune defenses. The first level is 
the formation of biofilms, thin layer of bacterial populations, stacked to each other and adhering 
to a surface. The substance that each bacterium secretes extracellularly allows to enclose the 
populations to protect them from entry of anti-microbial substances (Tremblay, Hathroubi et al. 
2014). The second line of defense is the external part of bacterium it-self, which is the first 
thing detected and targeted by the immune system: the cell wall. Some bacteria have acquired 
a capsule along evolution. This additional external layer allows to bacteria to be protected from 
phagocytosis, but also allows the production of toxic compound for the host, and the adhesion 
to the host cells (Reddick and Neal 2014, Zhou, Shi et al. 2015, Bizzell 2018). Other bacteria 
modified their membrane components, including efflux pumps or LPS to avoid the detection 
by the immune system or to repel the positively charged host effectors. For example, E. coli 
acylates the lipid A of its LPS to change the charge, becoming positively charged. Finally, 
another defense strategy is to directly inhibit the host effectors (Raetz, Reynolds et al. 2007). 
The third line consists to secrete effectors playing a role at different levels: the inhibition of 
the phagocytosis, of the lysosomal fusion, of the DCs maturation, of the T cells activation, etc. 
For example, when Mycobacterium tuberculosis is internalized and follows the endocytic 
trafficking in macrophages, the acidification of its compartment will trigger the secretion of 
virulent effectors, like a tyrosine phosphatase called Serine/threonine-protein phosphatase 2A 
activator (PtpA) which inhibits an ATPase required for the lysosomal fusion and hence its 
degradation (Reddick and Neal 2014, Zhou, Shi et al. 2015, Bizzell 2018). 
An expert in the “not to be detected” mechanisms? Brucella! 




  Brucella and brucellosis 
 Discovery of brucellosis 
Brucellosis is not an emerging disease. Indeed, indirect proofs suggest that the first tracks of 
brucellosis could date from 2.5 millions of years, when Australoptithecus started to eat meat 
(D'Anastasio, Zipfel et al. 2009). Later, specific lesions of brucellosis have been discovered on 
Egyptian skeleton in 750 BC (Moreno 2014), and an examination of skeletons of humans dead 
in 79 BC during the Mount Vesuvius eruption has revealed typical bones lesions of brucellosis 
in more than 17 % of cases (Capasso 2002). This was not really surprising as one of the main 
sources of food at this moment were goats, sheep and their products (Capasso 2002), meaning 
one of the main source of contamination as it has been discovered later (Zammit 1905, Eyre 
1908). But one of the first direct proof of brucellosis presence dates from 10-13 century, when 
genetic analyses have revealed Brucella DNA on lesions located on human lumbar and thoracic 
vertebrae (Mutolo 2011). The first “real” description of the disease dates from 1861, and was 
made by J. Marston (Marston 1861) (see BOX-1 for further explanations). 
BOX-1. On the route of Brucella discovery. Jeffery Allen Marston, an assistant surgeon of 
the British Army in the Medical Department, described in the reports of the Army the illness 
he himself contracted in Malta and which causes fever (Marston 1861). In 1875, Maclean, a 
professor of military medicine of the Army, published about the “Malta fever”. Indeed, he 
observed soldiers from Malta in bad condition and having distressing fever, what he called the 
Malta fever (Maclean 1875). The cause of this fever was unknown, but the most frequent 
characteristics of the disease were the followings: a very long fever (sometimes up to seventy 
days (Maclean 1875) or even several years (Bruce 1907), the fever does not rise very rapidly 
and seems to be transient, a headache, an affected spleen, an alteration of the liver functions, a 
destruction of the lungs, neuralgic and rheumatic pains, and also articular and muscular pains. 
These last ones seemed to appear after the first weeks of the disease (Maclean 1875).  
In 1887, the Surgeon Captain David Bruce of the Royal Army published his notes about the 
examinations of the bodies of dead soldiers suffering of fever. During these post-mortem 
examinations, D. Bruce observed that the spleens and other organs like the liver or kidneys 
were similar to the organs in other diseases involving microorganisms. Based on that, he 
decided to look for a microorganism which could explain the fever. From spleens of dead 
British soldier, D. Bruce succeeded to isolate the microorganism responsible for the “Malta 




fever”, which was negative for the Gram staining (Bruce 1887). At the opposite of Gram 
positive bacteria, the Gram negative ones have a thinner layer of peptidoglycan but possess an 
outer membrane composed of LPS. This thin layer of peptidoglycan allows the destaining of 
Gran negative bacteria with alcohol during Gram staining. The organism was called 
Micrococcus melitensis by D. Bruce in 1893 as the Roman name for Malta was “Melita” 
meaning “honey-isle” in reference to the unique brand of honey in Malta. Another micro-
organism was discovered by Bang in 1895. This Bacillus, called Bacillus abortus, was 
responsible for abortion in cows (Bang 1897) (see BOX-2). 
BOX-2. Link between the infectious agent and the zoonotic nature of the disease. In 1895, 
the veterinary Bernhard L. F. Bang and his assistant Stribolt decided to prove that the abortions 
of cows that were frequent these years were linked to the bacteria they found in post-mortem 
examinations of cows. They found a “bacillus” that they cultured and injected in the vagina of 
pregnant cows. After the abortion 2 months later, they concluded that this “bacillus” was 
responsible for the abortion in the cattle (Bang 1897). The “bacillus” will be called the “Bang’s 
bacillus” or Bacillus abortus. It is in 1905, thanks to the experiments of Zammit, that the link 
between Micrococcus melitensis and the goats is done. Indeed, after feeding goats with 
“bacilli”-containing food, he observed that the goats were susceptible to brucellosis, the 
“bacilli” were present in the blood, urine and milk of the infected animals, and that people 
consuming the infected goats milk can become sick (Zammit 1905, Eyre, Durh et al. 1908).  
In 1918, an American microbiologist, Alice Evans, suggested in the “Journal of Infectious 
Disease” that the Bang’s bacillus and the Bruce’s micrococcus were indistinguishable based on 
morphological, biochemical and serological studies and were only one and same genus. She 
proposed that the form of this organism was not a “bacillus” or a “coccus” but a “coccobacillus” 
(Evans 1918). Meyer proposed in 1920 a generic name for the genus: Brucella (B.), in honor of 
David Bruce (Meyer and Shaw 1920). This bacterium belongs to the alpha-proteobacteria 
class (E., E. et al. 1990). 




 Animal brucellosis 
 Brucella species and host specificity 
In the following years, other species of genus Brucella were discovered, the most known being: 
B. suis, B. ovis, B. neotomae (Stoenner and Lackman 1957), B. canis (Carmichael and Kenney 
1968), B. ceti and B. pinnipedialis (Foster, Osterman et al. 2007), B. microti (Scholz, Hubalek 
et al. 2008), B. inopinata (Scholz, Nockler et al. 2010), B. papionis (Whatmore, Davison et al. 
2014), and B. vulpis (Scholz, Revilla-Fernandez et al. 2016) (Figure 4). The main 
distinguishable characteristic between these species is the main host they infect. Indeed, even 
if crossed infections can occur, B. abortus has for example a tropism for the livestock, B. 
melitensis for the sheep, B. canis for dogs, and B. suis for pigs and wild boars (Figure 4) (Bang 
1897, Zammit 1905, Carmichael and Kenney 1968). The host specificity is not completely 
understood yet. Genomic studies between B. melitensis and B. suis revealed that they have a 
very similar genome (Paulsen, Seshadri et al. 2002). Indeed, more than 90 % of their genes have 
98-100 % of identity at the nucleotide level, but this small variability could explain the variation 
in host specificity (Viana, Comos et al. 2016). For example, the different genes are coding for 
outer membrane proteins (OMP), membrane transporters, putative invasins or adhesins, that are 
probably exposed to the surface (Tsolis 2002). Even if B. melitensis and B. suis genomes are 
very close, another study showed that B. abortus and B. melitensis would be the closest Brucella 
species (Figure 4) (Halling, Peterson-Burch et al. 2005).  
Figure 4: Different species of Brucella in relation with their potential host(s). Link between the diversity and the phylogeny. 
The number are in millions of years (Guzman-Verri, Gonzalez-Barrientos et al. 2012). 




 Natural routes of infection 
The transmission intra-species can occur by different routes, through direct or indirect contacts, 
in horizontal or vertical manners. Horizontally, the contamination by the ingestion of the 
Brucella abortus-infected birthing fluids and tissues (placenta or aborted fetuses for examples) 
was suggested as possible by Plommet and colleagues in 1973 (Plommet, Fensterbank et al. 
1973). The infection by contaminated aerosols produced during abortion that another animal 
can breathe is a non-negligible route as an infected placenta or aborted fetus can contain up to 
1014 B. abortus (Alexander, Schnurrenberger et al. 1981). The infection via a direct contact of 
these aborted tissues with a cutaneous lesion or conjunctive tissues is also possible, even if the 
percentage of this route of infection is difficult to determine. The transmission by blood-sucking 
insects as vectors is not to be excluded. Indeed, the idea of a transmission via an insect was 
already reported in 1951 (Wellmann 1951). Finally, it is known that Brucella has a tropism for 
the reproductive tracts (semen, epididymitis, testicles, uterus, vaginal excretions, placenta, etc). 
Between 100 to 50,000 bacteria / mL can be found in the male semen for example. But despite 
that, it was suggested that the contamination from one partner to another one during the mating 
could be rare (Figure 5) (Manthei, DE. et al. 1950, Morgan 1979). 
Another direct contamination is the vertical transmission from a mother to its offspring that 
can occur in two ways (Figure 5). First, via the milk sucking as Brucella can be isolated from 
the milk of sheep (B. melitensis) (Grillo, Barberan et al. 1997), goats (B. melitensis) (Renoux, 
Alton et al. 1957), cows (B. abortus) (Carpenter 1926, Philippon, Renouy et al. 1971) and also 
mice (B. melitensis) (Bosseray and Dufrenoy 1982, Jansen, Demars et al. 2020). Grillo also 
Figure 5: Routes of brucellosis transmission in animals. The horizontal transmission of Brucella can occur via aerosols, 
cutaneous lesions, ingestion of contaminated products, and rarely via sexual contacts. The vertical transmission occurs 
during the pregnancy, the delivery, but also during the milk consumption. 




suggested that this mode of transmission intra-species could be the main one in animals (Grillo, 
Barberan et al. 1997). Second, it is known since at least 1962 that Brucella abortus 
preferentially invades the fetal tissues such as the fetal cotyledons, the chorions, or the fetal 
fluids rather than the adult’s ones (Smith, Williams et al. 1962). Plommet and colleagues 
showed in 1973 that B. abortus was transmitted in utero in the cattle population. Even if they 
did not exclude a transmission by the placenta ingestion, via aerosols production or via the 
colostrum consumption, they concluded that the in utero infection was probably the main route 
of vertical contamination, as they separated the calf from the mothers directly after the birth 
(Plommet, Fensterbank et al. 1973).   
 Symptoms 
The main consequences of Brucella infection in animals are abortion of pregnant females, 
infertility, orchitis2, epididymitis, and hygromas3.  
The bacteria, once in the organism, can easily enter the bloodstream to finally reach the uterus. 
In this organ, B. abortus is found in macrophages, but mainly in trophoblasts, cells for which 
Brucella has a tropism (Payne 1959, Anderson and Cheville 1986, Meador and Deyoe 1989), 
which could be explained by the presence of erythritol, a sugar particularly appreciated by 
different species of Brucella such as B. abortus, B. melitensis, and B. suis (McCullough 1951, 
Smith, Williams et al. 1962). The abortion could be triggered by the TH1 response established 
in the uterus in presence of Brucella, compromising the homeostasis of uterus (see BOX-3). 
BOX-3. Brucella and abortion. In 2009, Xavier and colleagues experimentally infected cows 
with B. abortus and studied the lesions caused by the bacteria in the cows and in the fetuses. 
They showed that the placenta of pregnant cows was full of lesions, necrotic and fibrinous, with 
a lot of neutrophils (Xavier, Paixa ̃o et al. 2009). It has been shown that the immune response 
triggered by Brucella (TH1 / IFN-γ response) leads to damages in trophoblasts tissues and that 
IFN-γ inhibited the growth hormone secretion, both compromising the survival of the fetus 
(Smith, Williams et al. 1962, Wegmann, Lin et al. 1993). It is estimated than around 60 to 70 
 
2 Inflammation of testis 
3 Inflammation of serous bursa in articulations 




% of the infected pregnant females abort (Diaz Aparicio 2013). Even if animals stay infected 
all their entire lives, the pregnant females usually abort only once (Nicoletti 2013). 
Orchitis and epididymitis are inflammations of the testis or epididymis, respectively. 
Complications of these consequences can lead to infertility in infected males (Khan and Zahoor 
2018). Finally, hygromas, which is inflammation of synovial bursae, are also consequences of 
brucellosis, leading to articular pain (Henning 1956, Thienpont, Vandervelden et al. 1961). 
 Treatment 
Once animals are infected, they are usually slaughtered to limit the dissemination of Brucella 
to other animals or humans (Corbel 2006). Consequently, this leads to a huge economic loss. 
For example, the production loss of milk and meat induces annual economical shortfall of 600 
millions of dollars by year in Latin America (Acha and Szyfres 2003). In countries where 
brucellosis is endemic, prophylactic vaccines can be administrated to animals. Currently, there 
are 3 main vaccines, all live attenuated vaccines. Briefly, the “S19” (Buck 1930) and “RB51” 
(Schurig, Roop et al. 1991) vaccines were obtained from B. abortus strain, and the “Rev1” 
(Herzberg and Elberg 1953) vaccine was obtained from B. melitensis. However, these vaccines 
have several main disadvantages such like reversion risks, human infection, diagnostic 
interference, abortion induction, etc. For now, and despite their limitations, live attenuated 
vaccines are the most commonly used vaccines to protect animals against brucellosis. The ideal 
vaccine should (1) induce an efficient TH1 response, (2) be an attenuated strain, stable, with no 
risk of virulence for humans, (3) confer a long term protection with only one dose and without 
triggering the abortion, (4) be practical for massive use. Moreover, the ideal vaccine should not 
produce antibodies that will interfere with diagnosis tests (Dorneles, Sriranganathan et al. 
2015).  
The S19 strain (from B. abortus 2308) is the first vaccine to be extensively used to control 
bovine brucellosis (Manthei 1960). This attenuated strain was isolated in 1923 by John Buck, 
after one year spent, accidentally, in cow’s milk at room temperature, attenuating its virulence 
(Buck 1930, Graves 1943). This attenuated strain showed a good protection with 82-95 % of 
vaccinated cattle that are protected (Dorneles, Sriranganathan et al. 2015). Experimentally, the 
S19 vaccinated mice develop IFN-γ producing-CD4 T cells and cytotoxic CD8 T cells, but the 
attenuated S19 strain presents several problems. First of all, the induced antibodies are 
indistinguishable from the antibodies induced after a natural infection (WHO/EMC/ZDI/98.14 




1997). Then, the vaccination of pregnant female can lead to abortion in certain cases (Nicolletti 
1981). After a high dose of vaccination (>109 CFU), the strain is rapidly cleared of cervical 
lymph nodes but can sometimes persist and then be extracted in the milk (LA. and CG. 1981). 
The strain can also cause testis inflammation as a virulent strain of Brucella.  
Some years later, the attenuated strain B. abortus 2308 RB51 has been developed, via 
successive passages in a rich medium, by Gerhardt Schurig in 1982 (Schurig, Roop et al. 1991). 
It is a rough strain, interfering less with the diagnosis tests. But in this case, the medium used 
for the successive passages was supplemented with antibiotics, Penicillin and Rifampicin. This 
last one is used as antibiotic treatment against human brucellosis (Schurig, Roop et al. 1991). 
The Rifampicin acts by binding the RNA polymerase of bacteria, leading to an inhibition of 
RNA synthesis. The successive passage of RB51 strain in medium with antibiotics leads to a 
resistance of the RB51 strain to Rifampicin, which is the main problem of this vaccine strain 
(Ashford, di Pietra et al. 2004). The attenuated RB51 strain is protective, but not as much as 
than S19 vaccine: around 70 % of the vaccinated bovine are protected (Cheville, Stevens et al. 
1993). In addition, the strain is eliminated from the cervical lymph nodes 6 to 10 weeks after 
the vaccination (Cheville, S.C. et al. 1996). Abortions of vaccinated pregnant females can also 
occur (Cheville, Stevens et al. 1993).   
Finally, the attenuated strain B. melitensis Rev.1 was obtained by reversion of a strain naturally 
resistant to Streptomycin in the middle of 1950’s (Herzberg and Elberg 1953). The virulence 
attenuation of this strain could be explained by mutations mainly in ABC transporters, as some 
of them are required for the type IV secretion system in B. ovis (Silva, Mol et al. 2014, Issa and 
Ashhab 2016). B. melitensis Rev.1 confers a very good protection against future infections with 
B. melitensis (Lalsiamthara and Lee 2017) but also against B. ovis with 90 % of the vaccinated 
animals which are protected (Fensterbank, Pardon et al. 1982). However, another study revealed 
that Rev.1 strain, despite the fact that it limits the infection dissemination in 80 % of cases, only 
protects 35 % of the vaccinated animals (Brinley Morgan, Littlejohn et al. 1966). The 
vaccination via parenteral route offers a better protection than a vaccination via oral route 
(Olsen 2013, Olsen, Boggiatto et al. 2017). The rate of abortion is quite high with this strain, 
but the injection of the vaccinated strain by conjunctive route would reduce this percentage 
(Jiménez de Bagüés, Marin et al. 1989). As for the RB51 strain, the main problem of this 
vaccine is its resistance to an antibiotic required to treat brucellosis. 




Campaign to vaccinate wild animals like buffalo, reindeer or bison have been tried with the B. 
abortus RB51 strain, via conjunctive or sub-cutaneous routes. However, the efficiency of this 
vaccination seems to vary a lot (Olsen 2013). The 3 main vaccines present clearly a set of 
disadvantages such as a not 100 % efficiency (El Idrissi, Benkirane et al. 2001), the possible 
induction of abortion in vaccinated pregnant animals (Smith and Ficht 1990), the risk of 
reversion into a virulent strain for humans (Spink, Hall et al. 1962, Thomas, Bracewell et al. 
1981, Ashford, di Pietra et al. 2004, Sfeir 2018) or the resistance to antibiotics used to treat 
human brucellosis such as Rifampicin or Streptomycin. High doses of bacteria (around 5x109) 
are usually used, in one (or two) injection(s). Moreover, S19 and Rev1 vaccines present an 
interference with the diagnostic tests as these tests mainly detect LPS epitopes, preventing the 
distinction between naturally infected and vaccinated animals (Barrio, Grillo et al. 2009, Avila-
Calderon, Lopez-Merino et al. 2013). Different researches have been conducted to develop new 
vaccine approaches: inactivated, recombinant subunit, DNA, and vectored experimental 
vaccines. But up to now, no alternative has demonstrated a sufficient protection to make it 
commercially available (Carvalho 2016). 
 Human brucellosis  
 Incidence 
  
Figure 6: Map of the distribution of caprine brucellosis all over the world. Brucellosis is mainly reported  in south of America, 
Africa, South of Europe, and the Middle-East (Rossetti, Arenas-Gamboa et al. 2017) 
 
Humans can be infected by different species of Brucella, mainly by B. abortus, B. melitensis, 
and B. suis, B. melitensis being the main species isolated in human population (Corbel 2006). 




Humans are considered as accidental hosts as they are not able to transmit the disease to another 
host. Up to 12,500,000 new cases of brucellosis could be reported each year according to the 
WHO, with for examples an incidence of 34.9 cases per 100,000 person per year in Chad (South 
of Africa), 4 to 32 in Greece and 1.4 in Italy (South of Europe), 88 in Kyrgyzstan (Asia) and 
12.8 and 25.7 in Argentina and Mexico (Latina America), respectively (Figure 6) (Pappas 2006, 
Dean 2012).  
 Natural routes of transmission  
In the developed countries, brucellosis is considered as an occupational disease. Indeed, the 
researchers in laboratories (Ollé-Goig and Canela-Soler 1987, Staszkiewicz, Lewis et al. 1991, 
Fiori, Mastrandrea et al. 2000) and people working with animals or tissues are the most at risks 
(vets, butchers, farmers, etc) (Wallach, Samartino et al. 1997). A non-negligible route of 
transmission is via direct contact between a cutaneous lesion and infected tissues or fluids. This 
route of transmission is complicated to evaluate due to the rapid suppression of cutaneous 
manifestations (Berger 1981). The infection by contaminated aerosols is also an important route 
of infection (Hendricks, Borts et al. 1962). It is estimated that 10 to 100 bacteria are sufficient 
to infect a human via aerosols (Bossi 2004). In the developing countries, where the consumption 
of dairy milk products is widespread, or in the traveler population, the contamination by 
ingestion is also considered as a main route of infection (Figure 7) (Eckman 1975, Young 1975, 
Turgut, Turgut et al. 2006).  
Figure 7: The different modes of human brucellosis transmission. Humans can be infected by ingestion of unpasteurized milk 
products, via contaminated aerosols, direct contact between a cutaneous lesion and a contaminated fluid or tissue, etc. The 
human-to-human transmission is very rare. 




The transmission between humans is very rarely reported and very speculative. Some studies, 
by elimination, concluded that the sexual transmission was the only possible route of infection 
(Goossens 1983, Ruben 1991). The infections by blood transfusion  (Wood 1955, Doganay 
2001) or bone-marrow transplantation have also already been described in rare cases 
(Naparstek, Block et al. 1982). The vertical transmission from a mother to her child during the 
pregnancy or delivery is really rare (Figure 7) (Alsaif, Dabelah et al. 2018). 
 Symptoms 
The Brucella infection is characterized by two phases; the acute one and the chronic one if the 
first one is not treated. According to the WHO, the period of incubation can last between 2 and 
4 weeks, and in its chronic form, brucellosis can persist several years. Most of the time, human 
brucellosis is asymptomatic (Zhen, Lu et al. 2013), which is one of the reason of the difficulty 
to estimate the real burden of the disease. When symptoms are present, they are not specific 
and very difficult to link to brucellosis, which is another reason of the under estimation of the 
disease. Among the flu-like symptoms (tiredness, muscular pain, skeletal pain, etc.), the main 
one and maybe the most characteristic is the undulant fevers, with night sweats. In some cases, 
a clinical exam can reveal a splenomegaly or hepatomegaly (Memish, Mah et al. 2000, Basappa, 
Mallanagouda et al. 2006, Zhen, Lu et al. 2013). If brucellosis is not treated, two outcomes can 
occur: in the first one, the patients spontaneously recover or, in the second one, the disease 
evolves towards its chronic form. In this case, the subacute focalized form appears as the 
bacteria reach different organs, and can cause arthritis, spondylitis, meningitis, endocarditis, 
neurological disorders. Even if the death is rarely observed (less than 2 %), the majority of the 
death cases are due to cardio-vascular complications (Raju, Solanki et al. 2013). After this 
subacute phase, the chronic phase appears (until one year after the infection) and can stay for 
years. 
In pregnant women, a first case of abortion was reported in 1908 (Eyre 1908), but since, few 
reports have been listed (Schreyer, Caspi et al. 1980). The studies were usually made in endemic 
countries, making the link between brucellosis and abortion difficult to prove (Yousuf Khan, 
Mah et al. 2001, Karcaaltincaba and Yalvac 2010, Ali, Akhter et al. 2016).  





The treatment against human brucellosis had to be initiated rapidly to avoid the establishment 
of the chronic infection. The WHO recommends a therapy based on the combination of two 
antibiotics, one from the Tetracyclin family (Doxycyclin) and the other one from either the 
aminosides family (Streptomycin, or Gentamycin) or Rifamycin family (Rifampicin) (WHO 
1986). The duration of the treatment is variable and depends on the disease phase: 6 weeks for 
a treatment taken just after the infection, more than 3 months for the phase during which 
Brucella is already focalized and less accessible for antibiotics (WHO 1986). Unfortunately, it 
is too late to treat during the chronic phase. Currently, there is no vaccine for humans due to 
unacceptable levels of virulence, but the WHO wants to make human vaccine discovery one of 
its priorities (WHO 1997). The current strategy to avoid human infection and eradicate human 
brucellosis is to limit the cases of animal brucellosis through veterinary vaccination campaigns. 
Animals are also tested to identify the infected animals, which will be eliminated if they are 
positive to avoid the dissemination of brucellosis. However, even if the control of domestic 
animals is possible, the infected wild animals cannot be tested and identified. The transmission 
of brucellosis from wild to domestic animals remains possible. The BOX-4 summarizes the 
situation in Belgium. 
BOX-4. And today, brucellosis in Belgium? Thanks to a campaign of eradication of the 
brucellosis, the disease gradually decreased since 1989 with around 500 cases of bovine 
brucellosis, to only 2 cases in 1999 (Godefroid 2002). Belgium became a brucellosis-free 
country in 2003 according to the European Union (Commission Decision 2003/467/EC). 
Surveys and random controls in farms are made to ensure the brucellosis-free status. Only some 
strains of Brucella, such as B. suis biovar4 2, are still present in wild animals, in hares and boars, 
in several countries including Belgium. In 2012, brucellosis has been discovered in farms of 
the Namur Province (Fretin, Mori et al. 2013). The few human cases now reported in Belgium 
are certainly imported cases from people coming back from Mediterranean countries, as it is 
the case  in France for example (Mailles, Garin-Bastuji et al. 2016).    
 
4 Sub-group of a strain that can be differentiate from another biovar based on biochemical modifications 





Different diagnostic tests, most of the time serodiagnostic tests, can be used to detect Brucella 
in samples. As false-negative, false-positive results, and cross reactions with other infections 
like Yersinia enterolitica O9, Vibrio cholerae, and Francisella tularensis are frequent, the 
combination of several tests is often used. The directs tests used to detect the Brucella in 
samples are (1) the polymerase chain reaction (PCR) test (Fekete, Bantle et al. 1990), resulting 
in the amplification of the Brucella DNA, and (2) the hemoculture test, consisting in the search 
of Brucella in samples of lymph nodes, bone-marrow, etc (Gotuzzo, Carrillo et al. 1986). But 
the test currently used and recommended by the WHO is the Wright test, an indirect test. This 
test allows to detect the presence of IgM mainly, and consists in the agglutination and 
precipitation of antibodies-antigens complexes (Wright and Semple 1897).  
 Brucella inside the host cells: what do we know? 
 How to invade the cells? - Entry of Brucella 
Being intracellular bacteria, Brucellae will rapidly enter inside cells once in an organism. In 
vivo, the main infected cells are myeloid professional phagocytic cells such as macrophages 
and DCs (Billard, Cazevieille et al. 2005, Archambaud, Salcedo et al. 2010, Copin, Vitry et al. 
2012). But other non-professional phagocytic cells can be infected such as the trophoblast 
(Payne 1959), or non-phagocytic cells such as erythrocytes (Vitry, Mambres et al. 2014). The 
entry and the intracellular trafficking of Brucella have been described in vitro these last years. 
The internalization of Brucella inside the host cell could occur depending on two different 
mechanisms still little known. The first mechanism of entry could be dependent on the lipid raft 
and independent of opsonization. A study described that a first contact between the host and 
the pathogen was essential to induce the phagocytosis. The interaction components between 
Brucella and the plasma membrane of macrophages is still unknown, but different hypotheses 
are highlighted. It could be an interaction between a class A scavenger receptor (SR-A) of host 
cells with components of the outer membrane such as LPS for example (Kim, Watarai et al. 
2004). Several more recent studies have shown that adhesins from the autotransporter family 
such as Putative surface-exposed virulence protein BigA (Czibener, Merwaiss et al. 2016), 
Brucella trimeric autotransporter (Bta) E (Ruiz-Ranwez, Posadas et al. 2013), or BtaF (Muñoz 
González, Sycz et al. 2019) were involved in the adhesion of Brucella to extracellular matrix 
of cells and could be the first contact between Brucella and cells. After this first contact, 




Brucella was shown to “swim” along the macrophage surface (Watarai, Makino et al. 2002). 
During this time, the phagosomes transiently form, incorporating components of the plasma 
membrane lipid rafts (cholesterol, glycosylphosphatidylinositol (GPI)-anchored proteins, and 
ganglioside GM1) to their membrane with bacterium inside (Naroeni and Porte 2002).  
The second mode of entry could be opsonins-dependent: once bacteria are opsonized by IgG, it 
will be recognized by surface receptors of the host cell, interact, and induce signals transduction 
to trigger the polymerization of actin at one site and then the phagocytosis (Greenberg, El 
Khoury et al. 1991).  
 How to reach the paradise? - Intracellular trafficking 
The first steps after the internalization seem independent of the Type 4 Secretion System 
(T4SS), composed of virB genes, placed in operon (see BOX-5) (Comerci, Martinez-Lorenzo 
et al. 2001, Delrue, Martinez-Lorenzo et al. 2001). 
BOX-5. As major actor of the entry and the surviving of Brucella inside its host: the virB 
operon. Briefly, the virB operon is a type IV secretion system first described in Agrobacterium 
tumefaciens (Ward, Akiyoshi et al. 1988), and then discovered in Brucella (O'Callaghan, 
Cazevieille et al. 1999). It is composed of 11 virB genes, and the proteins are assembling 
together in the envelope to form a transporter of molecules between the bacterium (cytoplasm 
or periplasm) and the outside (the vacuole or the host cytosol) (O'Callaghan, Cazevieille et al. 
1999). It was shown later that virB operon is essential for the virulence of Brucella in in vitro 
(O'Callaghan, Cazevieille et al. 1999, Foulongne 2000) and in vivo (Hong, Tsolis et al. 2000, 
Sieira 2000) models, injecting its effectors in the host cell cytoplasm to control its intracellular 
trafficking.  
Indeed, both Brucella-containing vacuoles (BCV) containing either wild type (wt) or virB-
mutated strain acquire the markers of early endosomes such as Early Endosome Antigen 1 
(EEA1) (Comerci, Martinez-Lorenzo et al. 2001) and transit to the phagocytic pathway 
(Pizarro-Cerda, Meresse et al. 1998). Around 12-24h post infection, during maturation of the 
BCV, the compartment with living bacteria has a pH decrease until 4 - 4.5. This acidification 
is dependent on vacuolar proton ATPases and is important for the bacteria replication (Porte, 
Liautard et al. 1999). The acidification was shown to be the trigger of the virB expression 
(Boschiroli, Ouahrani-Bettache et al. 2001) and thus indirectly to promote the secretion of 




effectors essential for the trafficking of Brucella in the macrophages (Figure 8). Up to now, 
about 15 effector proteins have been identified, most of them without associated function (Ke, 
Wang et al. 2015), see Table 3. BtpA (or TcpB) is known to interact with MYD88, an adaptor 
host protein for TLR2 and TLR4. This interaction triggers the degradation of MYD88 and hence 
so the decrease of the signaling TLR2/4 pathways (Radhakrishnan and Splitter 2010). SepA has 
been shown to inhibit the fusion with lysosomes by excluding the LAMP1 lysosomal marker 
(Dhomer, Valguarnera et al. 2014) and RicA to regulate the vesicles trafficking (de Barsy, 
Jamet et al. 2011, Smith, Cotto-Rosario et al. 2020) (Figure 8). All these effectors are proposed 
to be used by Brucella at a perfect coordinated timing with the key steps of the host intracellular 
trafficking (Celli 2019). It has also been shown that the fusion between BCV and lysosomes 
was avoided thanks to another element, the periplasmic cyclic-β1-2 glucan (Arellano-Reynoso, 
Lapaque et al. 2005).  
Table 3: the 15 known effectors secreted by Brucella through its T4SS 
Figure 8: Intracellular trafficking of Brucella. After internalization, Brucella is in the BCV, that will interact with the different 
vesicles of the endocytic pathway of the host. At the same time, the BCV acquires specific markers. After kiss and run with 
lysosomes, the BCV acidifies, which triggers the expression of virB operon. Different effectors are then secreted and inhibit 
the complete fusion with lysosomes and promote their trafficking to the ER-like compartment (rBCV). The virB-deficient strain 
will fuse with lysosomes and, in the end, will be degraded. Modified from (Celli 2015). 
 
 




At the contrary of wt strains, the virB-mutated strains are unable to escape the fusion with 
lysosomes, as the BCVs have sustained association with LAMP1 and cathepsin D markers 
(Comerci, Martinez-Lorenzo et al. 2001, Delrue, Martinez-Lorenzo et al. 2001). The virB-
mutated strain is thus degraded (usually between 24 and 48 h post-infection) (Figure 8), 
explaining why these strains are avirulent (Sieira 2000). Once the fusion with lysosomes is 
avoided, wt Brucella will reach an ER-like compartment, their replicative niche (in vivo and in 
vitro) (Figure 8) (Anderson, Cheville et al. 1986, Detilleux, Deyoe et al. 1990, Pizarro-Cerda, 
Meresse et al. 1998, Sedzicki, Tschon et al. 2018). Once in the ER, Brucella will trigger its 
replicative cycle and its growth. The replicative BCV (rBCV) is in interaction with the ER and 
Golgi apparatus, from which Brucella is able to use the resources of the host. More the bacteria 
replicate inside the replicative niche, more the structure of the ER is modified (Celli, de 
Chastellier et al. 2003, Celli 2019). Following replication in the ER, the rBCV are transformed 
into autophagic BCV (aBCV) through a mechanism dependent on the autophagy initiation 
process, involving Beclin1 and Autophagy-related protein (ATG) proteins and the formation of 
a double membrane around Brucella. This structure will help the egress of bacteria outside the 
cell, ready to infected new cells and to start a new cycle of replication, at 72 h post infection 
(Starr, Child et al. 2012, Celli 2015). 
 How to reproduce? - Replication of Brucella  
It has been shown that B. abortus is blocked in G1 phase, the first step of the replicative cycle, 
during the first hours post infection in HeLa cells and RAW 264.7 macrophages. B. melitensis, 
such as the other Brucella species, contains two unique chromosomes of 2.1 and 1.15 millions 
of base pairs for each chromosome (Michaux, Pailisson et al. 1993). Each chromosome has its 
own origin of replication and its own segregation system. Chromosomal replication and 
bacterial growth are two mechanisms taking place at the same time (Figure 9 a). The membrane 
staining with the Texas Red Succinimidyl Ester (TRSE) allows to study the replication of 
Brucella by labelling the primary amines of its outer membrane (Deghelt, Mullier et al. 2014). 
Thanks to the polar growth and asymmetric division of Brucella, the different phases of division 
are easily discerned (Figure 9 b). At the beginning of the staining, all bacteria are labelled. 
Then, after growth and division, the newly formed bacteria lose the TRSE staining, allowing to 
distinguish the bacteria from the infectious dose (mother bacteria) of the bacteria after growth 
and division (daughter bacteria) (Figure 9 b). The eFluor670 staining works in the same way, but 
is conjugated to another fluorochrome.  




a.      b. 
Figure 9: Replication of Brucella chromosomes (a), and labeling of outer membrane proteins to distinguish mother and 
daughter bacteria (b). A. To replicate, Brucella initiates first the replication of its 1st chromosome, followed by initiation of 
the replication of the 2nd one (during the S phase). At the same time, the bacterium grows. Then, during the G2 phase, the 
septation is initiated, followed by the division. Each newborn bacterium possesses the two chromosomes, with their own origin 
of replication. B. Schematization of a modified strain that expresses constitutively the mCherry gene and labelled before use 
with eFluor670. The “mother bacteria” are positive for both stainings (mCherrry and eFluor670). As Brucella has a unipolar 
growth, and that primary amines do not move in the outer membrane, the “daughter bacteria” loose the eFluor670 staining 
after growth and division. 
 
 How to be a perfect Trojan horse?  - Adaptations to the host 
Both passive and active mechanisms allow to Brucella to be almost undetected by the immune 
system and to have a chance to survive in an austere environment. 
As passive mechanisms, there is for example the modification or the absence of elements that 
are normally detected by the host TLRs: the PAMPs. For Example, Brucella does not possess 
pili, fimbriae, or capsules (Moreno and Moriyon 2002). Moreover, its LPS, lipoproteins and 
flagellin components are poorly detected by the host immunity. Indeed, the Lipid A of the 
Brucella LPS contains a long fatty acids chain of 16-18 carbons (rather than 12-14 in LPS of 
other bacteria), leading to a poor endotoxicity and a low detection by the immune system 
(through the MD2-TLR4 complex) (Conde-Alvarez, Arce-Gorvel et al. 2012). In addition, the 
O-chain of Brucella LPS is longer than in other bacteria, leading to a steric hindrance, avoiding 
the action of complement (Barquero-Calvo, Chaves-Olarte et al. 2007). Finally, as both the 
Lipid A and the core of Brucella LPS present  lower number of charged groups leads to a low 
permeability and so a resistance to cationic peptides action (Martinez de Tejada, Pizarro-Cerda 
et al. 1995, Barquero-Calvo, Chaves-Olarte et al. 2007). As the LPS is poorly detected, the 
macrophages are weakly activated and induce low amount of pro-inflammatory cytokines such 
as TNF-α, IL-1β, IL-6 or IL-10 (Barquero-Calvo, Chaves-Olarte et al. 2007).  




As active mechanisms, it has been published that Brucella was able to decrease the secretion 
of TNF-α, in an outer membrane protein (OMP)-25 and micro-RNA dependent manner (Billard, 
Dornand et al. 2007, Luo, Zhang et al. 2018). This leads to a weak maturation of DCs, with 
only a small increase in the maturation markers C-C chemokine receptor (CCR)7 and CD83. 
Due to this, the activation of naive T lymphocytes is weakly induced (Billard, Dornand et al. 
2007). As already mentioned, Brucella is also able to inhibit the TLR4 signaling pathway via 
its effector molecule TcpB interfering with upstream elements (Sengupta, Koblansky et al. 
2010) and to induce IL-10 by Treg cells in order to inhibit TH1 response (Corsetti, de Almeida 
et al. 2013) 
  




II. The comparison of the routes of infection 
 
 What is known from the different in vivo infection murine 
models 
Despite the fact that natural  hosts of B. abortus, B. melitensis, and B. suis are cattle, sheep and 
goats, and suidae, respectively, the mice are often used as an experimental model to study 
brucellosis (Grilló, Blasco et al. 2012). To infect mice, different routes of injection have been 
used, with results sometimes completely different. Here are some examples of used routes. 
 The intraperitoneal route, the most currently used 
The intraperitoneal (i.p.) route consists in injecting B. melitensis in the right side of the 
peritoneum of the mice. This route of injection allows the use of big volume (500 µl / mouse) 
limiting the precision errors. However, it is absolutely not physiological as numerous defenses 
are bypassed such as the mucosal barriers. After this inoculation, the bacteria directly reach the 
bloodstream and quickly colonize the spleen, only after 10 minutes with a high dose of 108 
bacteria per mouse (Copin, Vitry et al. 2012). B. melitensis can persist in the spleen for more 
than 50 days (Machelart, Khadrawi et al. 2017). Once the blood and the spleen infected, the 
colonization of the other organs rapidly expands. It has been shown in this model that the main 
infected cells in the spleen are the resident macrophages (the red pulp and the marginal zone 
macrophages), the recruited monocytes, and the inflammatory DCs (Copin, Vitry et al. 2012). 
In the primary response against B. melitensis, the IFN-γ cytokine is crucial to control the 
infection. IFN-γR-knock-out (KO) mice have an excessive recruitment of neutrophils, and a 
higher number of granulomas formation than wt mice. These IFN-γR-KO mice die of lack of 
monocytes and hyper-neutrophilia, demonstrating the importance of an efficient TH1 response 
in this model. Indeed, the TH1 CD4 T cells are indispensable to control the infection, as infected 
MHCII- and IL12p35-deficient mice have a higher number of colony forming units (CFU) than 
wt mice (Vitry, De Trez et al. 2012). Even if CD8 T cells and B cells are also activated, their 
role is not indispensable (Vitry, De Trez et al. 2012). Granulom formation was observed in the 
spleen of infected mice. These structures are composed of infected macrophages and DCs, 
surrounded by T cells and their role is to centralize the bacteria near an arsenal of destruction 




(Copin, Vitry et al. 2012). During a second infection, humoral and cellular responses are 
indispensable. Indeed, MuMT-deficient mice (mice deficient for B cells) are more susceptible 
to the B. melitensis secondary infection than wt mice. In the same study (Vitry, Hanot Mambres 
et al. 2014), it is suggested that IgM alone seem to be sufficient for the control of the second 
infection. As the MHCII- and IL12p35-deficient mice have an increase in CFU in comparison 
to wt mice, that suggests that TH1 CD4 T cells are a key element in the control of secondary 
infection by Brucella, after an i.p. injection (Vitry, Hanot Mambres et al. 2014). 
 The intragastric and oral routes 
Through the intragastric route, by gavage, a lot of challenges are highlighted: the microbiota, 
the acidity of the stomach, the epithelial cells, the local immune responses, the bile salts, etc. 
To successfully infect mice via this route, a high dose of B. melitensis (1010 bacteria per mouse) 
is recommended to obtain a systemic infection of mice, especially at early infection stages 
(Paixao, Roux et al. 2009). The first sites of Brucella entry are the small intestine, the Gut-
Associated lymphoid tissues (GALT), but also the Peyer’s patches and the mesenteric and 
cervical lymph nodes (Paixao, Roux et al. 2009, von Bargen, Gagnaire et al. 2014). Even if 
some bacteria also enter by the upper tract, one problem of this route of infection is that a lot of 
bacteria directly arrive in the stomach, extracellularly, and without food bolus around. This 
leads to a direct contact with bile salts and acidity that affect bacteria. It has been shown that a 
neutralization of the acidity leads to a faster and homogenous infection (Pasquali, Rosanna et 
al. 2003). To survive in these unfavorable conditions, Brucella bacteria possesses bile salts 
hydrolase (Delpino, Marchesini et al. 2007) and urease. B. abortus (Sangari, Seoane et al. 2007) 
and B. suis (Bandara, Contreras et al. 2007) seem to have a higher urease activity than B. 
melitensis (Paixao, Roux et al. 2009). One of the main problem of this mouse model is the 
bypass of the upper digestive tract tissue.  
In another more recent model, mice are orally infected with 10 µL of B. melitensis suspension 
in milk, using a micropipette (von Bargen, Gagnaire et al. 2014). In this model, B. melitensis 
could be internalized by DCs that migrate into the cervical lymph nodes (von Bargen, Gagnaire 
et al. 2014). This site could play a role of filter, but also of reservoir for Brucella (von Bargen, 
Gagnaire et al. 2014). The bacteria which bypass the local immune response of the host could 
invade the gastrointestinal tract via the M cells of the Peyer’s Patches (Nakato, Hase et al. 
2012). Following this infection, bacteria are directly in contact with saliva, containing 




lysozyme, lactoferrin, peroxidases, and IgA, but also with gingival fluid, containing 
complement molecules, neutrophils, etc. In the mucosal tissue, the infected cells migrate into 
the lymph nodes to activate the T cells. Bacteria are found in these lymph nodes for weeks (von 
Bargen, Gagnaire et al. 2014). This could be the natural entry of Brucella after the ingestion of 
contaminated products, but also a good reservoir (von Bargen, Gagnaire et al. 2014). 
 The intranasal route, a physiological one? 
 Generalities 
A more physiological route of infection is certainly the infection by aerosols using an exposure 
chamber and a nebulizer. Experimentally, the infection by aerosols has been demonstrated in 
guinea pigs in 1948 with B. melitensis and B. suis (Elberg and Henderson 1948). Around 240 
organisms were sufficient to infect the half of the animals (Elberg and Henderson 1948). The 
intranasal infection can also require only anesthesia and a micropipette (Mense, Van De Verg 
et al. 2001). It is not to exclude that conjunctival, or oral mucosal infections occur during this 
mode of infection (Grillo, Blasco et al. 2012). After an intranasal route of infection, the bacteria 
are rapidly found in the lungs at almost similar doses than the infectious dose (Hanot Mambres, 
Machelart et al. 2016). However, bacteria are not found in the bloodstream, at any tested times 
(Hanot Mambres, Machelart et al. 2016), suggesting why Brucella only reaches the spleen and 
other organs after around 6 days post infection, with a dose of 2x104 bacterial / mouse (Hanot 
Mambres, Machelart et al. 2016). At the local site of the infection, no alterations are observed: 
no histopathological lesions, no granuloma, no cells recruitment during the first 48 hours (Hanot 
Mambres, Machelart et al. 2016).  
 Mucosal immunity 
After intranasal infection, Brucella first joins the upper airways, constituted of the oral and 
nasal cavities, and the larynx. The lower airways are composed of trachea, bronchi, bronchioles 
and alveoli (Figure 10). The role of bronchioles is mainly to ensure the air conduction from 
outside to inside. The function of alveoli is to ensure the gaseous exchange. As the functions 
are different, it is normal that the structure and the immunity of these different parts are different 
too. The tracheal mucosal barrier is constituted of pseudo-stratified layer composed of ciliated 
epithelial cells, Goblet cells, and undifferentiated basal cells. This barrier is one of the first ones 
encountered by Brucella after an intranasal infection. It is characterized by the production of 
mucus, composed of mucin and glycoproteins, by the Goblet cells and the Mucosal-associated 




lymphoid tissue (MALT), but also defensins, cytokines, chemokines. The mucus is the first 
physical barrier that pathogenic agents have to face. The viscosity of the mucus prevents the 
adhesion of pathogenic agents to the epithelium, traps the pathogenic agents or debris that will 
be expelled thanks to mechanic movements of cilia and sneezing and coughing. In addition, the 
mucus contains antimicrobial peptides, lysozyme and surfactant that affect the bacterial 
membranes (Chairatana and Nolan 2017). The IgA also present in the mucus allow to clutter 
the bacteria and prevent them to adhere to the epithelium (Chairatana and Nolan 2017). In the 
case of Brucella infections, the humoral response itself does not seem to have an important role 
(Hanot Mambres, Machelart et al. 2016). The non-lymphoid tissues are composed of different 
immune cells such as macrophages, DCs, lymphocytes, etc., leading to a good detection of 
pathogenic agents and a good immune stimulation. As already mentioned, the epithelial cells 
express TLRs and are able to secrete cytokines and chemokines in response to pathogenic 
agents detection. DCs and macrophages are then activated, T cells and neutrophils are recruited. 
Once infected, APCs (Antigen presenting cells) directly migrate, via the lymphatic vessels, to 
lymph nodes to activate lymphocytes. If Brucella successes to bypass the first barriers, bacteria 
will reach the alveoli, and infect alveolar macrophages, the first and main infected cells up to 
48 h post infection (Figure 10). The alveolar macrophages are specific macrophages from 
alveoli, and are able to patrol and control in and between alveoli. They have a high efficiency 
to phagocyte inhaled bacteria as the lungs are in contact with non-sterile air constantly 
(Neupane, Willson et al. 2020). But then, Brucella is able to evade these cells and to disseminate 
Figure 10: The lower respiratory tract is composed of the trachea and large bronchi (1), the bronchioles (2), and the alveoli 
(3).  The membrane of trachea and bronchi is mainly composed of ciliated epithelial cells, basal cells, Goblet cells, producing 
the mucus. The bronchial mucosa is mainly composed of ciliated epithelial cells, and basal cells. Finally, the alveoli are 
composed of alveolar macrophages, interstitial macrophages, smooth muscle cells, blood vessels. 




to other organs such as the spleen, and several lymph nodes such as the mediastinal ones 
(Archambaud, Salcedo et al. 2010). As the mucosal immunity is in contact with the external 
environment, the immune response is a precise balance to tolerate the commensal bacteria but 
fight against the external bacteria. The alveolar macrophages, the DCs, the neutrophils, and the 
lymphocytes must be highly regulated. 
Concerning the primary immune response against Brucella, in the lungs of C57BL/6 mice, an 
IL-17-mediated response associated to γδ T cells is indispensable the first 5 days p.i. (Hanot 
Mambres, Machelart et al. 2016). Later, at 12 days p.i., IL-12/IFN-γ axis, in association with 
CD4 T cells, is indispensable in the lungs (Hanot Mambres, Machelart et al. 2016). Finally, in 
the spleen after 12 days p.i., IFN-γ, produced by CD4 T cells, is essential. However, B cells are 
dispensable (Hanot Mambres, Machelart et al. 2016). After a secondary infection with Brucella, 
a good protection is observed in the lungs. This protection is associated to T cells (αβ CD3 T 
cells), suggesting a compensatory role of CD4 and CD8 T cells (Hanot Mambres, Machelart et 
al. 2016). As either IL-12p35- or IL-17-deficient mice are not susceptible to the infection, this 
also suggests a compensatory role between TH1 and TH17 responses (Hanot Mambres, 
Machelart et al. 2016). In contradiction with the i.p. model, B cells are dispensable, even after 
a secondary infection, suggesting that bacteria could already be intracellular (Hanot Mambres, 
Machelart et al. 2016). IL-1, via the action of IL-1β and “NOD-like receptor family, pyrin 
domain containing 3” (NLRP3) inflammasome, could play a role in the control of Brucella in 
the lungs (Hielpos, Fernandez et al. 2018). 
 The intradermal route 
 Generalities 
As mentioned above in the general introduction, Brucella infection via cutaneous lesion can 
occur in natural wild life, but also in some work like it is the case for vets or butchers for 
examples. To mimic this route of infection, an intradermal model with injection in the footpad 
has been developed. The infection in the footpad has the advantages that the site of infection is 
drained by an easy take-away lymph node (popliteal one) (Kawashima, Sugimura et al. 1964), 
and that local and systemic studies are possible (Pardon 1977). The injection being made with 
a needle in a small place, skin lesion, tissue destruction, and so local inflammation are produced 
(Gray and Jennings 1955, Kamala 2007). However, this could actually mimic the skin lesion 
made with a vets or butcher’s instrument (knife, scissors, needle, etc.), but also by a bite of 




insects. Indeed, an experiment showed that B. abortus could persist transiently in the midgut of 
Musca autumnalis, a face fly very abundant in the cattle population (Cheville, Rogers et al. 
1989). Taken together, and with the fact that Brucella is able to invade erythrocytes of mice 
(Vitry, Mambres et al. 2014), the contamination with Brucella by a bite of insects, through the 
dermis, is a plausible hypothesis.  
After the mice intradermal injection, bacteria are rapidly found in the popliteal lymph node 
(Pardon 1977), in the blood and in the spleen (Plommet and Plommet 1983).  
 Skin immunity 
The skin constitutes the layer at the interface between outside and inside environments and is 
composed of three sub-layers: epidermis, dermis and hypodermis. The first one is directly in 
contact with the environment. Thanks to lamellar bodies and lipids, a hydrophobic barrier is 
created. The epidermis is a stratified epithelium mainly composed of keratinocytes, which are 
continually renewed, and Langerhans cells. The dermis is mainly composed of macrophages, 
DCs, and T cells (Matejuk 2018). 
By producing keratin, a fibrous protein, keratinocytes play a role of protection and support. 
They also produce antimicrobial peptides playing an important role of defense against 
pathogenic agents invasion. Keratinocytes express TLRs, allowing them to produce IFN-γ upon 
activation (Lebre, van der Aar et al. 2007, Miller 2008). These cells also express MHCII on 
their surface. Finally, keratinocytes are able to produce different cytokines (IL-1β, IL-10, etc.) 
and chemokines (CXCL9, CXCL10, CCL20, etc.) (Lebre, van der Aar et al. 2007). The 
Langerhans cells are the resident DCs of the skin. Their main role is to capture antigens thanks 
to their dendrites and they are also able to secrete different cytokines such as TNF-α upon 
stimulation of their expressed TLRs (Miller 2008). 
In the dermis, the dermal DCs are able to stimulate B cells leading to the production of IgM 
(Dubois, Bridon et al. 1999). As keratinocytes, dermal DCs express TLRs at their surface 
(Angel, Lala et al. 2007) and are able to produce TNF-α and iNOS. The T lymphocytes (CD4 
and CD8) continually circulate and other are recruited at the site of infection when necessary. 
The lymphocytes role was detailed above in the general introduction. The mast cells, the 
macrophages and the innate lymphoid cells also play a great role in the skin immunity by 
secreting different enzymes, cytokines, chemokines to modulate the immune system (Burke, 




Issekutz et al. 2008). The mouse skin has the particularity to have a specific population of T 
cells expressing the γδ-TCR receptor: the dendritic epidermal T cells (DETCs). These cells 
monitor and recognize the non-self antigens and the stress signals of surrounding cells. Once a 
stress is detected, the DETC secrete chemokine and cytokines such as IL-17 and IFN-γ, etc. to 
modulate the skin inflammation (Asarnow, Goodman et al. 1989, Nielsen 2014). 
 Other routes of infection 
Briefly, the mode of transmission via the milk was suggested by Grillo et al. who showed that 
one of the targeted organ of Brucella could be the lymph nodes of the mammary glands (Grillo, 
Barberan et al. 1997). However, other sources suggested that there are few Brucella in the 
mammary gland (1 to 103) - in a mouse model - and that the successive sucking could proffer a 
resistance to this bacterium (Bosseray and Dufrenoy 1982) as well as the transfer of protective 
antibodies (Brambell 1970) leading to a low level of infection via the milk. 
Bosseray also showed in a mouse model that 60 % of the offspring was infected at birth 
probably by vertical transmission, and that the placental barriers, in a same uterus, could have 
a different efficiency to protect the fetus as all the fetuses from a same uterus were not infected 
(Bosseray and Dufrenoy 1982).   
  





Live attenuated vaccines are considered as the most efficient vaccines against intracellular 
pathogens. They are able to mimic natural infections, to induce a long-term humoral and cellular 
immunity. The first generations of live attenuated vaccines were produced in an empiric 
manner, by successive passages in different media, waiting for spontaneous mutations. But this 
empiric production cannot prevent the risk of reversion to wild type virulence or the risk of 
disease in immune compromised people or animals. A rational development of live attenuated 
vaccines should bypass these problems and produce more safety vaccines. In this development, 
a first step is to better understand the influence of the infection route in the identification of 
infected cells, virulence genes and the nature of the protective immune response. For that, we 
decided to compare different parameters in three in vivo infection models. After intraperitoneal, 
intranasal or intradermal mouse infection by Brucella melitensis, we will compare the course 
of the infection in organs, the main cellular reservoirs of infection and the virulence genes 
involved in the persistence of B. melitensis. Another very important parameter is the 
identification of immune markers of protection, such as the type of T helper response and the 
lymphoid subpopulations indispensable to have a protective immunity.  
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Live attenuated vaccines play a key role in the control of many human and animal
pathogens. Their rational development is usually helped by identification of the reservoir
of infection, the lymphoid subpopulations associated with protective immunity as well as
the virulence genes involved in pathogen persistence. Here, we compared the course of
Brucella melitensis infection in C57BL/6 mice infected via intraperitoneal (i.p.), intranasal
(i.n.) and intradermal (i.d.) route and demonstrated that the route of infection strongly
impacts all of these parameters. Following i.p. and i.n. infection, most infected cells
observed in the spleen or lung were F4/80+ myeloid cells. In striking contrast, infected
Ly6G+ neutrophils and CD140a+ fibroblasts were also observed in the skin after i.d.
infection. The virB operon encoding for the type IV secretion system is considered
essential to deflecting vacuolar trafficking in phagocytic cells and allows Brucella to
multiply and persist. Unexpectedly, the !virB Brucella strain, which does not persist in
the lung after i.n. infection, persists longer in skin tissues than the wild strain after i.d.
infection. While the CD4+ T cell-mediated Th1 response is indispensable to controlling
the Brucella challenge in the i.p. model, it is dispensable for the control of Brucella in
the i.d. and i.n. models. Similarly, B cells are indispensable in the i.p. and i.d. models
but dispensable in the i.n. model. !"+ T cells appear able to compensate for the
absence of #$+ T cells in the i.d. model but not in the other models. Taken together,
our results demonstrate the crucial importance of the route of infection for the host
pathogen relationship.
Keywords: Brucella melitensis, brucellosis, infection control, live vaccine, virulence genes, reservoir cells
INTRODUCTION
Live attenuated vaccines (LAVs), composed of live pathogens that are made much less virulent than
the pathogenic parental strains, are one of the most cost e!ective health tools in medical history
[for review see (1–3)]. The advantages of LAVs include their mimicry of natural infections, the
stimulation of long-term humoral and cellular immunity and their intrinsic adjuvant properties.
First generation LAVs relied on empirical and somewhat unpredictable attenuation. In the present
regulatory environment, the use of LAVs has been limited by safety concerns, especially due to
the risk of reversion to wild-type virulence and the possibility of causing disease in immune
compromised individuals. However, advances in immunology, molecular virology and bacteriology
have paved the way for the rational design of LAVs while avoiding the unpredictability of empirical
attenuation to thus reduce the safety risks.
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Rational design of LAVs requires good knowledge of the in
vivo infection process. In particular, the pathogen’s cell cycle,
main reservoirs of infection and the virulence genes involved
in persistence of the pathogen can be characterized in order to
help select the most e!ective candidate vaccines. However, one of
the biggest remaining challenges is the identification of immune
markers of protection, such as the type of T helper response
and the lymphoid subpopulations associated with protective
immunity (4). In the current study, we use the Brucella infection
in mice as a model to investigate the impact of the route of
infection on the identification of these parameters.
Brucella (an alphaproteobacterium) is a facultative
intracellular Gram-negative coccobacillus that infects wild and
domestic mammals and causes brucellosis. Human brucellosis
is among the most common zoonoses (5). The vast majority
of cases worldwide are attributed to B. melitensis [reviewed in
Pappas et al. (6)]. Although it is rarely fatal, Brucella can cause a
devastating multi-organ disease in humans with serious health
complications in the absence of prolonged antibiotic treatment
(6, 7). Human brucellosis primarily occurs following mucosal
exposure to contaminated aerosols or ingestion of contaminated
foods (8–12). However, in some occupational groups, such as
cattle dealers, butchers, veterinarians, and farmers, it is well-
documented that brucellosis can be acquired directly through
contact of broken skin with infected animals (13, 14). The
frequency of direct cutaneous infection is di"cult to determine
and could be underestimated as cutaneous manifestations
of brucellosis are known to disappear spontaneously in
patients (15).
During infection, B. melitensis mainly leads a stealthy
intracellular lifestyle (16). E!ector proteins secreted by the type
IV secretion system (T4SS), which is encoded by the virB operon,
are involved in the establishment of intracellular replicative
niches. B. melitensis strains lacking a functional T4SS appear
to be highly attenuated in mice and in their natural host, the
goat [reviewed in De Jong and Tsolis (17)]. In vitro experiments
using macrophage cell lines have shown that the T4SS is required
for maturation of the Brucella phagosome into an endoplasmic
reticulum-derived compartment (18).
Although the most frequent natural routes of Brucella
infection are mucosal or cutaneous, the main experimental
model for studying brucellosis in mice is intraperinoneal (i.p.)
infection, which bypasses mucosal immune defenses and leads
to infection that very rapidly becomes systemic. Over the last
decade, our group characterized the phenotype of infected
cells and the protective response against Brucella in an i.p.
model (19, 20) and compared it to a model of intranasal
(i.n.) infection (21). Taken together, those studies demonstrated
that the lymphocyte populations required to control a Brucella
challenge in each infectious model di!ered widely. The CD4+T
cell-mediated Th1 response and B cells are indispensable in
the i.p. model (20) but appear to be dispensable in the i.n.
model (21).
To our knowledge, there is no described experimental model
of cutaneous Brucella infection in mice. Only one study (22)
describes cutaneous injection with Brucella abortus in the
footpad of guinea pigs and the development of protective
memory. Thus, in the present study, we developed and
characterized an original intradermal (i.d.) infection model in
mice. We compared the dissemination of wild-type and virB-
deficient strains of Brucella and the type of cells infected
and the protective immune response in the i.d., i.n., and i.p.
models. This approach led us to conclude that the route of
infection has unexpected major consequences on the host-




The procedures used in this study and the handling of
the mice complied with current European legislation
(Directive 86/609/EEC) and the corresponding Belgian
law “Arrêté royal relatif à la protection des animaux
d’expérience” of 6 April 2010 and published on 14 May
2010. The Animal Welfare Committee of the Université
de Namur (UNamur, Belgium) reviewed and approved the
complete protocol for Brucella melitensis infection (Permit
Number: UN-LE-13/195).
Mice and Bacterial Strains
Wild-type C57BL/6 and BALB/c mice were acquired fromHarlan
(Bicester, UK). TCR-!!/!, CD3"!/!, TCR-#!/!, MuMT!/!,
CCR2!/!, and CCR7!/! C57BL/6 were all purchased from The
Jackson Laboratory (Bar Harbor, ME). IFN-$R!/! (23) and IL-
12
!/!
p35 C57BL/6 mice (24) were acquired from Dr. B. Ry!el
(University of Orleans, France). IL17RA!/! C57BL/6 mice (25)
were acquired from Dr. K. Huygen (Belgian Scientific Institute
for Public Health, Brussels, Belgium). TNFR1!/! C57BL/6 (26)
were acquired from Dr. C. De Trez (Vrije Universiteit Brussel).
TAP1!/! C57BL/6 mice (27) andMHCII!/! C57BL/6 mice (28)
were acquired from Jörg Reimann (University of Ulm, Ulm,
Germany). All wild-type and deficient mice used in this study
were bred in the animal facility of the Gosselies campus of the
Université Libre de Bruxelles (ULB, Belgium). We used wild-
type strains of Brucella melitensis 16M. We also used Brucella
melitensis 16M stably expressing a rapidly maturing variant of
the red fluorescent protein DsRed (29), the mCherry protein,
under the control of the strong Brucella spp. promoter, psojA.
The construction of the mCherry-expressing Brucella melitensis
(mCherry-B) strain has been described previously in detail (30).
The !virB mutant was constructed in the mCherry-B strain by
triparental mating to introduce the pJQ200 UC1-virB plasmid
from the E. coli DH10B strain [described in Nijskens et al. (31)]
into the mCherry-B strain using the E. coli MT 607 (pro-82 thi-
I hsd R17 (r-m+) supE44 recA56 pRK600) strain [described in
Casadaban and Cohen (32)], and the allelic replacement was
performed as described previously for other gene deletions (33).
Deletion of the virB operon was checked by PCR using the virB-
F-check 5"-CGCTCGGCTATTATGACGGC-3" and virB-R-check
5"-CGCCGATCATAACGACAACGG-3" primers.
Cultures were grown overnight with shaking at 37#C in 2YT
liquid medium (Luria-Bertani broth with double quantity of
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yeast extract) and were washed twice in RPMI 1640 (Gibco
Laboratories; 3,500x g, 10min) before inoculation of the mice.
Brucella melitensis was always handled under BSL-3
containment according to Council Directive 98/81/EC of
26 October 1998 and a law of the Walloon government of 4
July 2002.
Brucella melitensis Staining With eFluor670
For some experiments, we stained Brucella melitensis with
eFluor670 labeling. Cultures were grown overnight as indicated
above and we then incubated the bacteria for 20min in
the dark with eFluor670 dye at the final concentration of
10µM. After incubation, the bacteria were washed three
times in PBS and once in RPMI before inoculation of
the mice.
Measurement of Brucella melitensis
Multiplication in vitro
The growth of Brucella melitensis in liquid culture was monitored
continuously using the multiwell Bioscreen system (Thermo
Fisher, ref. 110001-536). The B. melitensis cultures in 2YT
medium were centrifuged, washed once with PBS and diluted
to an OD600 of 0.05 in 2YT to start culture in the Bioscreen
system. Each sample (200 µl per well) was cultured at
37!C for 48 h.
Brucella melitensis Infection in vivo
We used wild-type or mCherry-expressing Brucella melitensis
in RPMI [described in Copin et al. (30)]. Control animals were
inoculated with the same volume of PBS. The infectious
doses were validated by plating serial dilutions of the
inoculums. For i.n. infection, mice were anesthetized with
a cocktail of Xylasine (9 mg/kg) and Ketamine (36 mg/kg)
in PBS before being inoculated with 30 µl of the indicated
dose of Brucella melitensis. For i.d. infection, mice were
anesthetized by inhalation of Isofluran before injecting
20 µl of the indicated dose of Brucella melitensis. For i.p.
infection, mice were injected with 500 µl intraperitoneally
without anesthesia.
Protocol for Secondary Infection With
Brucella melitensis
C57BL/6 mice were immunized intranasally (i.n.), intradermally
(i.d.) or intraperitoneally (i.p.) as indicated, with 2" 104 CFU of
live wild type B. melitensis. The infectious doses were validated by
plating serial dilutions of inoculums. 28 days after immunization,
the mice were given antibiotics for 15 days to clear the infection.
This oral treatment was a combination of rifampicin (12 mg/kg)
and streptomycin (450 mg/kg; adapted from Vitry et al. (20)]
prepared fresh daily and given in the drinking water. To ensure
that the antibiotic treatment was e!ective, some mice in each
group were sacrificed 1 week prior to the challenge and the
CFU counts were evaluated in the spleen. After resting for an
additional 15 days, the mice were challenged i.n., i.d. or i.p., as
indicated with 2 " 104 CFU of live mCherry-B. melitensis and
sacrificed at the indicated times.
Footpad Lesion Monitoring
The thickness of Brucella melitensis infected footpads was
measured regularly with a metric caliper, and corresponded to
the size of the footpad lesions.
Brucella melitensis Counting in Mice
At the selected time post infection, we collected 75 µl of
blood from the mice. They were then sacrificed by cervical
dislocation. Immediately after sacrifice, the spleen, liver (one
lobe), footpad, lung (left), mediastinal lymph node, thymus,
muscle (1 square cm of thigh muscle), heart, brain, tail
(2mm), ovary, popliteal lymph node (depending on the
experiment) were collected for bacterial counting. Tissues were
crushed and transferred to PBS/0.1% X-100 Triton (Sigma-
Aldrich). We performed successive serial dilutions in PBS to
obtain the most accurate bacterial count and plated them
on 2YT agar plates. The CFU were counted after 5 days of
culture at 37!C.
Cytofluorometric Analysis
The lungs were harvested and cut into small pieces. As
described previously (21), spleens and footpad lesions were
harvested, cut into small pieces and incubated for 1 h at 37!C
with a mix of 100µg/ml of DNAse I fraction IX (Sigma-
Aldrich) and 1.6 mg/ml of collagenase (400 Mandl U/ml).
The cells were then washed and filtered, and incubated with
saturating doses of purified 2.4G2 (anti-mouse Fc receptor,
ATCC) in 200 µl PBS, 0.2% BSA, 0.02% NaN3 (FACS bu!er)
for 20min at 4!C to prevent antibody (Ab) binding to the
Fc receptor.
3–5 " 106 cells were stained on ice with various fluorescent
mAb combinations in FACS bu!er. We acquired the following
mAbs from BD Biosciences: BV421-coupled T45-2342 (anti-
F4/80), BV421-coupled M1/70 (anti-CD11b), fluorescein
(FITC)-coupled 145-2C11 (anti-CD3!), FITC-coupled
30-F11 (anti-CD45), FITC-coupled M1/70 (anti-CD11b),
phycoerythrin (PE)-coupled HL3 (anti-CD11c), PE-coupled
1A8 (anti-Ly6G), allophycocyanin (APC)-coupled BM8
(anti-F4/80), biotin-coupled 2G9 (anti-MHCII, I-A/I-E).
Biotin-coupled APA5 (anti-CD140a/ PDGFRA) was purchased
from eBioscience. The biotin-coupled Abs were incubated
with streptavidin-coupled APC for 30min. The cells were
analyzed on a BD FacsVerse flow cytometer. Dead cells and
debris were eliminated from the analysis according to size
and scatter.
Fluorescence Microscopy of Brucella
melitensis in vitro
Brucella melitensis strains were observed with a Nikon 80i
(objective phase contrast " 100, plan Apo) connected to
a Hamamatsu ORCA-ER camera. For the observation of B.
melitensis, 2 µl of an exponential phase culture was dropped on
an agarose pad (solution of 1% agarose in PBS) and sealed with
VALAP (1/3 vaseline, 1/3 lanoline and 1/3 para"n wax). Images
were taken manually every 20min at 32 !C with NIS-Element
software (Nikon).
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Immunofluorescence Microscopy of Tissue
Spleens and lymph nodes were fixed for 2 h at RT in 2%
paraformaldehyde (PFA) (pH 7.4), washed in PBS, and incubated
overnight at 4!C in a 20% PBS-sucrose solution. Lungs were
fixed for 20min at RT in 2% PFA. Then, lungs were placed
under a vacuum until no air was present in the lungs in 2%
PFA for 2 h. After fixation, lungs were incubated overnight
at 4!C in a 20% PBS-sucrose solution. Tissues were then
embedded in Tissue-Tek OCT compound (Sakura), frozen in
liquid nitrogen, and cryostat sections (5µm) were prepared. For
staining, tissue sections were rehydrated in PBS and incubated in
a PBS solution containing 1% blocking reagent (Boeringer) (PBS-
BR 1%) for 20min before incubation overnight in PBS-BR 1%
containing any of the following mAbs or reagents: DAPI nucleic
acid stain Alexa Fluor 350, 488 phalloidin (Molecular Probes),
APC-coupled BM8 (anti-F4/80, Abcam), Alexa Fluor 647-
coupled M5/114.15.2 (anti-I-A/I-E, MHCII, BioLegend), Alexa
Fluor 647-coupled HL3 (anti-CD11c, BD Biosciences), biotin-
coupled 1A8 (anti-Ly6G, BioLegend), biotin-coupled APA5
(anti-CD140a/ PDGFRA, eBioscience). The biotin-coupled Ab
was incubated with streptavidin-coupled APC for 2 h. Slides were
mounted in Fluoro-Gel medium (Electron Microscopy Sciences,
Hatfield, PA). Labeled tissue sections were visualized with an
Axiovert M200 inverted microscope (Zeiss, Iena, Germany)
equipped with a high-resolutionmonochrome camera (AxioCam
HR, Zeiss). Images (1,384 " 1,036 pixels, 0.16 µm/pixel)
FIGURE 1 | Each route of infection leads to a specific pattern of infected organs. Wild-type C57BL/6 mice were intraperitoneally (i.p.), intranasally (i.n.), or
intradermally (i.d.) infected with a dose of 2 " 104 CFU of mCherry-B. melitensis and sacrificed at the indicated times. (A,B) The data represent the CFU count per ml
of blood or per spleen, as indicated. Gray bars represent the median. The significant differences between the indicated groups are marked with asterisks: *p < 0.1,
**p < 0.01, ***p < 0.001. (C) The individual kinetic CFU data are summarized in a matrix giving the median level of CFU (n = 7) by tissue according to the route of
infection. These results are representative of two independent experiments. h, hours; d, days; LN, lymph node; p.i., post infection; n, number of mice per group. (D)
Hypothetical model summarizing the spread of Brucella from the primary site of infection to the spleen for each route of infection.
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FIGURE 2 | The type of cells infected is dependent on the route of infection. Wild-type C57BL/6 mice (n = 5) were infected intraperitoneally (i.p.) (A), intranasally (i.n.)
(B), or intradermally (i.d.) (C) with a dose of 108 (A,B) or 107 (C) CFU of eFluor670 labeled B. melitensis and sacrificed at 2 and 24 h post infection. The spleen (A),
lung (B), or footpad lesion (C) were harvested and the cells were isolated and then analyzed by flow cytometry for the expression of eFluor670, CD45, F4/80,
CD140a, and CD11b as indicated. Numbers in blue indicate the percentage of eFluor670+ cells in each quadrant out of the total cells. These results are
representative of three independent experiments.
were acquired sequentially for each fluorochrome with A-
Plan 10x/0.25N.A. and LD-Plan-NeoFluar 63x/0.75N.A. dry
objectives and recorded as eight-bit gray-level !.zvi files. At least
3 slides were analyzed per organ from 3 di!erent animals and the
results are representative of 2 independent experiments.
Confocal Microscopy
Confocal analyses were performed using a LSM780 confocal
system fitted on an Observer Z 1 inverted microscope equipped
with an alpha Plan Apochromat 63x/1.46 NA oil immersion
objective (Zeiss, Iena, Germany). DAPI was excited using a
405 nm blue diode, and emission was detected using a band-
pass filter (410–480 nm). The 488 nm excitation wavelength
of the Argon/2 laser was used in combination with a band-
pass emission filter (BP500-535 nm) to detect Alexa Fluor 488
phalloidin. The 543 nm excitation wavelength of the HeNe1 laser
and a band-pass emission filter (BP580–640 nm) were used for
the red fluorochromemCherry. The 633 excitation wavelength of
the HeNe2 laser and a band-pass emission filter (BP660–695 nm)
were used for far-red fluorochromes such as APC. To ensure
optimal separation of the fluorochromes, blue & red signals
were acquired simultaneously in one track and green & far red
signals were acquired in a second track. The electronic zoom
factor and stack depth were adjusted to the region of interest
while keeping image scaling constant (x-y: 0.066 micron, z: 0.287
micron). A line average of 4 was used and datasets were stored
as 8-bit proprietary !.czi files. The images were displayed using
Zen2012 software (Zeiss) with linear manual contrast adjustment
and exported as 8-bit uncompressed !.TIF images. The figures,
representing single optical sections across the region of interest,
were prepared using the Canvas program.
Enzyme-Linked Immunosorbent
Assay (ELISA)
The presence of Brucella melitensis specific murine IgM, IgG1,
IgG2a, and IgG3 was determined by ELISA. As already described
(17), polystyrene plates (269620; Nunc) were coated with HK
B. melitensis (107 CFU/mL) and incubated overnight at 4"C. The
plates were blocked for 2 h at RT with 200 µl/well of PBS-3.65%
casein. Then, plates were incubated with 50 µl/well of plasma in
serial dilutions in PBS-3.65% casein. The plasma of uninfected
mice and PBS were used as negative controls and a 12B12 mAb
specific to Brucella LPS (34) was used as a positive control. After
four washes with PBS, isotype-specific goat anti-mouse HRP
conjugated Ab were added (50 µl/well) at appropriated dilutions
(anti-IgM from Sigma-Aldrich; LO-MG1-13 HRPO, LO-MG2a-
9 HRPO, and LO-MG3-13 HRPO from LOIMEX). After 1 h of
incubation at RT, plates were washed four times in PBS and 100
µl/well of substrate solution (BD OptEiA Kit) was added. After
15min of incubation at RT in the dark, the enzyme reaction was
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FIGURE 3 | Following intradermal infection with Brucella melitensis, fibroblasts, neutrophils, and macrophages were found to be infected in the footpad lesion.
Wild-type C57BL/6 mice were infected intradermally with a dose of 107 CFU of mCherry-B. melitensis. Mice were sacrificed at 24 h post infection and the footpad
lesions were collected and analyzed by confocal microscopy for the expression of mCherry and CD140a, LY6G, and F4/80 markers. The panels are color-coded with
the text for DAPI, the antigen examined or mCherry-Brucella. Scale bar = 5µm. Yellow arrowheads indicate the cells infected. The data are representative of two
independent experiments.
stopped by adding 25 µl/well of 2N H2SO4. The absorbance was
measured at 450 nm.
Statistical Analysis
We used a (Wilcoxon-)Mann-Whitney test provided by the
GraphPad Prism software to statistically analyse our results. Each
group of deficient mice was compared to the wild-type mice. We
also compared each group with the other groups and displayed
the results when required. Values of p < 0.05 were considered to
represent a significant di!erence. !, !!, !!! denote p < 0.05, p <
0.01, p < 0.001, respectively.
RESULTS
Each Route of Brucella Infection Is
Associated With a Specific Pattern of
Organ Infection
In order to determine the impact of the route of Brucella infection
on the pattern of infected organs in mice, we administered 2 "
104 CFU of mCherry-Brucella melitensis via i.p., i.n. or i.d. route
to wild-type C57BL/6 mice. Mice were bled for CFU counting in
the blood and then sacrificed at 1 h, 1, 5, 12, 28, and 50 days post
infection and a large number of organs and tissues were collected
(lung and draining mediastinal lymph node (LN), spleen, liver,
thymus, skeletal muscle of the thigh, heart, brain, fragment of
the tail, ovary, footpad lesion, and draining popliteal LN) and the
CFU count was measured by plating, as described in the Material
and Methods.
Our results, presented in Figures 1A,B and Figures S1, S2,
showed drastic di!erences between the pattern of tissues infected
via the i.p., i.n., and i.d. routes. A table providing an overview of
the individual kinetic CFU data with the average CFU by tissue
according to the route of infection is presented in Figure 1C.
As previously reported by us, CFU are not detectable in blood
following i.n. infection (21, 35) but are detectable following i.p.
and i.d. infection (Figure 1A). However, CFU in blood were 10–
100-fold lower following i.d. infection compared to i.p. infection.
Despite these di!erences, which led to very di!erent kinetics
and levels of spleen infection in the first 12 days of infection,
the spleen appears to be infected at almost comparable levels at
28 days post infection in all three models (Figure 1B). Several
interesting observations can be made based on Figure 1C which
summarizes our CFU data. They confirm that i.p. infection can be
considered as a systemic model of infection as all tissues collected
were found to be infected early and the majority of lymph nodes
tested were still infected at 50 days post infection (Figure S3).
In striking contrast, the i.n infection model produced a very
narrow infection pattern: only the mediastinal LN (draining the
lung) and spleen were infected persistently. The lung, liver, heart,
and brain were infected significantly but only transiently. The
i.d. infection model gave an intermediate infection pattern. The
skin footpad lesion, popliteal LN (draining the footpad lesion),
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FIGURE 4 | The essentiality of virB is dependent on the route of infection and organ. Wild-type C57BL/6 mice were infected intraperitoneally (i.p.) (A), intranasally (i.n.)
(B) or intradermally (i.d.) (C), with a dose of 2 ! 104 CFU of mCherry-B. melitensis or with mCherry-!virB B. melitensis. Mice were sacrificed at the indicated times.
The data represent the CFU count per lung, spleen, or footpad lesion. Gray bars represent the median. Significant differences between the indicated groups are
marked with asterisks: *p < 0.1, **p < 0.01, ***p < 0.001. These results are representative of two independent experiments. h, hours; d, days; n, number.
mediastinal LN, spleen, and liver were infected persistently.
Skeletal muscle and the brain were only infected transiently.
Importantly, we observed that Brucella persists over the long
term, until 50 days post infection, mainly in lymphoid tissues,
such as the LN and spleen, in all models and in the thymus in
the i.p. model. A proposed model for the spread of Brucella from
the primary site of infection to the spleen in the three models of
infection is presented in Figure 1D.
The Type of Cells Infected Depends on the
Route of Infection
In the past (30, 36), we have used a Brucella melitensis 16M
strain expressing the mCherry fluorescent tracer to detect
and phenotype Brucella infected cells in situ by fluorescent
microscopic analysis. However, this approach is very long and
is not appropriate for the quantitative analysis of many organs.
Flow cytometry analysis would be more suitable. Unfortunately,
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FIGURE 5 | The !virB B. melitensis strain multiplies differently depending on
the tissue. Wild-type C57BL/6 mice were infected intraperitoneally (i.p.) (A),
intranasally (i.n.) (B) or intradermally (i.d.) (C), with a dose of 107 CFU of
eFluor670 labeled mCherry-B. melitensis or with eFluor670 labeled
mCherry-!virB B. melitensis. Mice were sacrificed at the indicated times and
the spleen, lung or footpad was harvested, fixed and analyzed by fluorescent
microscopy. The data represent the percentage of eFluor670 negative bacteria
among mCherry positive bacteria. Bars represent the standard deviation.
Significant differences between the indicated groups are marked with
asterisks: **p < 0.01, ***p < 0.001. These results are representative of two
independent experiments with 3 mice per condition. h, hours; n, number of
bacteria analyzed in each condition.
in the absence of an available yellow laser, the fluorescence of the
mCherry-Brucella strain is too low to permit the direct detection
of infected cells by flow cytometry. To avoid this technical
problem, we developed a protocol using the dye eFluorTM 670
(eFluor670) that produces intense fluorescent staining of the
bacterial cell wall. Brief incubation of bacteria with eFluor670
leads to intense, stable and homogeneous staining of Brucella that
FIGURE 6 | !virB B. melitensis actively multiplies in the footpad lesion.
Wild-type C57BL/6 mice were infected intradermally (i.d.) with a dose of 107
CFU of eFluor670 labeled wild-type or !virB mCherry-B. melitensis. Mice were
sacrificed at 24 h post infection and the footpad was harvested, fixed, and
analyzed by confocal microscopy. (A,B) show representative images for
wild-type or !virB mCherry-B. melitensis, respectively. The panels are
color-coded with the text for DAPI, Phalloidin, mCherry, and eFluor670. Scale
bar = 5µm. pos, positive; neg, negative.
can be detected by flow cytometry (Figure S4A. This staining
does not negatively a!ect Brucella growth in vitro in a rich
medium culture (Figure S4B) or in mice in the i.n (Figure S4C)
and i.p. infection models (Figure S4D).
As shown in Figure 2, eFluor670 staining allowed for
rapid flow cytometric detection and quantification of Brucella
infected cells present within tissues harvested at 2 and 24 h
from infected mice. Our data confirm that, as previously
reported by microscopic analysis, infected spleen cells in
the i.p. model (30) (Figure 2A) and infected lung cells in
the i.n. model (37) (Figure 2B) are mainly CD45+ F4/80+
myeloid cells, presumably red pulp macrophages and alveolar
macrophages, respectively. In striking contrast, the same analysis
of footpad lesion cells from the i.d. infection model showed
that two clearly distinct cell populations, CD45neg and CD45+,
are infected by Brucella (37) (Figure 2C). Infected CD45neg
cells express high levels of the CD140a fibroblast marker
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FIGURE 7 | Intradermally infected IFN!R and TNFR1!/! mice display
significant footpad swelling and CFU counts. Wild-type, IL12p35!/!,
IFN!R!/!, IL-17RA!/!, and TNFR1!/! C57BL/6 mice were infected
intradermally with a dose of 2 " 104 CFU of mCherry-B. melitensis. (A) At the
indicated time post infection, the swelling of the lesion was measured for each
mouse. The error bars are the SD. (B) At the indicated times, mice were
sacrificed and the footpad, draining popliteal lymph node, and spleen were
harvested. The data represent the CFU count per organ. Gray bars represent
the median. The significant differences between the indicated groups are
marked with asterisks: **p < 0.01, ***p < 0.001. These data are representative
of two different experiments. d, days; n, number; LN, lymph node.
and infected CD45+ cells express CD11b myeloid markers
(Figure S5), which can be subdivided into CD11b+ F4/80+
Ly6Gneg/med and CD11b+ F4/80neg/med Ly6Ghigh (Figure S6).
Confocal microscopic analysis of footpad samples collected
at 24 hours from infected mice demonstrated that CD140+,
Ly6G+, and F4/80+ cells are indeed infected and display
typical morphology of fibroblasts, neutrophils, and macrophages,
respectively (Figure 3).
On the whole, these data showed that the type of cells infected
by Brucella is strongly dependent on the route of infection.
Although the infected cells are mainly macrophages in the i.p.
and i.n. models, fibroblasts, and neutrophils are also infected in
the i.d. model.
Identification of Virulence Factors Is
Affected by the Route of Infection and
Organ Analyzed
In the rational development of LAVs, it is essential to identify
virulence factors allowing for escape from the immune response
and persistence in the host. LAVs must be able to establish
infection in order to stimulate an adaptive immune response
without persisting or disseminating deeply in the host. The most
studied virulence factor in Brucella is undoubtedly the virB T4SS.
In vitro in RAW 264.7 macrophages, a !virB Brucella strain is
unable to escape the phagolysosome system and appears to be
highly attenuated (38).
In order to determine the impact of the route of infection on
the type of virulence factors required to establish a successful
infection in vivo, we compared the course of wild-type and
!virB Brucella strains in wild-type C57BL/6 mice (Figure 4).
As previously described (39), the !virB Brucella strain appears
attenuated but able to persist for several weeks in the spleen in
the i.p infection model (Figure 4A). In this model, we observed
that the !virB Brucella strain is also attenuated in the lung. It
persists at#100 CFU between 2 h and 5 days post infection and is
no longer detectable from 28 days. In striking contrast, in the i.n.
model (Figure 4B), the !virB Brucella strain appears completely
unable to multiply in the lung and reach the spleen. In the lung,
the number of CFU drops by 3 log between 2 h and 5 days post
infection. A complemented !virB strain recovers the ability to
multiply in the lung, demonstrating that the inability of the!virB
strain to persist in the lung is specific and related to the virB
deficiency only (Figure S7). More surprising, in the i.d. model,
the !virB strain persists longer in the primary footpad lesion
than the wild-type Brucella strain. At 50 days post infection, the
!virB strain is still present in the footpad while the wild-type
strain has already disappeared at 28 days (Figure 4C). In the
spleen, the !virB strain remains attenuated (Figure 4C).
The di!ering behavior of the!virB strain observed depending
on the route of infection and the tissue may be due to a
di!erence in the ability to actively multiply or to passively
persist (i.e., persistence without multiplication). Brucella has
been widely described to display atypical unipolar growth (40).
Unlabelled daughter cells can be visualized upon the resumption
of growth following staining of the bacteria with Texas red
conjugated to succinimidyl ester (TRSE) (41). Here, we chose
to replace TRSE with eFluor670 staining, which is compatible
with the mCherry Brucella strain. Thus, newly formed bacteria,
called “newborn” bacteria, appear as mCherry+ eFluor670neg
(Figure S8A). We confirmed by fluorescence microscopy the
stability and absence of transfer of eFluor670 staining during
Brucella growth and division in vitro (Figure S8B). Using this
tool, we tried to quantify multiplication of the wild-type and
!virB Brucella strains in situ. Mice were infected by i.p., i.n.
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FIGURE 8 | IFN!R deficiency leads to the massive recruitment of neutrophils in dermal tissue. Wild-type, IFN!R!/!, IL-17RA!/!, and TNFR1!/! C57BL/6 mice
were infected intradermally with a dose of 2 " 104 CFU of mCherry-B. melitensis. Control wild-type mice were injected with PBS. Mice were sacrificed at 3 days post
infection and the footpad was harvested and analyzed by fluorescent microscopy. The panels are color-coded with the text for DAPI, phalloidin, mCherry-B.melitensis,
and LY-6G. Scale bar = 100µm. These data are representative of two different experiments.
or i.d. route with eFluor670-stained wild-type mCherry-B and
!virB mCherry-expressing Brucella strains. 24 and 48 h later,
mice were sacrificed and the organs of interest were harvested
and analyzed by confocal microscopy. Figures 5A–C show
the frequencies of mCherry+ eFluor670neg (newborn) bacteria
among the mCherry+ bacteria in the spleen, lung and footpad
lesion at 24 and 48 h post infection from i.p., i.n., or i.d. infected
mice, respectively. Figure 6 presents representative images from
infected footpads. As expected, wild-type Brucella appears able to
multiply in all tissues analyzed based on the abundant presence of
mCherry+ eFluor670neg newborn bacteria at 48 h post infection.
The frequency of newborn Brucella in the spleen from wild-type
and !virB Brucella infected mice was similar (Figure 5A). In
contrast, the frequency of newborn Brucella in the lung from
!virB Brucella infected mice is strongly reduced (#15 times)
compared to wild-type Brucella infected mice (Figure 5B). In
the footpad lesion, the situation appears to be intermediate. The
frequency of newborn Brucella from!virB Brucella infectedmice
is only reduced by#2-fold. These results suggest that the absence
of persistence of !virB Brucella in the lung is due to a reduced
ability to multiply and that persistence in the spleen and footpad
lesion is associated with active multiplication.
We can conclude that the impact of virB deficiency appears
vary widely as a function of the route of infection and organ
analyzed, suggesting that the identification of virulence factors
could be strongly impacted by these parameters.
In the next part of this article, we will focus on the impact
of the route of infection on the type of immune response
and lymphocyte populations involved in primary and secondary
control of Brucella melitensis infection.
Th1 Immune Response Is Crucial to
Control of the Primary Cutaneous
Brucella Infection
To our knowledge, the type of immune mechanism underlying
cutaneous Brucella infection has never been investigated in a
mouse model. As reported in i.p. (42) and i.n. (21) infectious
models, BALB/c mice appear to be more susceptible to cutaneous
B. melitensis infection compared to C57BL/6 mice (Figure S9).
In order to identify the T helper subset of immune response
associated with Brucella control in skin lesions, we compared




!/!, IL-17RA!/!, and TNFR1!/! C57BL/6 mice.
We observed that Brucella infection in wild-type and IL-
17RA!/! mice leads to moderate footpad lesions at 3 days post
infection that disappeared spontaneously at 7 days (Figure 7A).
The lesions persisted longer in IL-12
!/!
p35 mice, but regressed
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FIGURE 9 | Impact of CCR2 and CCR7 deficiency on the course of
intradermal Brucella infection. Wild-type, CCR2!/!, and CCR7!/! C57BL/6
mice were infected intradermally with a dose of 2 " 104 CFU of B. melitensis
and sacrificed at the indicated times. The data represent the CFU count per
organ. Gray bars represent the median. The significant differences between
the indicated groups are marked with asterisks: *p < 0.1, **p < 0.01, ***p <
0.001. These results are representative of three independent experiments. LN,
lymph node; d, days; n, number.
spontaneously at 14 days. In striking contrast, lesions in
IFN!R!/! and TNFR1!/! mice displayed uncontrolled growth
until 14 days (Figure 7A) and become necrotic (data not
shown). Growth and necrosis of the lesion were higher in
IFN!R!/! mice. The severity of the footpad lesion in all
groups of mice appeared to be closely correlated with the
corresponding CFU level (Figure 7B). We have previously
reported (21) a dramatic di!erence between IL-12
!/!
p35 and
IFN!R!/! mice in control of a Brucella infection in the i.n.
infection model. In this model, IFN!R!/! mice, but not IL-
12
!/!
p35 mice, display severe neutrophilia and succumb to the
infection, suggesting that this lack of control and mortality result
from the complete absence of IFN-! and are not proportional to
its level.
Fluorescent microscopic analysis of the footpad lesion at 3
days in wild-type, IL-17RA!/! and TNFR1!/! infected mice
showed a moderate presence of neutrophils, identified by Ly-
6G staining (Figure 8). In contrast, the dermis of the lesion
from infected IFN!R!/! mice displayed very intense neutrophil
recruitment. This was confirmed by flow cytometric analysis of
the footpad lesion (Figure S10A). In wild-type mice, Brucella
infection led to the recruitment of CD11b+ F4/80+ Ly6Gneg
monocytes that peaked at 7 days post infection with only
moderate recruitment of CD11b+ F4/80neg Ly6G+ neutrophils.
In infected IFN!R!/! mice, neutrophils constituted the major
population in the footpad lesion and the frequency of monocytes
appeared to be strongly reduced (Figure S10B).
As our microscopic analysis showed that F4/80+
monocytes/macrophages appear to be infected by Brucella
in the skin of i.d. infected mice (Figure 3) and their recruitment
is correlated with the control of Brucella (Figure S10B), we
investigated the impact of chemokine receptor CCR2 and CCR7
deficiency on Brucella control in our i.d. infection model.
Monocyte emigration from bone marrow during bacterial
infection requires signals mediated by CCR2 (43) but seems to
be dispensable for the maintenance of dermal macrophages and
dendritic cells (44). In contrast, CCR7 regulates the migration
of inflammatory monocytes (45), and dendritic cells (46) from
skin to the draining lymph node under inflammatory conditions.
We observed that i.d. infected CCR2!/! mice display delayed
monocyte recruitment and a higher rate of neutrophils at 7 days
post infection in the footpad lesion (Figure S10B) associated
with an increased CFU count in the footpad lesion, popliteal
draining LNs, and spleen (Figure 9), confirming the importance
of monocyte recruitment in the local and systemic control of
Brucella infection. Interestingly, CCR7 deficiency led to retention
of Brucella in the lesions and seemed to delay its dissemination
to the popliteal draining LNs and spleen, suggesting that Brucella
dissemination is partially dependent on monocyte and dendritic
cell migration. In agreement, flow cytometry analysis of footpad
lesions and popliteal draining LNs from mice i.d. infected with
eFluor670+ bacteria showed that, while the eFluor670+ cells
in the lesion are mainly CD11c and MHCII negative, they
are mostly positive in the LNs (Figures 10A–C). Interestingly,
the frequency of CD11c+ MHCII+ infected dendritic cells is
drastically reduced in CCR7!/! mice compared to wild-type
mice (Figure 10C).
Finally, using a battery of genetically-deficient C57BL/6 mice,
we investigated the role of lymphoid populations in the control
of i.d. Brucella melitensis infection. Comparison of the course of
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FIGURE 10 | CCR7 deficiency reduced the frequency of infected dendritic cells in popliteal draining lymph nodes. Wild-type and CCR7!/! C57BL/6 mice were
infected intradermally with a dose of 107 CFU of eFluor670+ labeled B. melitensis and sacrificed at 24 h post infection. The footpad lesion and the popliteal draining
lymph nodes were harvested and the cells were isolated and then analyzed by flow cytometry for the expression of eFluor670, MHCII, and CD11c as indicated. The
data represent the frequency of eFluor670+ cells in cells from footpad lesions (A) and popliteal draining lymph nodes (B) and the phenotype of eFluor670+ cells in
these tissues (C). Percentage indicates the percentage of cells in each quadrant out of the total cells (A,B) or of the eFluor670+ cells (C). LN, lymph node. These
results are representative of three independent experiments.
Brucella infection in wild-type, CD3!/! (deficient for T cells),
TCR-!!/! (deficient for "!T cells), TCR-#!/! (deficient for both
CD4+T and CD8+T cells), MHCII!/! (deficient for CD4+T
cells), TAP1!/! (deficient for CD8+Tcells), and MuMT!/!
(deficient for B cells) mice showed that CD4+T cells are strictly
required for Brucella control in the footpad lesion and popliteal
draining lymph node (Figure 11). Interestingly, CD4+T cells
appear to be dispensable in the spleen, as only CD3 and TCR-#
deficiency negatively impaired Brucella control there. CD8+T cell
deficiency significantly favored Brucella control in the draining
lymph node but not in the lesion or spleen. This may be the
consequence of the higher number of CD4+T cells in absence
of CD8+T cell in TAP1!/! mice. In a previous study (47), we
demonstrated that even though the amounts of IFN-" produced
by CD8+T cells and CD4+T cells are similar, CD8+T cells
are unable to replace CD4+T cells in their control of Brucella
infection, suggesting that CD4+T cells deploy as yet unidentified
e!ector mechanisms that may be independent of IFN-". In
the i.d. infection model, "!+T cells appeared to be dispensable
for the control of i.d. Brucella infection. Despite the detectable
humoral response (Figure S11A), similar to that observed in the
i.p. infection model (Figure S11B), B cells also appeared to be
dispensable. However, though the finding was not statistically
significant, we did observe a repeated tendency of MuMT mice
to display increased CFU counts in draining lymph nodes at 50
days post infection (Figure 11).
Taken together, our data demonstrate that the control of
primary cutaneous Brucella infection mainly required an IFN-"-
mediated Th1 response, TNF-$ production and CD4+ T cells but
not an IL-17RA-mediated Th17 response. They also show that
monocyte recruitment plays a crucial role in both the control and
dissemination of cutaneous Brucella infection.
The Type of Immune Response Controlling
Secondary Brucella Infection Is Dependent
on the Route of Infection
In order to establish the main features of the protective immune
response induced by i.d. Brucella infection, we started by
comparing the course of i.d. mCherry-B. melitensis infection in
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FIGURE 11 | Impact of various lymphocytes deficiencies on the course of intradermal Brucella infection. Wild-type, CD3!/!, TCR!"!/!, TCR#$!/!, MHCII!/!,
TAP1!/!, and MuMT!/! C57BL/6 mice were infected intradermally with a dose of 2 " 104 CFU of B. melitensis and sacrificed at the indicated times. The data
represent the CFU count per organ. Gray bars represent the median. The significant differences between the indicated groups are marked with asterisks: *p < 0.1,
**p < 0.01, ***p < 0.001. These results are representative of three independent experiments. LN, lymph node; d, days; n, number.
naive mice (primary infection group) and in mice previously i.d.
infected with wild-type-B. melitensis for 28 days and then treated
with antibiotics (secondary infection group), as described in the
Material and Methods.
Antibiotic treatment is indispensable to the comparison of
wild type and genetically deficient mice. It is well known that the
persistence of a pathogen generates chronic inflammation and
can cause a “Mackaness e!ect”(48, 49). Without antibiotics, the
level of persistence of the vaccine strain would be very di!erent
between wild-type mice and mice deficient for key components
of the immune response against Brucella, which would make our
results very di"cult to interpret. It has been reported that Rev1
infection in sheep (50, 51) and rams (52) is fully cleared between
the second and third month after subcutaneous or conjunctival
vaccination. Thus, by eliminating the primary infection at 28
days in our experimental model, we are not so far away from the
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FIGURE 12 | Comparison of protection in control mice and mice previously immunized with live B. melitensis. C57BL/6 mice were immunized intradermally (i.d.) with
2 ! 104 CFU of live wild type B. melitensis and treated with antibiotics, as described in the Materials and Methods. Naive (primary infection group) and immunized
(secondary infection group) mice were challenged i.d. with 2 ! 104 CFU of live mCherry-B. melitensis and sacrificed at the indicated times. The data represent the
CFU count per organ or per ml of blood. Gray bars represent the median. Significant differences between the indicated groups are marked with asterisks: *p < 0.1,
**p < 0.01, ***p < 0.001. These results are representative of three independent experiments. LN, lymph node; d, days; h, hours; n, number.
conditions of the natural host vaccinated with the reference Rev1
vaccine against Brucella melitensis.
Our results (Figure 12) demonstrated that i.d. infection leads
to the development of an adaptive immune response able to
e!ciently control secondary i.d. infection in the footpad lesion,
blood, popliteal draining lymph node and spleen. It is interesting
to note that while Brucella is almost completely eliminated in
the footpad lesion, blood, and spleen, it nevertheless persists at
a significant level in the lymph nodes, suggesting that it may be
sheltered from the adaptive immune response at this site.
The type of immune mechanism required for the protective
secondary immune response appears to be dramatically
dependent on the tissue analyzed. As shown in genetically-
deficient mice, e"ective control in the footpad lesion is
dependent on TNFR1 and IL-17RA but not IL-12p35 and,
in the spleen, is dependent on TNFR1 but not IL-17RA and
IL-12p35. In the popliteal lymph node, the absence of IL-12p35,
IL-17RA, or TNFR1 does not have a significant impact on the
CFU count (Figure 13). Similarly, only CD4+T cells, and no
other lymphoid populations, are essential to control Brucella
in the footpad lesion, but CD4+T cells are dispensable in the
popliteal draining lymph node and spleen. In the spleen, B cells
are strictly required but only the absence of all T cells in CD3"/"
mice leads to a significant loss of Brucella control, suggesting
that the absence of a T cell subpopulation can be compensated
for by the other subpopulations in this organ. Unexpectedly,
the absence of T cells in CD3"/" mice, and especially of
CD8+T cells in TAP1"/" mice, improved the control of Brucella
in popliteal draining lymph nodes, suggesting that Brucella
persistence there implicates CD8+T cells (Figure 14). Regulatory
CD8+CD122+PD-1+T cells, which are located in lymph nodes
and act in a non-antigen-specific manner, have been described
in persistent viral infection (53, 54). These cells have not been
described in a Brucella model but could be responsible for
this phenomenon.
It would also have been interesting to test the ability of
IFN-!R"/" mice to develop a protective memory response
against Brucella. However, these mice develop highly necrotic
footpad lesions and, for ethical reasons, we therefore limited our
observations of these mice to 14 days post infection.
Lastly, to summarize the impact of the route of infection on
the type of protective immune memory response, we compared
the results obtained in the i.d. infection model with those
obtained by our group in the i.p. (20) and i.n. (21) infection
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FIGURE 13 | Comparison of protection in wild-type and various deficient mice
previously immunized by intradermal route with live B. melitensis. Wild-type,
IL-12p35!/!, TNFR1!/!, IL-17RA!/! C57BL/6 mice were immunized
intradermally (i.d.) with 2 " 104 CFU of live wild-type B. melitensis and treated
with antibiotics, as described in the Materials and Methods. Naive (primary
infection group) and immunized (secondary infection group) mice were
challenged i.d. with 2 " 104 CFU of live mCherry-B. melitensis and sacrificed
at 12 days post infection. The data represent the CFU count per organ. Gray
bars represent the median. The significant differences between the indicated
groups are marked with asterisks: *p < 0.1, **p < 0.01. These results are
representative of three independent experiments. LN, lymph node; n, number.
FIGURE 14 | Comparison of protection in wild-type and various
lymphocyte-deficient mice previously immunized by intradermal route with live
B. melitensis. Wild-type, CD3!/!, TCR!"!/!, TCR#$!/!, MHCII!/!,
TAP1!/!, and MuMT!/! C57BL/6 mice were immunized intradermally (i.d.)
with 2 " 104 CFU of live wild-type B. melitensis and treated with antibiotics, as
described in the Materials and Methods. Naive (primary infection group) and
immunized (secondary infection group) mice were challenged i.d. with 2 " 104
CFU of live mCherry-B. melitensis and sacrificed at 12 days post infection. The
data represent the CFU count per organ. Gray bars represent the median. The
significant differences between the indicated groups are marked with
asterisks: **p < 0.01, ***p < 0.001. These results are representative of three
independent experiments. LN, lymph node; n, number.
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models (Figure 15). Note that the requirements were completed
in the i.p. model to allow for a full comparison with other
models (Figure S12). Figure 15 shows clearly that the type
of lymphoid cells and T helper response required to control
secondary Brucella infection is strongly dependent on the route
of infection and the tissues infected. For example, CD4+T
cells are indispensable in the footpad lesion in the i.d. model
and in the spleen in the i.p. model but are dispensable in
the spleen level in both the i.d. and i.p. models. B cells are
indispensable in the i.d. and i.p. models but dispensable in the
i.n. model. The IL-12p35 dependent Th1 response is only required
in the spleen in the i.p. model and in the footpad lesion in
the i.d. model. It is dispensable in the i.d. and i.n. models in
the spleen. Thus, we can conclude that the identification of
immune markers associated with protection against infection
is strongly a!ected by the route of infection used and the
organ analyzed.
DISCUSSION
There are well-documented cases in which generalization of use
of a new drug favors, in just a few decades, the development
of resistance leading to treatment failure [reviewed in Zur
Wiesch et al. (55)]. This problem has become so acute that drug
resistance is viewed as one of the major challenges in public
health, reinforcing the importance of vaccines in the control
of epidemics.
Historically, highly successful global vaccination campaigns
have been associated with the administration of live-attenuated
vaccines (LAVs) (1). Today, modern vaccination strategies focus
mainly on the use of subunit vaccines (SUVs) with an adjuvant
(56–58). Compared to LAVs, SUVs o!er several advantages:
(i) their supposed safety because they exclude all risks of
reversion of attenuated pathogens to a virulent form, (ii) their
high specificity limiting the risk of autoimmune diseases, and
(iii) the ease to produce, conserve, and transport them. But
the benefits of SUVs hide some weaknesses. In addition to
their classical antigen- or target-specific protective e!ects, LAVs
can induce non-specific protective e!ects. Epidemiological data
suggest that vaccination with smallpox, measles, BCG or oral
polio vaccines results in increased overall childhood survival
[reviewed and discussed in Benn et al. (59) and de Bree et al.
(60)]. These observations can be partially explained by the
poly-specificity of antigenic T and B receptors, the Mackaness
e!ect and the induction of innate immune memory (trained
immunity) (61). SUVs drive immune responses against a reduced
number of dominant antigens and are associated with a modern
adjuvant selected for its low inflammatory potential. Because
this design reduces the possibilities of TCR and BCR-mediated
cross-protection and a short-lived, low level of activation of
innate immune response, it limits the possibility of non-specific
protection. More importantly, vaccine resistance, although rare,
is now well-documented for several SUVs (62). This seems
mainly due to single mutational events, suggesting that small
variations of pathogens can allow them to escape to sharp antigen
selection pressure generated by SUVs. These weaknesses of SUVs,
combined with the growth of antibiotic resistance, could in the
near future leave us extremely helpless in the face of epidemics.
One solution to this problem is the rational development
of second-generation LAVs retaining the e"ciency of first-
generation LAVS but compatible with current safety standards.
This goal is achievable thanks to our better understanding of
the genetics of microorganisms. However, we lack a rigorous
methodology for selecting candidate vaccines in animal models.
Ideally, an e!ective and safe LAV should induce strong
and adapted mucosal and systemic immunity against the
target pathogen, without persisting or disseminating in the
host. This requires, in particular, that the natural niche
of pathogen persistence, the virulence genes necessary for
pathogen persistence and the immune markers associated with
the protective memory state be identified. The vast majority
of studies attempting to identify these factors in animal
experimental models are carried out using a single route of
infection. Often, for historical or convenience reasons, a single
route of infection is considered as the reference. In the case
of studies to select candidate vaccines against Brucella in mice
models, the reference is the intraperitoneal (i.p.) route (63)
that leads to a rapid systemic infection. Rare studies use the
more physiological intranasal (i.n.) or oral infection routes.
The purpose of the present study was to highlight the impact
of the route of infection on the identification of infection
niches, virulence genes and immune markers associated with
the development of a protective immune memory in the
Brucellamodel.
We took advantage of the fact that we have already studied
the reservoir of infection and the type of protective immune
response in the i.p. (19, 20, 30) and i.n. (21, 36) Brucella infection
models. In order to include a third model of infection in our
comparison, we developed and characterized an original model
of intradermal (i.d.) infection in this study. Contamination by
cutaneous route is not the most common for Brucella, but it is
however well-documented in certain occupational groups (13–
15).We have chosen to characterize this route, rather than amore
common type of Brucella contamination such as the oral route,
because of its technical simplicity and because a large number
of vaccines are given subcutaneously, including some Brucella
vaccines in animals.
We observed that, following i.d. infection, Brucella
disseminates immediately into the spleen and liver through
the bloodstream and reaches the popliteal draining LNs in
24 h. Brucella is detected later in the mediastinal lymph nodes,
muscles, and brain. At 50 days post infection, Brucella persists
only in the spleen and LNs. As expected, control of the primary
cutaneous infection requires a functional IL-12p35/IFN! axis,
TNF", as well as CD4+T cells. CD8+ T cells, !#+T cells, B cells
and IL-17RA deficiencies appear to be dispensable. Thus, the
i.d. model seems to be similar to the i.p. model (19). It di!ers
strongly from the i.n. infection model which requires !#+T cells
and IL-17RA to control Brucella during the early phase of lung
infection (21).
The i.d. model is characterized by recruitment of monocytes
and neutrophils at sites of skin infection in association with
transitory moderate swelling. A deficiency of CCR2 results in a
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FIGURE 15 | Summary of the immune response components indispensable to the control of secondary Brucella infection as a function of the route of infection.
Wild-type, CD3!/!, TCR!"!/!, TCR#$!/!, MHCII!/!, TAP1!/!, MuMT!/!, IL-12p35!/!, and IL-17RA!/! C57BL/6 mice were infected intradermally (i.d.),
intranasally (i.n.) or intraperitoneally (i.p.) with 2 " 104 CFU of live wild-type B. melitensis and treated with antibiotics, as described in the Materials and Methods. Naive
(primary infection group) and immunized (second infection group) mice were challenged i.d., i.n., or i.p. with 2 " 104 CFU of live mCherry-B. melitensis and sacrificed
at 12 days post infection (for i.d.) or 28 days post infection (for i.n. and i.p.). The data represent a qualitative approximation of the CFU count per organ in the present
article (i.d. model and Figure S8 for i.p. model) or in our group’s previous article characterizing the i.p. (20) and i.n. (21) models. The CFU counts of mice which do not
control the secondary infection are in red. “/”, not tested. Note that “Th1 or Th17” indicates that the Th1 response can compensate for the absence of the Th17
response and vice versa.
delay in the recruitment of monocytes and a transitory lack of
Brucella control at the cutaneous lesion and popliteal draining
LN. IFN#R deficiency also reduces monocyte recruitment and
is associated with a strong influx of neutrophils in the footpad
lesion, development of necrosis and a high CFU count in the
lesion, LN, and spleen. In contrast, as previously reported by
us (21), in the i.n. Brucella infection model, monocyte and
neutrophil recruitment is not observed in the lung and CCR2
deficiency does not a!ect the control of infection. Interestingly,
in the i.d. model, CCR7 deficiency leads to a significant reduction
of the spread of Brucella from the footpad lesion to the draining
LN and the spleen at 1 and 3 days post infection, and an
important increase in the number of bacteria in the cutaneous
lesion at 7 and 14 days. Taken together, our data suggest that
recruited monocytes play a key role in the control of Brucella
in the i.d. model. They also suggest that dissemination of
Brucella from the primary lesion to the draining LN and spleen
could implicate CCR7-dependent cell migration. In agreement,
Archambaud et al. (37) have shown that Brucella can migrate
from the lung to draining LNs by infecting dendritic cells and
alveolar macrophages.
An original and surprising observation in the i.d. infection
model is the inability of the protective memory response
to prevent establishment of Brucella in popliteal draining
lymph nodes. The memory response eliminates Brucella in the
cutaneous lesion, blood, and spleen, but fails to control Brucella
in the draining LN, suggesting that there is a special reservoir
protecting Brucella in this tissue. These LN reservoir cells should
be better characterized, as von Bargen et al. (64) reported that LNs
constitute the first site of Brucella infection and multiplication
during oral infection in mice and humans. Unfortunately, in
our i.d. model, the low CFU counts in LNs at later times of
infection did not allow us to analyse the LN reservoir cells by
flow cytometry and made it very di"cult to visualize them by
fluorescence microscopy.
By comparing i.p., i.n., and i.d. models, we observed that
the host-pathogen relationship is strongly a!ected by the route
of infection.
Frontiers in Immunology | www.frontiersin.org 17 July 2019 | Volume 10 | Article 1589
Demars et al. Immune Responses Against Brucella Infection
First, the pattern of tissue infection appears to vary widely
depending on the route of infection. The i.p. route of infection
leads to immediate systemic dissemination of Brucella to all
tissues tested. In contrast, i.n. infection displays a more restricted
pattern of infected tissues, including mainly the lung, mediastinal
draining LNs and spleen. The i.d. model presents an intermediate
pattern, with systemic dissemination to the spleen and liver and
localized strong persistence of Brucella in the cutaneous lesion
and popliteal draining LNs. The impact of the route of infection
on the spread of bacteria has already been documented by
whole body imaging inmice with radiolabelled or bioluminescent
bacteria. However, only high bacteria levels in tissues is detected
by this approach. Consequently, high doses of bacteria need to
be administered and weakly infected organs are not identified.
In the Francisella model (65), 2 ! 109 radiolabelled bacteria
were administrated and their dissemination was only monitored
until 20 h post infection. Inmodels using bioluminescent Brucella
melitensis (66) and Brucella suis (67), 1! to 2.5 ! 107 bacteria
were injected. In the spleen of mice infected with 2.5 ! 107
CFU of B. melitensis, no bioluminescence was detected despite
the detection of 4.8 ! 103 CFU by plating (66), confirming the
very poor sensitivity of bioluminescence detection. In contrast,
though time-consuming, our classical approach based on the
plating of select tissues detects up to 10 bacteria per tissue and
allows us to use a moderate dose of infection, 2 ! 104 CFU
per mouse. Our results showed that, at 50 days post infection,
Brucella persists mainly in lymphoid organs, such as the spleen
and LNs in the three models, but also in the thymus in the i.p.
model. However, our goal here was not to identify all possible
Brucella persistence sites in mice and Brucella may persist in
other tissues, such as the bone marrow as recently described (68).
Second, using eFluor670 labeled Brucella, we demonstrated
that the type of cells infected first depends on the route of
infection. As previously observed, we confirmed that the main
cells infected in the lung of i.p. and i.n. infected mice at 2
and 24 h post infection were F4/80+ red pulp macrophages (30)
and alveolar macrophages (37), respectively. Surprisingly, we
observed that, in addition to F4/80+ monocytes/macrophages,
Ly6G+ neutrophils and CD45neg CD140a+ fibroblasts also
appear to be infected in the footpad lesion of i.d. infected wild-
type mice. Brucella-infected neutrophils have been described
in pathological conditions (69). To our knowledge, this is the
first description of Brucella-infected fibroblasts in vivo in wild-
type mice. Infection by Brucella of neutrophil and fibroblasts
in the footpad lesions was confirmed by confocal microscopy.
The infection of di!erent cell types can have a significant impact
on the persistence of Brucella. It has been observed in vitro
that the intracellular tra"cking of Brucella is dependent on the
type of cells infected. For example, Brucella abortus replicates
in a vacuole derived from the LAMP1neg endoplasmic reticulum
in epithelial cells, macrophages and dendritic cells, although in
extravillous trophoblasts it replicated within single-membrane
acidic LAMP1pos inclusions (70).
Third, we observed that the route of infection a!ects the
identification of a major virulence gene. The !virB Brucella
strain, known to be attenuated in the i.p. infection model but
able to persist for several weeks in the spleen (39), is unable
to persist beyond 48 h in the lung in the i.n. infection model
but, surprisingly, persists longer than the wild-type strain in
cutaneous lesions in the i.d. infection model. This unexpected
result is probably due in part to the di!erent type of cells
infected. It has been reported that !wadC (unable to encode
LPS core glysosyltransferases) Brucella abortusmultiplies in bone
marrow-derived macrophages, RAW264.7 macrophages or HeLa
cells but is killed in bone marrow-derived dendritic cells (71).
Microscopic analysis showed that the !virB Brucella melitensis
strain multiplies very weakly in alveolar macrophages, "15-fold
less than the wild type strain. In striking contrast, it multiplies at
the same level as the wild-type strain in splenic macrophages and
at an intermediate level in dermal cells,"2-fold less than the wild
type strain. This slightly lower multiplication rate of the !virB
Brucella strain in the footpad lesion may make Brucella more
stealthy and thus less detectable by the immune system and able
to persist longer than the wild type strain. Taken together, our
data lead us to conclude that a bacterial strain can be considered
as attenuated or not depending on the route of infection and the
tissues analyzed.
Fourth, we demonstrate that the route of infection also a!ects
the identification of immunemarkers associated with a protective
memory response. As summarized in Figure 15, which compares
the results obtained in this article in the i.d. infection model as
well as those obtained previously by us in the i.p. (20) and i.n.
(21) infection models, Brucella control in the spleen in challenge
conditions required di!erent lymphocyte subsets and T helper
responses depending on the route of infection. Control in the
i.p. model appears to be dependent on IL-12p35, CD4+T cells
and B cells (20). In the i.n. model, only !"+T cells appear
to be strictly required. A deficiency of CD4+T cells, CD8+T
cells, B cells or IL-12p35 has no significant impact on Brucella
control in the spleen. Only the simultaneous deficiency of IL-
12p35 and IL17RA leads to a lack of control (21). Finally, in the
i.d. infection model, B cells appear to be indispensable, like in the
i.p. model, but CD4+T cells are required in the lesion but not
in the spleen. More surprisingly, Brucella control in the lesion
required IL-17RA, whereas it was not necessary for control of the
primary infection. And conversely, IL-12p35, which is needed to
control the primary infection, is no longer essential to control the
challenge in the lesion.
It may seem surprising that, depending on the route
of infection, control of Brucella in the same organ, the
spleen, requires di!erent types of lymphocyte populations and
di!erent T helper responses. These di!erent needs may be the
consequence of the specific immune conditions prevailing at
the primary infection site in the di!erent models. It is well-
established that the composition of immune and stromal cells,
as well as the phenotype of those cells, the nature of the
microenvironment and the isotypes of the antibodies di!er in
each tissue and a!ect the ability of the immune system to control
both infections and tumor growth [reviewed in Engwerda et al.
(72) and Pao et al. (73)]. Therefore, depending on the route
of infection and on the primary infection site, the bacterial
load reach in the blood and spleen may di!er significantly.
We observed this in practice when comparing our 3 models
(Figure 1D). The need for B cells is correlated with the rapid
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spread of bacteria in the blood, like in the i.p. and i.n. models. In
the i.n. model, B cells are not needed and Brucella is not detected
in the blood at any time. The same reasoning can be applied to
the requirement for IL-12p35. IL-12p35 is indispensable in the
spleen only in the i.p. model, where the bacterial load reaching
the spleen is the highest. Regardless of the dose reaching the
organ over time, Brucella could also reach the spleen in di!erent
forms depending on the route of infection. During the first
24 h following i.p. infection, Brucella is found in the blood in
extracellular form (35). In the i.n. model, Brucella disseminates
from the lung to draining lymph nodes inside dendritic cells and
alveolar macrophages (37). Therefore, Brucella could reach the
spleen by being protected from antibodies within a cell, which
would explain that B cells are not necessary.
The route of infection has been reported to impact the nature
of the protective immune response in certain other infection
models. For example, control of an i.p. Listeria monocytogenes
challenge strictly requires memory CD4+ and CD8+ !"+T
cells producing IFN# (74). But in the oral L. monocytogenes
infection model, intestinal multifunctional #$+T cells able to
simultaneously produce IFN# and IL-17A can provide enhanced
protection against infection and even compensate for the absence
of !"+T cells (75). However, the impact of di!erent routes
of infection on the type of protective memory response is
rarely compared and should be more systematic in view of
its importance.
One of the major interests of our comparison of the i.p.,
i.n., and i.d. infection routes is that all of our experiments were
conducted using the same strains of Brucella melitensis 16M and
C57BL/6 mice, with the same infectious dose and under the same
animal facility conditions. There is a large body of available data
on mice infected i.p. or i.n. by Brucella in the literature. It is
very di"cult, however, to truly compare the data from these
models because the infectious doses and the strains of Brucella
and mice are often di!erent. For example, the study of Hielpos
et al. (76) showed that B. abortus persisted at high levels in the
lungs for at least 7 days and was detected in the spleen as early
as 24 h p.i., much earlier than in our i.n. model of infection.
However, BALB/cmice, that aremore susceptible to Brucella than
the C57BL/6 strain, were used in the Hielpos study and were
infected with 106 CFU of B. abortus, at a dose 50 times higher
than our infection dose. Under these experimental conditions, it
is therefore quite normal that Brucella was detected in the spleen
much faster than in our model. Even though the experimental
conditions seem similar, it is well-known that, depending on the
animal facility conditions, the immunological experience of mice
can a!ect their ability to control an infection non-specifically
and that a strain of bacteria can drift in the laboratory and
present slightly di!erent virulence. Consequently, comparisons
between di!erent models of in vivo infections that are not
performed under exactly the same experimental conditions are
often hazardous.
It is important to point out that, since the mouse is not
the natural host of Brucella melitensis, we do not consider
that one particular route of infection in a mice model is more
physiological or informative than another regarding what is
happening in the natural host during a Brucella infection. This
work must be seen as fundamental research work carried out
with the aim of improving the methodology for the rational
design of LAVs in animal models. However, our comparison
of three routes of infection allows us to draw some practical
conclusions. We observed that both the humoral response
and the cellular response are essential to the control of a
challenge in the i.p. and i.d. models, which is not the case in
the i.n. model where a humoral response and even !"T cells
are dispensable. As discussed previously, this can be explained
by the fact that the i.p. and i.d. routes of infection lead to
massive dissemination of Brucella in the blood, which is not
the case for the i.n. route. Likewise, in sheep, inoculation by
the subcutaneous route produced wider and more generalized
infections than the conjunctival route (50). Thus, the i.p. and
i.d. routes lead to systemic infection that therefore appears to
be more di"cult to control than a mucosal i.n. infection and
consequently may be amore demanding test in mice for assessing
the protective capacity of a vaccine candidate. If we compare
i.p. and i.d. models, the latter display the advantage of being
close to the subcutaneous vaccination route conventionally used
with the REV1 B. melitensis vaccine in small ruminants. The
i.d. model of infection in mice also displays a pattern of tissue
infection that is quite similar to that described in the goat
(77) following subcutaneous infection with a virulent strain of
Brucella melitensis. Thus, for these reasons, i.d. could constitute a
new promising route of delivery for tests of candidate vaccines in
a mouse model.
In summary, our study demonstrates that the identification of
candidate LAVs and immune protection markers in an animal
model can be strongly a!ected by the route of infection used. We
therefore recommend that researchers systematically compare
di!erent routes of infection, identified as those closest possible
to the natural host infection, and not be limited to the analysis
of a single tissue type. As the infectious doses (78) as well as the
strain of pathogen analyzed (79) can also strongly a!ect the type
of protective immune response, as has been well-documented in
the experimental mouse model of Leishmania major infection,
we can conclude that the selection process of candidate LAVs is
much more complex than expected.
DATA AVAILABILITY
The raw data supporting the conclusions of this manuscript will
be made available by the authors, without undue reservation, to
any qualified researcher.
ETHICS STATEMENT
The procedures used in this study and the handling of the
mice complied with current European legislation (Directive
86/609/EEC) and the corresponding Belgian law Arrêté royal
relatif à la protection des animaux d’expérience of 6 April 2010
and published on 14 May 2010. The Animal Welfare Committee
of the Université de Namur (UNamur, Belgium) reviewed and
approved the complete protocol for Brucella infection (Permit
Number: UN-LE-13/195).
Frontiers in Immunology | www.frontiersin.org 19 July 2019 | Volume 10 | Article 1589
Demars et al. Immune Responses Against Brucella Infection
AUTHOR CONTRIBUTIONS
AD and EM wrote the article. AD, AL, AM, MV, and J-MV
realized experiments. GP, XD, J-JL, and EM provided reagents.
FUNDING
This work was supported by grants from the Fonds National
de la Recherche Scientifique (FNRS) (convention FRSM FNRS
1.4.013.16.F and 3.4.600.06.F, Belgium). EM is a Senior Research
Associate from the FRS-FNRS (Belgium). AD, AM, and GP hold
FRIA PhD grants from the FRS-FNRS (Belgium). AD and GP
were supported by Fonds Spécial de Recherche (FSR) PhD grants
from the UNamur (Belgium).
ACKNOWLEDGMENTS
The authors thank Katy Poncin, Manon Merckx, Audrey
Comein, and Maxime Lagneaux for their helpful contribution.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fimmu.
2019.01589/full#supplementary-material
Figure S1 | Each route of infection leads to a specific pattern of infected organs
(part 1). Wild-type C57BL/6 mice were infected intraperitoneally (i.p.), intranasally
(i.n.) or intradermally (i.d.) with a dose of 2 ! 104 CFU of mCherry-B. melitensis
and sacrificed at the indicated times. The data represent the CFU count per
footpad lesion, popliteal LN, lung, or mediastinal LN. Gray bars represent the
median. The significant differences between the indicated groups are marked with
asterisks: "p < 0.1, ""p < 0.01, """p < 0.001. These results are representative of
two independent experiments. LN, lymph node; h, hours; d, days; n, number of
mice per group.
Figure S2 | Each route of infection leads to a specific pattern of infected organs
(part 2). Wild-type C57BL/6 mice were infected intraperitoneally (i.p.), intranasally
(i.n.) or intradermally (i.d.) with a dose of 2 ! 104 CFU of mCherry-B. melitensis
and sacrificed at the indicated times. The data represent the CFU count per
skeletal muscle, heart, tail, brain, liver, or ovary. Gray bars represent the median.
The significant differences between the indicated groups are marked with
asterisks: "p < 0.1, ""p < 0.01, """p < 0.001. These results are representative of
two independent experiments. h, hours; d, days; n, number of mice per group.
Figure S3 | Intraperitoneal Brucella infection leads to infection of a large panel of
lymph nodes. Wild-type C57BL/6 mice were infected intraperitoneally (i.p.) with a
dose of 2 ! 104 CFU of mCherry-B. melitensis and sacrificed at 50 days post
infection. The data represent the CFU count per lymphoid organs (spleen, right
inguinal LN, right axillary LN, mediastinal LN, mesenteric LN, and right popliteal
LN). Gray bars represent the median. These results are representative of two
independent experiments. LN, lymph node; n, number of mice per group.
Figure S4 | Impact of eFluor670 staining on Brucella growth in vitro and in vivo.
(A) 4 ! 104 CFU/ml of mCherry-B. melitensis were prepared from an overnight
liquid culture and stained with the eFluor670 fluorochrome. Bacteria were fixed
and then analyzed by flow cytometry. (B) Comparison by Bioscreen analysis of the
growth of mCherry-B. melitensis and eFluor670 stained mCherry-B. melitensis in
rich medium (2YT). These data represent the mean of three independent
experiments. (C) Wild-type C57BL/6 mice were infected i.n. with a dose of 2 !
104 CFU of mCherry-B. melitensis or eFluor670 labeled mCherry-B. melitensis
and sacrificed at 5 or 12 days post infection. The data represent the CFU count
per lung. (D) Wild-type C57BL/6 mice were infected i.p. with a dose of 105 CFU
of mCherry-B. melitensis eFluor670 labeled mCherry-B. melitensis and sacrificed
at 5 or 12 days post infection. The data represent the CFU count per spleen.
These results (C,D) are representative of two independent experiments. Gray bars
represent the median. d, days; n, number. The significant differences between the
indicated groups are marked with asterisks: "p < 0.1.
Figure S5 | Phenotype of infected footpad lesion cells from wild type mice.
Wild-type C57BL/6 mice were infected intradermally with 107 CFU of
B. melitensis. Control wild-type mice were injected with PBS. The footpad lesions
were harvested at 2 or 24 h post infection and the cells were analyzed by flow
cytometry. The data result from the flow cytometry analysis of eFluor670, CD45,
CD140a, and CD11b expression on footpad cells. The data show the
representative dot plot from individual mice. These results are representative of
three independent experiments.
Figure S6 | Phenotype of infected CD11b-positive footpad lesion cells from wild
type mice. Wild-type C57BL/6 mice were infected intradermally with 107 CFU of
B. melitensis. Control wild-type mice were injected with PBS. The footpad lesions
were harvested at 2 or 24 h post infection and the cells were analyzed by flow
cytometry. The data result from the flow cytometry analysis of eFluor670, F4/80,
Ly6G, and CD11b expression on footpad cells. The data show the representative
dot plot from individual mice. These results are representative of three
independent experiments.
Figure S7 | Complemented !virB strain growth in the lung. Wild-type C57BL/6
mice were infected i.n. with a dose of 105 CFU of wild type mCherry-B. melitensis,
!virB mCherry- B. melitensis or complemented !virB mCherry-B. melitensis
(!virB mCherry-B. melitensis pvirB). Mice were sacrificed at 5 days post infection
and the lung was collected. The data represent the CFU count per lung. Gray bars
represent the median. Significant differences between the indicated groups are
marked with asterisks: ""p < 0.01, """p < 0.001. These results are representative
of two independent experiments. n, number of mice per group.
Figure S8 | eFluor670 labeling identified newborn Brucella. mCherry Brucella
melitensis is labeled with eFluor670. (A) Schematic representation of unipolar
growth of eFluor670 labeled mCherry-Brucella. As eFluor670 does not move in
the bacterial membrane, the newly formed bacterium, called the newborn, loses
the eFluor670 labeling, allowing its identification by fluorescent microscopy. (B)
Representative image at 0 and 24 h of eFluor670 labeled mCherry-Brucella
extracellular growth in vitro. The 24 h image shows a division and a newborn cell
(mCherry+ eFluor670#). The panels are color-coded with the text for mCherry and
eFluor670. Scale bar = 5µm. h, hours; n, newborn; pos, positive; neg, negative.
Figure S9 | BALB/c mice are more susceptible to cutaneous Brucella infection
than C57BL/6 mice. Wild-type C57BL/6 and BALB/c mice were infected
intradermally with a dose of 2 ! 104 CFU of B. melitensis and sacrificed at the
indicated times. The data represent the CFU count per organ. Gray bars represent
the median. The significant differences between the indicated groups are marked
with asterisks: "p < 0.1, ""p < 0.01, """p < 0.001. These results are
representative of two independent experiments. LN, lymph node; d, days; n,
number of mice per group.
Figure S10 | Neutrophils constitute the major population in the footpad lesion
from infected IFN!R#/# mice. Wild-type, IFN!R#/#, and CCR2#/# C57BL/6
mice were infected intradermally with a dose of 2 ! 104 CFU of mCherry-B.
melitensis. Control wild-type mice were injected with PBS. The footpad lesions
were harvested at 3 and 7 days post infection and the cells were analyzed by flow
cytometry. (A) Flow cytometry analysis of CD11b, F4/80, and LY6G expression on
footpad cells. The data show the representative dot plot from individual mice. (B)
Data represent the mean frequency (n = 4) of neutrophils and monocytes in the
footpad lesion at the indicated time of infection. These results are representative of
three independent experiments. Cont, control; d, days.
Figure S11 | Humoral immune response induced by intradermal Brucella
infection. Wild-type C57BL/6 mice were infected intradermally (A) or
intraperitoneally (B) with a dose of 2 ! 104 CFU of mCherry-B. melitensis. Serum
was collected at the indicated times, and ELISA was performed to determine the
isotype distribution of the Brucella-specific antibodies. The data represent the
means ± SEM of results for 8 mice. These results are representative of three
independent experiments. O.D, optical density; d, days.
Figure S12 | Comparison of protection in wild-type and various deficient mice
previously immunized by intraperitoneal route with live B. melitensis. Wild-type,
TCR!"#/#, MHCII#/#, TAP1#/#, Il-12p35#/#, and IL-17RA#/# C57BL/6 mice
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were immunized i.p. with 2 ! 104 CFU of live wild-type B. melitensis and treated
with antibiotics, as described in the Materials and Methods. Naive (primary
infection group) and immunized (secondary infection group) mice were challenged
i.p. with 2 ! 104 CFU of live mCherry-B. melitensis and sacrificed at 12 days post
infection. The data represent the CFU count per spleen. Gray bars represent the
median. The significant differences between the indicated groups are marked with
asterisks: ""p < 0.01. These results are representative of two independent
experiments. n, number of mice per groups.
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Supplementary figures 
Figure S1. Each route of infection leads to a specific pattern of infected organs (part 1). Wild-type 
C57BL/6 mice were infected intraperitoneally (i.p.), intranasally (i.n.) or intradermally (i.d.) with a dose 
of 2 × 104 CFU of mCherry-B. melitensis and sacrificed at the indicated times. The data represent the 
CFU count per footpad lesion, popliteal LN, lung, or mediastinal LN. Gray bars represent the median. 
The significant differences between the indicated groups are marked with asterisks: *p < 0.1, **p < 0.01, 
***p < 0.001. These results are representative of two independent experiments. LN, lymph node; h, 




Figure S2. Each route of infection leads to a specific pattern of infected organs (part 2). Wild-type 
C57BL/6 mice were infected intraperitoneally (i.p.), intranasally (i.n.) or intradermally (i.d.) with a dose 
of 2 × 104 CFU of mCherry-B. melitensis and sacrificed at the indicated times. The data represent the 
CFU count per skeletal muscle, heart, tail, brain, liver, or ovary. Gray bars represent the median. The 
significant differences between the indicated groups are marked with asterisks: *p < 0.1, **p < 0.01, ***p 
< 0.001. These results are representative of two independent experiments. h, hours; d, days; n, number 




Figure S3. Intraperitoneal Brucella infection leads to infection of a large panel of lymph nodes. Wild-
type C57BL/6 mice were infected intraperitoneally (i.p.) with a dose of 2 × 104 CFU of mCherry-B. 
melitensis and sacrificed at 50 days post infection. The data represent the CFU count per lymphoid 
organs (spleen, right inguinal LN, right axillary LN, mediastinal LN, mesenteric LN, and right popliteal 
LN). Gray bars represent the median. These results are representative of two independent 





Figure S4. Impact of eFluor670 staining on Brucella growth in vitro and in vivo. (A) 4 × 104 CFU/ml of 
mCherry-B. melitensis were prepared from an overnight liquid culture and stained with the eFluor670 
fluorochrome. Bacteria were fixed and then analyzed by flow cytometry. (B) Comparison by Bioscreen 
analysis of the growth of mCherry-B. melitensis and eFluor670 stained mCherry-B. melitensis in rich 
medium (2YT). These data represent the mean of three independent experiments. (C) Wild-type 
C57BL/6 mice were infected i.n. with a dose of 2 × 104 CFU of mCherry-B. melitensis or eFluor670 
labeled mCherry-B. melitensis and sacrificed at 5 or 12 days post infection. The data represent the CFU 
count per lung. (D) Wild-type C57BL/6 mice were infected i.p. with a dose of 105 CFU of mCherry-B. 
melitensis eFluor670 labeled mCherry-B. melitensis and sacrificed at 5 or 12 days post infection. The 
data represent the CFU count per spleen. These results (C,D) are representative of two independent 
experiments. Gray bars represent the median. d, days; n, number. The significant differences between 




Figure S5. Phenotype of infected footpad lesion cells from wild type mice. Wild-type C57BL/6 mice 
were infected intradermally with 107 CFU of B. melitensis. Control wild-type mice were injected with 
PBS. The footpad lesions were harvested at 2 or 24 h post infection and the cells were analyzed by flow 
cytometry. The data result from the flow cytometry analysis of eFluor670, CD45, CD140a, and CD11b 
expression on footpad cells. The data show the representative dot plot from individual mice. These 




Figure S6. Phenotype of infected CD11b-positive footpad lesion cells from wild type mice. Wild-type 
C57BL/6 mice were infected intradermally with 107 CFU of B. melitensis. Control wild-type mice were 
injected with PBS. The footpad lesions were harvested at 2 or 24 h post infection and the cells were 
analyzed by flow cytometry. The data result from the flow cytometry analysis of eFluor670, F4/80, 
Ly6G, and CD11b expression on footpad cells. The data show the representative dot plot from 





Figure S7. Complemented ΔvirB strain growth in the lung. Wild-type C57BL/6 mice were infected i.n. 
with a dose of 105 CFU of wild type mCherry-B. melitensis, ΔvirB mCherry- B. melitensis or 
complemented ΔvirB mCherry-B. melitensis (ΔvirB mCherry-B. melitensis pvirB). Mice were sacrificed 
at 5 days post infection and the lung was collected. The data represent the CFU count per lung. Gray 
bars represent the median. Significant differences between the indicated groups are marked with 
asterisks: **p < 0.01, ***p < 0.001. These results are representative of two independent experiments. n, 
number of mice per group. 
  
 
Figure S8. eFluor670 labeling identified newborn Brucella. mCherry Brucella melitensis is labeled with 
eFluor670. (A) Schematic representation of unipolar growth of eFluor670 labeled mCherry-Brucella. 
As eFluor670 does not move in the bacterial membrane, the newly formed bacterium, called the 
newborn, loses the eFluor670 labeling, allowing its identification by fluorescent microscopy. (B) 
Representative image at 0 and 24 h of eFluor670 labeled mCherry-Brucella extracellular growth in vitro. 
The 24 h image shows a division and a newborn cell (mCherry+ eFluor670−). The panels are color-coded 





Figure S9. BALB/c mice are more susceptible to cutaneous Brucella infection than C57BL/6 mice. Wild-
type C57BL/6 and BALB/c mice were infected intradermally with a dose of 2 × 104 CFU of B. melitensis 
and sacrificed at the indicated times. The data represent the CFU count per organ. Gray bars represent 
the median. The significant differences between the indicated groups are marked with asterisks: *p < 
0.1, **p < 0.01, ***p < 0.001. These results are representative of two independent experiments. LN, 




Figure S10. Neutrophils constitute the major population in the footpad lesion from infected IFNγR−/− 
mice. Wild-type, IFNγR−/−, and CCR2−/− C57BL/6 mice were infected intradermally with a dose of 2 × 104 
CFU of mCherry-B. melitensis. Control wild-type mice were injected with PBS. The footpad lesions were 
harvested at 3 and 7 days post infection and the cells were analyzed by flow cytometry. (A) Flow 
cytometry analysis of CD11b, F4/80, and LY6G expression on footpad cells. The data show the 
representative dot plot from individual mice. (B) Data represent the mean frequency (n = 4) of 
neutrophils and monocytes in the footpad lesion at the indicated time of infection. These results are 




Figure S11. Humoral immune response induced by intradermal Brucella infection. Wild-type C57BL/6 
mice were infected intradermally (A) or intraperitoneally (B) with a dose of 2 × 104 CFU of mCherry-B. 
melitensis. Serum was collected at the indicated times, and ELISA was performed to determine the 
isotype distribution of the Brucella-specific antibodies. The data represent the means ± SEM of results 




Figure S12. Comparison of protection in wild-type and various deficient mice previously immunized by 
intraperitoneal route with live B. melitensis. Wild-type, TCRγδ−/−, MHCII−/−, TAP1−/−, Il-12p35−/−, and IL-
17RA−/− C57BL/6 mice were immunized i.p. with 2 × 104 CFU of live wild-type B. melitensis and treated 
with antibiotics, as described in the Materials and Methods. Naive (primary infection group) and 
immunized (secondary infection group) mice were challenged i.p. with 2 × 104 CFU of live mCherry-B. 
melitensis and sacrificed at 12 days post infection. The data represent the CFU count per spleen. Gray 
bars represent the median. The significant differences between the indicated groups are marked with 
asterisks: **p < 0.01. These results are representative of two independent experiments. n, number of 
mice per groups. 




 Discussion and perspectives 
In this work, we compared the impact of the infectious route on different parameters such as 
the dissemination of bacteria in mice body, the reservoir cells, the nature of the lymphoid 
populations indispensable after a secondary infection, or one example of the virulence gene 
importance. To our knowledge, no previous study has answered to this very general question 
using a same strain of bacterium, a same infectious dose, a same protocol and mice hosted in a 
same environment and fed with a same food.   
 The different routes of infection: towards a general model 
The dissemination of B. melitensis and the nature of infected organs should logically depend 
on the route of infection used. Indeed, after intraperitoneal (i.p.), intranasal (i.n.), or intradermal 
(i.d.) infections, the barriers encounter by B. melitensis are different, but also the paths taken 
from the infectious site to the systemic organs. 
The non-physiological i.p. route allows a rapid and massive entry of bacteria, directly inside 
the peritoneal cavity (Vitry, Hanot Mambres et al. 2014). One of the main role of the peritoneal 
cavity is to support and protect the organs of abdominopelvic cavity. The cavity is a high 
vascularized place. Because of that, the i.p. route leads to a rapid entry of extracellular bacteria 
in the blood circulation and so a rapid systemic dissemination (Figure 11). Indeed, all tested 
organs are infected at least at one point of infection. After a primary i.p. injection, CD4 T cells 
are indispensable to control the infection in spleen, with a crucial role of IFN-γ and iNOS 
(Copin, De Baetselier et al. 2007, Copin, Vitry et al. 2012). However, following a secondary 
infection, CD4 T cells but also B cells appear indispensable to fully control and eliminate 
bacteria (Hanot Mambres, Machelart et al. 2016) 
By contrast, after an i.n. infection, the bacteria are rapidly internalized by alveolar macrophages 
in lungs ((Archambaud, Salcedo et al. 2010) G. Potemberg, A. Demars, not published). The 
mesenteric lymph nodes start to be infected after 5 days of infection. And the spleen is only 
infected between 5 and 12 days p.i., suggesting a very slow dissemination from the lungs to the 
systemic circulation. Moreover, no bacteria have been found in the blood at any tested times in 
this infectious model. The absence of detection of bacteria in the blood and the late 
dissemination to the spleen suggest that bacteria disseminate very slowly and intracellularly. 
The passage from the lungs to the spleen is still unknown, even it is thought via the blood. We 




think that in this model it is the homing of the infected cells that determine the dissemination 
of Brucella (Figure 11). After a primary i.n. infection, γδ T cells depending-IL-17 plays an 
indispensable role at 5 days post infection, and IFN-γ produced by CD4 T cells is indispensable 
later in the lungs (Vitry, Hanot Mambres et al. 2014, Hanot Mambres, Machelart et al. 2016). 
However, after a secondary infection, αβ T cells (CD4 and CD8 T cells) are indispensable to 
control the infection. In this model, the humoral response appears not indispensable (Hanot 
Mambres, Machelart et al. 2016). 
Finally, after an i.d. infection, the situation is probably intermediate between i.p. and i.n. 
models. Indeed, some extracellular bacteria should directly enter in the blood stream as the 
swelling of the footpad during the injection destructs the tissue and opens the access to the 
capillaries (Figure 11). But other bacteria should be internalized by APCs and follow a 
“classical” route from the local site of infection to the spleen, via infected cells and the lymph 
nodes (Figure 11). The control of Brucella at local site of infection seems required a TH1 
immune response, with CD4 T cells producing IFN-γ, probably because bacteria are 
intracellular and that microbicide functions of myeloid cells must be activated to eliminate the 
bacteria. In this model, IFN-γ could also play a role of myelopoiesis modulator, allowing the 
recruitment and differentiation of monocytes (MacNamara, Oduro et al. 2011). Indeed, the 
deficiency of IFN-γ leads to an increase in neutrophils recruitment in the footpad and to a 
necrosis. As in i.p. and i.n. models, B cells are dispensable to control the primary i.d. infection. 
However, we detected IgM at 6 days post infection and IgG1 at 50 days post infection. After a 
secondary i.d. infection, footpads and spleen are protected, notably via CD4 T cells action. As 
after i.p., B cells are crucial for a good protection. The fact that some extracellular bacteria 
Figure 11: Models of dissemination and immune response consequences depending on the route of infection. 
Adapted from (Hanot Mambres, Machelart et al. 2016)  




directly pass through the blood could explain why the B cells and probably antibodies are 
required in this model too (Figure 11).  
By comparing the 3 models, it seems that the rapid and massive entry of bacteria could be the 
reason why specific cellular and humoral responses are necessary. Indeed, probably that (1) the 
arsenal of responses should be deployed to fight a so high quantity of bacteria in the same time, 
and (2) the bacteria probably stay extracellular a certain time, making possible the action of 
memory B cells, “ready” for this second infection. The fact to block rapidly Brucella is crucial 
to avoid the establishment of bacteria in reservoir cells such as splenic macrophages, where 
their detection is probably less efficient because protected into splenic cells. 
A general model could be that 1) antibodies are never required during a primary infection as B 
cells do not have the time to develop, 2) antibodies are indispensable after secondary infections 
only if there is a massive passage of Brucella in the blood circulation, when cellular immune 
response is saturated and that bacteria are extracellular, and 3) more the bacteria arrive 
massively in an organ or are inside reservoir cells, more a TH1 cellular response is required 
(Figure 11).  
If the hypothesis that “massive entry of bacteria in blood is required to need humoral response 
after a secondary infection” is correct, maybe that an intranasal infection with a very high dose 
of Brucella will lead to a massive passage of bacteria in blood and a requirement of a very 
specific immune response with involvement of CD4 T cells and B cells. Thinking in terms of 
vaccine research, challenge in i.p. mouse model is finally interesting because it requires that the 
vaccine induces both a TH1-type humoral and cellular immune response to control Brucella. 
 
 Infection models in mice: critical, but not as much 
The models we used to mimic natural infections are of course objectionable. Indeed, the 
infection via aerosols is in fact replaced by an injection of liquid containing Brucella in the 
nostrils of mice. In addition, this technique requires a deep anesthesia of animals (see Materials 
and methods). It also has been shown that the volume used to infect animals can modify the 
results (Miller, Stabenow et al. 2012). Systems to induce aerosols exist, such as whole-body 
exposure chamber or nose-only inhalation exposure system (Tsenova, Moreira et al. 1997, 
Schwebach, Chen et al. 2002, Belser, Gustin et al. 2015). But these systems present several 




disadvantages like the requirement of anesthesia of mice, the use of restraint tubes and/or the 
training of mice, the need of a specific hood for the system, etc. (Belser, Gustin et al. 2015). 
The reproducibility between inoculations procedures, but also intra- and inter-groups is also 
debatable (Lucci, Tan et al. 2020). System to induce aerosols directly in trachea of mice also 
exist, via a syringe connected to a folded straw in which the liquid is expulsed and passes 
through an atomizer (Kunda, Price et al. 2018). This system could be interesting to test, as it 
would create aerosols, but it also requires anesthesia of mice as in our mode of infection and is 
not more physiological as the aerosols are directly injected in the trachea. In addition, studies 
comparing aerosolization and intranasal infection of viruses show no difference in terms of 
lethality, toxicity or level of infection between the two techniques (Belser, Gustin et al. 2015). 
After i.d. infection, tissue destruction during the infection is inevitable in our model. It could 
be seen as a negative point of the route of infection, but it can also be seen as a very good 
imitation of cutaneous lesions occurring when a vet, or butcher, or scientific hurts with a sharp 
object such as needle, scissors, or knife. It can also mimic the hurt of an animal in a meadow 
with barbed wires, making this mode of infection a good model of what happens naturally.   
 
 Lymph nodes: the perfect fortress? 
The only organs staying infected at 50 days p.i. after a primary infection, independently of the 
route of infection, are the secondary lymphoid organs, meaning the spleen and the lymph nodes. 
What is very surprising is that, after a secondary infection, Brucella still persists in lymph nodes 
while the spleen of mice is highly protected. A hypothesis is that some specific cells or specific 
structures like granulomas allow the long-term persistence of Brucella in lymph nodes via the 
presence of nutritive resources and/or the ability to hide from the immune system. A such 
persistence in lymph nodes has already been observed in other infections. Indeed, it has been 
shown in an in vivo model of cynomolgus and rhesus macaques infected with M. tuberculosis 
that granulomas formation in thoracic lymph nodes allows the persistence of bacteria  
(Ganchua, Cadena et al. 2018). The authors showed that the high bacterial burden in the thoracic 
lymph nodes of rhesus macaques was associated to granulomas (Ganchua, Cadena et al. 2018). 
Indeed, granulomas are structures composed of infected macrophages surrounded by 
lymphocytes, developing after infections in lungs, liver, or skin for examples. The function of 
these structures is to kill the microorganisms by assembling in a same place the arsenal of 
destruction of a pathogenic agent, by increasing the NO presence or cytokines in the center of 




the structure, and by decreasing the oxygen presence (Jamaati, Mortaz et al. 2017, Pagan and 
Ramakrishnan 2018). However, in this study, the lymph nodes granulomas in rhesus macaques 
are a bit different than the “classical” granulomas: the T cells seem push out, being replaced by 
CD11c CD68 macrophages (Ganchua, Cadena et al. 2018). Moreover, the blood vessels are 
disrupted and necrotic lesions are visible. Finally, the cytokinic production is reduced in 
comparison to a “classical” granulomas. All these events seem allow the increase in M. 
tuberculosis persistence in these lymph nodes (Ganchua, Cadena et al. 2018). It could be 
possible that this kind of structures exist in lymph nodes where Brucella persists at long term, 
even after secondary i.d. infection. Unfortunately, the low bacterial burden in infected lymph 
nodes prevents immunohistology studies of these organs to detect the presence of granulomas. 
Another explanation for the persistence of Brucella in lymph nodes could be the existence of a 
specific cell population in these organs. To maintain a perfect balance between reactivity to 
fight aggressions and inhibition of abnormal responses, it is necessary that the immune system 
differentiates between self- and non-self-antigens. A failure in this mechanism can lead to auto-
immune responses, allergies (if self-antigens are recognized by the immune system) or at the 
contrary to infections with huge consequences (Sakaguchi, Toda et al. 1996). A population of 
CD8 T regulatory cells has been identified in 1970 (Gershon and Kondo 1970). In function of 
the presence of not of programmed cell death (PD)-1 at their cell surface, the CD8+ CD122+ T 
cells can be distinguished in memory T cells (CD8+ CD122+ PD-1-) or in regulatory T cells 
(CD8+ CD122+ PD-1+) (Dai, Wan et al. 2010). The Treg have been shown to inhibit the immune 
response to pathogens by different mechanisms. For examples, CD8 Treg are able to secrete 
IL-10 and TGF-β that are inhibitory cytokines (Dai, Wan et al. 2010, Liu, Chen et al. 2015, Yu, 
Ma et al. 2018). Activated CD4 T cells can also be inhibited by CD8 Treg via the 
downregulation of costimulatory molecules such as CD86 and CD80, leading to a decrease in  
pro-inflammatory cytokines like IL-17 (Liu, Chen et al. 2015, Yu, Ma et al. 2018). CD8 Treg 
cells also secrete IFN-γ that will activate DC to produce NO (Liu, Chen et al. 2015, Yu, Ma et 
al. 2018). The Qa-1 protein, a non-classical MHC molecule, is essential for immune regulation 
and is linked to immune response suppression. In mice deficient for Qa-1 protein, CD8 Treg 
cells have a reduced activity, suggesting a link between Qa-1 and the regulatory CD8 T cells. 
Qa-1 protein recognizes MHCI on CD8 and inhibits the development of auto-immune disease. 
However, in absence of Qa-1 protein, CD8 Treg loss their activity and CD4 T cells show a 
better response (Hu, Ikizawa et al. 2004). A population of regulatory CD8 CD122 PD-1 T cells, 
located in the lymph nodes, has been described and involved in the persistence of γ-




Herpesviruses by suppressing the immune control via IL-10 secretion (Molloy, Zhang et al. 
2011). A such type of cells could explain the persistence of Brucella in lymph nodes, even after 
a secondary infection, as defense strategies are inhibited in lymph nodes in presence of CD8 
Treg cells. An interesting experiment to do could be to infect Qa-1-deficient mice following a 
secondary infection protocol and evaluate the bacterial load in lymph nodes (CFU) or to do 
flow cytometry on lymph nodes cells in order to study the cells present in these organs, using 
CD8, CD122, and PD-1 markers. The presence of CD8 Treg could explain the persistence of 
Brucella in lymph nodes after primary and secondary i.d. infections. 
 
 The essentiality of virB: questionable 
virB operon is known in vitro but also in some in vivo models to be one of the most important 
and indispensable virulence gene in Brucella infection (O'Callaghan, Cazevieille et al. 1999, 
Hong, Tsolis et al. 2000). However, in some models, virB genes appear dispensable. It is the 
case for example in vitro in specific JEG-3 trophoblasts, where B. abortus ∆virB9 is able to 
replicate, albeit a bit less than the wt strain (Salcedo, Chevrier et al. 2013). In vivo, we showed 
that the persistence of B. melitensis ∆virB strain is dependent on the route of infection and on 
the infected organ. For example, virB is dispensable in the spleen of intraperitoneally infected 
mice up to 4 weeks after infection (Demars, Lison et al. 2019). What is surprising in our model, 
is that after i.d. infection, not only virB is dispensable, but it seems deleterious in the footpad at 
28 and 50 days p.i.. This could be linked to specific cells that are infected. We observed that 
both strains of B. melitensis (wt and ∆virB) can invade fibroblasts in footpad after i.d. infection 
at early time points. To our knowledge, it was the first time that fibroblasts were shown to be 
infected by Brucella in vivo. It would be interesting to compare the reservoir of both strains at 
later times points to study the difference of replication between the two strains, but we did not 
study this in this thesis as the level of persisting bacteria is too low to study the Brucella 
reservoir by immunohistology. Another explanation of this surprising result could be that it 
exists a redundant system to virB operon which is not yet discovered, but which will be efficient 
only in specific cellular conditions. To investigate this point, it would be interesting to do a 
Transposon-sequencing (Tn-seq) analysis in the conditions where virB is not required or with 
a ∆virB-Brucella strain coming from infected mice organs. However, this would explain why 
the mutant persists in lesion, but not why it persists better than the wt.   










III. The role of Acod1 and itaconate 
 
 Therapeutic strategies against bacterial infection 
The discovery of synthetic antibiotics started in the 1932s with the sulfamides class (Aver, 
Mottin et al. 2017). However, only 4 years later, the first cases of resistance appeared. And each 
time a new class of antibiotic was discovered, resistance appears few years after. Moreover, 
since 1960s, few innovations in terms of antibiotic therapy were made, leading to the urgent 
need of therapeutic alternative to treat bacterial infections. Two main axes are possible: a host-
directed therapy, or a bacteria-directed therapy and here are general examples for each of them. 
 Host-directed therapy 
The host can be targeted by therapeutic molecules at different levels, trying to boost its immune 
defenses, or to eliminate a bacterial niche for examples. As described above in the introduction, 
macrophages are cells at the first line of defense and are often infected by intracellular bacteria 
such as Mycobacterium or Brucella. One strategy consists to target the uptake of bacteria by 
these cells. Imatinib is a molecule which inhibits tyrosine-kinases, including the ones involved 
in the entry of Mycobacterium in macrophages (Napier, Rafi et al. 2011). One major problem 
of this strategy, in addition to all side effects on the cells due to the mechanisms of action, is 
that the entry receptors are usually multiple, and this approach requires the identification and 
the inhibition all of them. When intracellular bacteria follow the intracellular trafficking of the 
host, it is possible to modulate the maturation of phagosomes in order to increase the direct 
bacterial killing, or to modulate the acidification of phagosomes (Bruns, Stegelmann et al. 
2012). Also, the IFN-γ is a key cytokine of the immune system as it allows to increase nitric 
oxide (NO), autophagy, cells activation, etc. (see general introduction above). In 2009, patients 
with pulmonary tuberculosis treated with nebulization of IFN-γ showed a reduced inflammation 
in lungs, an increase in STAT-1 and IRF-1 cytokines, a recruitment of lymphocytes and a 
reduction of neutrophils inflammation (Dawson, Condos et al. 2009).  
 Bacteria-directed therapies 
On the other hand, the bacteria themselves can be targeted by drugs in order to weaken them 
and so to support the immune system. For example, some drugs can decrease or stop the 




bacterial virulence until the immune system succeed to kill them. For that, toxins and secretion 
system are good targets. For example, Chir-1 (chitinase-related protein 1), which targets the 
T4SS of Helicobacter pylori, is currently a molecule in pre-clinical phase (Hilleringmann, 
Pansegrau et al. 2006). The T4SS inhibition blocks the virulent effectors that are usually 
secreted through this (Hilleringmann, Pansegrau et al. 2006). In the case of bacteria making 
biofilms, these last structures are good targets as their degradation make bacteria more sensitive 
to antibiotics. For that, the components allowing the quorum sensing can be targeted for 
example. In 2013, Conlon et al. published that the acyldepsipeptide antibiotic (ADEP4) 
activates the ClpP (Caseinolytic Mitochondrial Matrix Peptidase Proteolytic Subunit) protease 
leading to the degradation of around 400 proteins, resulting in the eradication of Staphylococcus 
aureus biofilms (Conlon, Nakayasu et al. 2013). Another example is the use of bacteriophages 
to kill pathogenic bacteria. In a model of antibiotic-resistant Pseudomonas aeruginosa in 
chronic otitis, bacteriophage therapy has been tested in a clinical phase on 24 patients suffering 
of ear infection. In this study, after being treated with a bacteriophage preparation with a single 
dose, the phage-treated group shows an improvement in comparison to the placebo group 
(Wright, Hawkins et al. 2009).  
 Acod1 and itaconate 
 Discover, and brief history  
As new therapeutic agent, itaconate (or itaconic acid) is more and more cited (Lampropoulou, 
Sergushichev et al. 2016, Naujoks, Tabeling et al. 2016, Meiser, Kraemer et al. 2018, Mills, 
Ryan et al. 2018). This compound has been identified for the first time in 1836 by a chemist 
during citric acid distillation (Baup 1836). Five years later, in 1841, Turner identified that 
itaconate synthesis is produced during the decarboxylation of cis-aconitate, an intermediate of 
Krebs cycle (Turner 1841). Then, it has been reported for the first time in 1931 by Kinoshita 
that itaconate was produced by Aspergillus itaconicus when growing on Czapek’s agar solution 
containing sucrose (Kinoshita 1931). It was suggested that itaconate production starts with 
sugar, with citric and cis-aconitic acids as intermediates (Kinoshita 1931). It was then 
mentioned that itaconate can be produced by other species of Aspergillus, such as A. terreus 
(Calam, Oxford et al. 1939). It seems that Aspergillus would be able to synthetize itaconate 
from glucose only when the environment modifies from neutral to acid conditions, suggesting 
that acidity would be necessary to synthetize enzyme essential to this conversion (Larsen and 
Eimhjellen 1955). For a long time, itaconate was used exclusively in industry (see BOX-6), but 




it becomes more and more interesting in the biology field as its importance in mammalian 
immunity slowly started to be discovered.  
BOX-6. Itaconate use. Itaconate compound was first produced by citric acid distillation 
(Kinoshita 1931), but then by fermentation of Aspergillus terreus (Pfeifer, Vojnovich et al. 
1952). It is used for the production of synthetic resins, fibers, for plastic, artificial glass, etc, 
and used in large range of sectors (agriculture, pharmacy, dental-care, etc). As the demand of 
itaconate production increases over the years, industries try to adapt (strain modification, 
primary substance replacement, etc) by decreasing the economic cost of production. Indeed, 
glucose as substrate being quite expensive, it is now replaced by starch, molasses, corn syrup 
for examples, that are cheaper but also less pure. In 2009, the annual production of itaconate in 
China was estimated to be 30,000 tons (Okabe, Lies et al. 2009). For a complete review, see 
(Okabe, Lies et al. 2009).  
Almost 30 years after the discovery of itaconate metabolite in Aspergillus, the itaconate 
metabolism was studied in 1961 in some bacteria and it was shown that Salmonella and 
Pseudomonas possess the enzymes for the itaconate metabolism (Martin, Frigan et al. 1961). 
Despite the fact that it is known since 1957 that exogenous itaconate can be catabolized by rats 
and guinea pigs liver mitochondria (Alder, Wang et al. 1957), it is only in 2010 that itaconate 
was identified in metabolic analyses of mammalian tissues (Wibom, Surowiec et al. 2010). But 
at this time, the itaconate origin was unknown: from the mammals cells themselves, the 
microbiota or a contaminant? (Wibom, Surowiec et al. 2010). In 2011, different articles showed 
that itaconate is produced in different contexts. First, Strelko et al. concluded that, in vitro, only 
macrophage lineage cells produced itaconate, at a concentration of 1.33 mM, and that this 
production was increased after ex vivo stimulation of peritoneal macrophages with E. coli.-LPS 
and IFN-γ, suggesting a role in the control of bacterial infections (Strelko, Lu et al. 2011). 
Second, after treatment of RAW 264.7 macrophages with E. coli.-LPS during 22 hours and 
after the study of the extracellular metabolites released in the culture medium, Sugimoto and 
colleagues showed that itaconate was one of the most increased metabolite (Sugimoto, 
Sakagami et al. 2011). And finally, Shin realized in vivo metabolomics studies and found that 
rats infected with M. tuberculosis showed more metabolic changes in comparison to uninfected 
rats and that these changes mainly concerned precursors of different metabolites, including 
itaconate (Shin, Yang et al. 2011). 




In 1995, Lee et al. showed after stimulation of RAW 264.7 macrophages with E. coli.-LPS that 
irg1 (immune responsive gene-1) - now called Acod1 for aconitate decarboxylase 1 - was one 
of the genes the most upregulated.  
The induction of Acod1 gene is mainly related to TLRs stimulation by PAMPs (Figure 12). For 
examples, it was shown that the TLR4 and its stimulation by E. coli.-LPS or Lipid A is required 
for the expression of Acod1 mRNA in DCs, BMDM and murine peritoneal macrophages. Acod1 
gene expression can also be induced by TLR2 in RAW264.7 macrophages and in BMDM (Wu, 
Chen et al. 2020). The detection of CpG-DNA by TLR9 is also able to lead to Acod1 gene 
expression in BMDM. It has been shown that the deletion of TLR2 or TLR4 blocks the 
induction of Acod1 gene expression, and that the overexpression of TLR4 increases the Acod1 
mRNA expression in ovine macrophages (Wu, Chen et al. 2020). MYD88 could be the adaptor 
protein recruited at the TLRs to induce the signaling cascade after TLRs stimulation. Indeed, in 
DC deficient for MYD88 (MYD88-/- DCs), the induction of Acod1 gene expression via TLR9 
decreases, suggesting a TLR9/MYD88/ACOD1 axis. However, it was not the case for TLR2 
induced by E. coli.-LPS, suggesting the existence of another pathway after TLR2 stimulation. 
In Mycobacterium, the induction of Acod1 gene is independent of TLR4 and MYD88 or TIRAP, 
 
Figure 12: Cascade of signalization leading to the induction of Acod1 gene. TLR can be stimulated by PAMPs, leading to 
the activation of NFκβ or IRF depending on the host cells and on the level of inflammation. MYD88 could be one of the adaptor 
protein, but it seems not required after TLR4 stimulation. A synergic effect between PAMPs and pro-inflammatory cytokines 
allows a strong induction of Acod1 mRNA. 




another adaptor protein. It seems that the induction of Acod1 gene in this model is IRF 
dependent. In addition to the stimulation of Acod1 after PAMPs detection, the pro-inflammatory 
cytokines produced following the same signalization cascade (such as IL-1β, IFN-β TNF-α 
cytokines) also increase the expression of Acod1 mRNA (Figure 12). Depending on the 
conditions, it seems that the signalization cascade could be dependent on STAT proteins. This 
suggests a synergic effect of PAMPs and cytokines to induce Acod1 gene during infection (Wu, 
Chen et al. 2020).  
The function of Acod1 was unknown until 2013 as this gene had no identity with other known 
genes (Lee, Jenkins et al. 1995). In 2013, a team found the link between Acod1 and itaconate. 
Indeed, Michelucci and colleagues used the siRNA technique to silence Acod1 gene in E. coli.-
LPS activated RAW 264.7 macrophages and found that, among the 260 impaired metabolites, 
itaconate was the most affected, with 60 % of decrease in comparison to macrophages 
transfected with the si-control (Michelucci, Cordes et al. 2013). In the same model of cells, they 
found that the intracellular concentration of itaconate is close to 8 mM, leading to the idea that 
a such high concentration of a metabolite could be linked to immunological function 
(Michelucci, Cordes et al. 2013). They confirmed in vivo that mice treated with E. coli.-LPS 
have an increase in Acod1 mRNA and a correlated high concentration of itaconate in their 
peritoneal macrophages, in comparison to mice treated with saline buffer (Michelucci, Cordes 
et al. 2013).  
The main roles of itaconate will be discussed later, but briefly, itaconate was already shown in 
1949 to inhibit the succinate dehydrogenase (SDH) in an enzymatic test (Ackermann and Potter 
1949) and in 1971 to inhibit the isocitrate lyase (ICL) of Pseudomonas indigofera (Williams, 
Roche et al. 1971, Rittenhouse and McFadden 1974, McFadden and Purohit 1977), but the 
metabolite was not considered as enough interesting at this time as it was not really involved in 
the Krebs cycle. It is only years later that its anti-bacterial and anti-inflammatory roles were 
investigated in infection models. 




 Metabolism of itaconate 
In mice, the formation of itaconate was shown to occur in two steps inside mitochondria: the 
citric acid from Krebs cycle is first dehydrated by an aconitase enzyme to cis-aconitate, with 
formation of a double bond between two carbons; then the cis-aconitate is decarboxylated by 
the cis-aconitate decarboxylase (ACOD1) to itaconate (Figure 13) (Kinoshita 1931, Bentley 
and Thiessen 1955, Bentley and Thiessen 1957, Bentley and Thiessen 1957, Bentley and 










Figure 13: Synthesis of itaconate, from citric acid, with cis-aconitate as intermediate. The citric acid is dehydrated by an 
aconitase in cis-aconitate, that will be decarboxylated in itaconate by the cis-aconitate decarboxylase enzyme (ACOD1). 
 
  
    
  
  
    
 
If itaconate  can  be  produced  in mammalian’s mitochondria after E.  coli.-LPS and  IFN-γ
stimulation, it can also be  metabolized  into  pyruvate  and  acetyl-CoA  in  a  3  steps  reactions
(Figure  14). First,  itaconate  is  activated  into  itaconyl-CoA  by  a  succinate  activating  enzyme 
(Succinyl-CoA  synthetase),  then  the  itaconyl-CoA  is  hydrated  into  citramalyl-CoA  by  a 
itaconyl-CoA  hydratase,  and  finally  the  citramalyl-CoA  is  cleaved  into  pyruvate  and  acetyl-
CoA  by  a  citramalyl-CoA  lyase (Alder,  Wang  et  al.  1957,  Wang,  Adler  et  al.  1961).  This 
itaconate catabolism  pathway is  also used  by  some  bacteria  as  resistance  mechanism  to 
itaconate.  It  is  for  example  the  case  of Yersinia  pestis and  Pseudomonas aeruginosa,  which 
used itaconate-CoA  transferase as first enzyme  of  this  3-steps  reaction (Figure  14) 
(Sasikaran, Ziemski et al. 2014).




 Transport of itaconate 
As mentioned above, itaconate is produced in some fungi, bacteria, and mammals. ACOD1 is 
present in mitochondria and allowed the production of itaconate inside mitochondria. But in 
1995, itaconate was found in the cytosol of eukaryotic cells, suggesting a possible transport of 
itaconate from mitochondria to cytosol (Horton, Park et al. 2006). As malate and itaconate are 
structurally very close to each other, Mills et al. hypothesized and showed that itaconate should 
be transported through the mitochondrial membranes via the same transporters than malate: via 
dicarboxylated, citrate and/or oxoglutarate carriers (Mills, Ryan et al. 2018). In another context, 
it was hypothesized that cells were able to release extracellularly itaconate as the it was found 
in the culture medium of RAW264.7 (Strelko, Lu et al. 2011). This was however not confirmed 
by another team which concluded later that the extracellular itaconate was the result of cell 
content released during cell apoptosis or eliminated at the end of the lysosomal pathway 
(Meiser, Kraemer et al. 2018). Indeed, as the itaconate is a charged molecule, it hardly crosses 
Figure 14: Three-steps reaction of itaconate metabolization into pyruvate and acetyl-CoA. Itaconate is first activated into 
itaconyl-CoA via a succinyl-CoA synthetase (Scs). Itaconyl-CoA is then hydrated into citramalyl-CoA via an itaconyl-CoA 
hydratase (Ich), and the citramalyl-CoA is cleaved into pyruvate and acetyl-CoA via a citramalyl-CoA lyase (Ccl). Adapted from 
(Sasikaran, Ziemski et al. 2014). 




the cell membrane, leading to the hypothesis that this compound acts locally (Meiser, Kraemer 
et al. 2018). For now, the mechanism of itaconate entry in bacteria is not known. 
 Itaconate and its anti-bacterial role 
In 1971, Williams showed that itaconate was able to inhibit the purified isocitrate lyase (ICL) 
of Pseudomonas indigofera in an uncompetitive way, at a succinate-specific site (Williams, 
Roche et al. 1971). ICL is a key enzyme of the glyoxylate shunt (Figure 15), an anabolic variant 
of the Krebs cycle, mainly present in plants, nematodes, and microorganisms (Kornberg and 
Krebs 1957). In microorganisms, this pathway is used to survive in low-glucose environment 
like in phagolysosomes for example (Uribe-Querol and Rosales 2017). Indeed, this alternative 
pathway allows to bypass the loss of two CO2 molecules which occurs in Krebs cycle (Figure 
15). In this low-glucose context, acetyl-CoA, generated by fatty acids β-oxidation, is the only 
source of carbon available, but the molecule only contains two carbons. To remedy this, the 
glyoxylate shunt bypasses two decarboxylation steps of the Krebs cycle by first hydrolyzing 
the isocitrate to succinate and glyoxylate, by the ICL. The succinate enters in the Krebs cycle 
and the glyoxylate (plus acetyl-CoA) synthetizes malate via the malate synthase (MS). The 
malate molecule enters at its turn in the Krebs cycle to produce glucose by neoglucogenesis 
Figure 15: The glyoxylate shunt. The glyoxylate shunt is an alternative pathway that certain microorganisms possess. It allows 
them to bypass the loss of carbons during the classical Krebs cycle in stressful nutritional conditions. Only two enzymes are 
involved in this pathway: the isocitrate lyase and the malate synthase.  




(Figure 15) (Kornberg and Krebs 1957). If in some bacteria, the MS is usually constitutive, the 
ICL is only active when two-carbon molecules are available. As there are exceptions, 
Pseudomonas for example possesses high concentration of ICL, even when the glyoxylate shunt 
is not required (McFadden and Purohit 1977). The ICL (and thus the glyoxylate shunt) was 
afterwards reported as essential for latent infection in different models. First, in Mycobacterium 
avium, Sturgill discovered a protein present in Mycobacterium after phagocytosis in 
macrophages in vitro by a two-dimensional gel analysis. This protein was shown later to be ICL 
(Sturgill-Koszycki, Haddix et al. 1997). Two years later, icl gene was confirmed to be one of 
the most upregulated gene in Mycobacterium tuberculosis during phagocytosis by human 
macrophages (Graham and Clark-Curtiss 1999). The same year, Honer demonstrated that in 
Mycobacterium, a second gene encodes for another protein with an isocitrate activity: aceA/icl2. 
But it seems to have a subordinate role, when the concentration of isocitrate is too high (Höner, 
Kerstin et al. 1999). Even if Mycobacterium ICL seems dispensable for growth during the acute 
phase, it seems crucial for long term persistence and virulence in mouse models. Indeed, a 
mutation in M. tuberculosis icl supported a role for the glyoxylate shunt in pathogenesis 
(McKinney, Honer zu Bentrup et al. 2000). In fungi, enzymes of the glyoxylate shunt (ICL and 
MS) are also required for the virulence in mice. Indeed, Saccharomyces cerevisiae, and 
Candida albicans show an upregulation of the expression of these genes when they are in 
contact with phagolysosomes during mouse infection, as suggested by genomic expression 
profile analyses (Lorenz and Fink 2001). The anti-bacterial role of itaconate, via the ICL 
inhibition, has been confirmed in Mycobacterium, Pseudomonas and Salmonella in vitro 
models (Rittenhouse and McFadden 1974, McFadden and Purohit 1977, Michelucci, Cordes et 
al. 2013). 
In infected mammal cells, a proximity between mitochondria (where itaconate is produced) and 
microorganisms has been reported several times: in 1999 for Chlamydia (Matsumoto, Bessho 
et al. 1991), in 2011 for Toxoplasma gondii (Sinai and Joiner 2001) and more recently in 2016 
and 2018 for Legionella (Naujoks, Tabeling et al. 2016) and Brucella (Lobet, Willemart et al. 
2018), respectively. Even if more investigations are needed, this proximity could be either an 
advantage for the host which will recruit somehow the microorganism-containing vacuole to 
bring it closer of the itaconate production center, or an advantage for the microorganism itself 
to be closer of the energetic central of the cell. Brucella possesses ICL and MS enzymes, but 
does not seem to use the glyoxylate shunt. Indeed, a study showed that B. abortus grows in 
vitro with 6 or 5-carbons sugars, compensated by amino acids, but without an important role of 




glyoxylate shunt (Zuniga-Ripa, Barbier et al. 2014). Moreover, the deletion of aceA gene 
(coding for ICL enzyme) has no impact on the in vitro growth in rich medium, and no impact 
in vivo, after an i.p. B. abortus infection (Zuniga-Ripa, Barbier et al. 2014). 
 Itaconate and its anti-inflammatory role 
In 2018, Nair and colleagues tested the hypothesis that itaconate could inhibit the ICL of 
Mycobacterium to decrease the infection rate. For that they first intranasally infected wt and 
Acod1-KO mice with a wt M. tuberculosis strain (Nair, Huynh et al. 2018). They observed that 
75 % of Acod1-KO mice died at 30 days post infection, contrary to wt mice that survived up to 
80 days post infection (Nair, Huynh et al. 2018). This highlights the importance of Acod1 and 
thus itaconate in the control of M. tuberculosis in vivo infection. Then they infected intranasally 
wt and Acod1-KO mice with M. tuberculosis wt or deficient for ICL (icl1). They observed that 
all the wt mice survived to the infection and all Acod1-KO mice died from the infection. 
However, in the Acod1-KO mice, the CFU of icl-deficient strain was higher than the CFU of 
wt strain, suggesting that even if itaconate was important in this model to control the infection, 
it was independent of the ICL, suggesting another mechanism of action of itaconate in vivo. As 
the Acod1-KO mice died with a phenotype close of IFN-γ-KO mice, Nair and his team 
hypothesized that maybe itaconate was linked to the inflammation (Nair, Huynh et al. 2018).   
1.3.5.1 Itaconate and IFN-dependent genes 
Pretreatment of Bone Marrow-Derived Macrophages (BMDM) with E. coli.-LPS and IFN-β 
increases the expression of Acod1 and the production of itaconate (Mills, Ryan et al. 2018). 
This increase, in part via type I IFNs, promotes the SDH inhibition, the Nuclear factor erythroid 
2-related factor 2 (Nrf2) activation (that will be discussed in the next two points), but also its 
own production via a negative feedback loop on IFN genes. The addition of 4 octyl-itaconate 
(4OI), a derivative of physiological itaconate,  - see BOX-7) to activate BMDM decreases type 










BOX-7. The different derivatives of itaconate (Hooftman and O'Neill 2019).  
Physiological itaconate needs derivatives for studies as it is 
not sure yet if/how this molecule is transported inside 
bacteria as it is a negatively charged non permeable form. 
The dimethyl-itaconate (DMI): the esterification of one 
carboxyl group of physiological itaconate allows a decrease 
in the negative charge of the molecule and provides a better 
membrane permeability. However, this modification leads 
to some negative impacts: the electrophilicity is increased and maybe lead to other effects of 
the molecule. Another problem is that the DMI is not metabolized to itaconate inside the cell, 
but instead could boost the biosynthesis of physiological itaconate. The DMI is able to 
inactivate the glutathione and to activate Nrf2 as the physiological itaconate. 
The 4-octyl-itaconate (4OI): the physiological itaconate has been modified by esterification 
to add an octyl ester to the double carbon-carbon bond responsible of the thiol reaction. The 
4OI can be hydrolyzed to itaconate inside the cell, even if in murine macrophages, stimulation 
by LPS is required. 4OI is able to modify the same cysteine on certain enzymes than 
physiological itaconate, but not on all enzymes. 
 
The same year, Naujoks studied the itaconate-IFN link on a Legionella in vivo model (Naujoks, 
Tabeling et al. 2016). In this study, the authors compared the genes expression in infected or 
control lungs mice and showed that more than 1,500 genes were up regulated after the infection. 
Among these genes, type I (mainly) and type II IFN were shown to be important for the control 
of Legionella infection (Naujoks, Tabeling et al. 2016). To know by which pathways IFN genes 
led to a better control of Legionella infection, they compared the proteomics of Legionella-
containing vacuole (LCV) in resting macrophages and in IFN-activated macrophages at 2 hours 
post infection. As the activation of macrophages with IFN did not change the markers of LCV 
and lysosomes, they concluded that IFN genes do not control the infection by inhibiting the 
establishment of the LCV or by triggering the fusion of the LCV with lysosomes (Naujoks, 
Tabeling et al. 2016). After having silenced IFN-dependent genes, they found that Acod1 
expression was impacted, leading to a better replication of Legionella in BMDM. By contrast, 
when BMDM were stimulated with IFN or infected with Legionella, Acod1 was upregulated in 




both situations. By Gas Chromatography Mass Spectrometry, they found that IFN stimulation 
or Legionella infection increase itaconate production in host cells. In vivo also, Acod1 gene was 
upregulated in lungs of mice after infection, and the presence of its metabolite itaconate was 
also increased, in an IFN-dependent manner (Naujoks, Tabeling et al. 2016).  
1.3.5.2 Itaconate and the inhibition of the SDH 
Different studies link itaconate to the inflammation by different mechanisms. Among others, it 
was shown that an activation of macrophages in vitro with E. coli.-LPS leads to the 
accumulation of succinate, this latter affecting a lot of different pathways by controlling the 
Reactive Oxygen Species (ROS) production, IL-1β and Hypoxia-Inducible Factor-1 (Kelly and 
O'Neill 2015). Itaconate was shown to inhibit SDH in 1949 (Ackermann and Potter 1949), but 
at this moment, as no effect on the Krebs cycle itself was observed, it did not raise interest of 
the scientific community. In 2016, Lampropoulou showed that after activation of BMDM with 
E. coli.-LPS, an increase in Acod1 gene expression and itaconate production was observed 
(Lampropoulou, Sergushichev et al. 2016). The authors also observed that addition of dimethyl-
itaconate (DMI), a permeable form of itaconate (BOX-7), to pre-treated BMDM with E. coli.-
LPS or IFN+ E. coli.-LPS decreases the production of iNOS, IL-6 and IL-12p70, leading to a 
weaker activation of pro-inflammatory macrophages. These decreases are not completely 
dependent on the nuclear factor-kappa β (NFκB) signaling as the authors did not observe any 
change in TNF-α production. To study the pathway impacted by itaconate, the authors did a 
RNAseq, comparing E. coli.-LPS activated BMDM with or without addition of DMI. In the 
activated BMDM treated with DMI, a decrease of pro-inflammatory transcript was observed, 
with the decrease of IL-6, IL-12 for examples (Lampropoulou, Sergushichev et al. 2016). The 
production of IL-1β was also decreased, which is normally induced under NLRP3-activating 
conditions. After a Salmonella infection of BMDM treated with DMI, they also observed a 
decrease of IL-1β, IL-6 and NO production in comparison to infected BMDM without DMI 
treatment (Lampropoulou, Sergushichev et al. 2016). Moreover, no difference in the number of 
bacteria per cell was observed between both conditions. Based on that, they concluded that 
itaconate does not have a direct bactericidal impact, but rather that an immune-regulatory role. 
To elucidate that, they did a computational analysis to link inflammation and metabolism in 
presence of itaconate, and they found that in presence of itaconate, the SDH was inhibited. This 
inhibition probably occurs via a competitive way, as the structure of itaconate is very close of 
the one of malonate, a known inhibitor of SDH (Lampropoulou, Sergushichev et al. 2016). 




Since the prediction in 1949 made by Ackermann and Poter, it is the first direct evidence in an 
inflammation model that itaconate could inhibit SDH. After purification of SDH in the presence 
or absence of itaconate, authors showed that the SDH activity was inhibited in presence of 
itaconate, and they observed an accumulation of succinate, the substrate of this enzyme. In vivo 
also Lampropoulou showed that DMI was able to inhibit SDH, impacting the ROS production, 
and so the ROS-dependent cytokines such as IL1-β. Indeed, SDH, in addition to being part of 
Krebs cycle, is also the second complex of the respiratory chain of electron (Lampropoulou, 
Sergushichev et al. 2016).  
1.3.5.3 Itaconate and the activation of Nrf2 
Another explanation of the decrease in IL-1β in presence of itaconate could be the activation of 
Nrf2, a transcriptional factor protecting against the oxidative stresses (Mills, Ryan et al. 2018). 
In unstressed conditions, Nrf2 is sequestered by Kelch-like ECH-associated protein 1 (KEAP1), 
an adapter protein of an ubiquitin ligase. It has been shown that 4OI, another permeable form 
of itaconate (BOX-7), modifies a cysteine on KEAP1 by alkylation, leading to its inactivation 
and hence so the activation of Nrf2 (Itoh, Wakabayashi et al. 1999). The DMI could also 
activates Nrf2 as DMI, being a Michael acceptor (see BOX-8), could have properties close of 
dimethyl-fumarate (DMF), which is known to activate Nrf2 (Brennan, Matos et al. 2015).  
BOX-8. Michael reaction of itaconate and cysteine (modified from (Bambouskova, Gorvel 
et al. 2018)). The Michael reaction is a reaction allowing mainly the link between two carbons. 
It consists in the addition of a carbanion (negative organic compound) to an α,β-unsaturated 
carbonyl compound. Itaconate contains an electrophilic α,β-unsaturated carboxylic acid and 
could alkylate other proteins on their cysteine residues, leading to the formation of 2,3-
dicarboxypropyl adducts. 
 




Once activated, Nrf2 is then able to modulate different anti-oxidant like glutathione (Itoh, 
Wakabayashi et al. 1999) and eliminate the ROS production via those different intermediates. 
Usually, ROS production leads to the formation of NLRP3-inflammasome and so to the 
activation of caspase-1. This last one cleaves the pro-IL-1β and pro-IL-6 into their mature 
forms. But in the presence of activated Nrf2, the elimination of ROS will lead to an indirect 
decrease in IL-1β and IL-6 (Martinon, Burns et al. 2002, Cruz, Rinna et al. 2007). Moreover, 
Nrf2 could also have a direct impact on IL-1β production inhibition by binding DNA close to 
IL-1β and IL-6 genes, leading to the inhibition of the transcription of these genes (Kobayashi, 
Suzuki et al. 2016). Both DMI and 4OI activate Nrf2 and decreases IL-1β levels. In vivo, Mills 
showed that injection of 4OI by i.p. increases the survival of mice previously injected with E. 
coli.-LPS, by increasing Nrf2, and hence so by decreasing some pro-inflammatory cytokines 
such as IL-1β production (Mills, Ryan et al. 2018).  
1.3.5.4 Itaconate and the ATF3/IκBζ axis 
It was already discussed above that DMI treatment of BMDM showed an increase in 
electrophilic stresses. The electrophilic stresses are able to inhibit NFκB inhibitor ζ (IκBζ) 
protein induction at a transcriptional level in a Nrf2-independent manner. As the Nrf2-deficient 
BMDM did not lead to the IκBζ and IL-6 inhibition, Bambouskova and its team did a RNA-seq 
in Nrf2-deficient and wt BMDM in the presence of itaconate in order to identify the inhibitor 
of IκBζ (Bambouskova, Gorvel et al. 2018). Among the differentially expressed genes, 
Activating transcription factor 3 (ATF3) was a good candidate as it is known to be a negative 
regulator of TLR4 (Gilchrist, Thorsson et al. 2006) and that IκBζ is one of the main 
transcriptional factor regulating TLRs stimulation after infection or E. coli.-LPS stimulation. In 
the presence of itaconate, this transcriptional factor and its associated genes (such as IL-12β 
and IL-6) were shown to be inhibited (Bambouskova, Gorvel et al. 2018). The authors found a 
great overlap between genes regulated by itaconate and those regulated by ATF3. In ATF3-
deficient BMDM, the levels of IκBζ and IL-6 were restored in presence of DMI, suggesting 
that ATF3 could mediate the action of DMI. So, DMI could negatively impact the expression 
of IL-6, IL-12 genes, dependent on IκBζ transcriptional factor, in a ATF3-dependent manner. 





Figure 16: Summarize of the different roles of itaconate. Itaconate, synthetized from cis-aconitate, has two main roles: an 
immune-regulator one, and an anti-bacterial one. In the first one, itaconate is able (1) to decrease the level of IL-1β via the 
inactivation of the succinate dehydrogenase (SDH), and via the activation of Nrf2, (2) to decrease the level of IL-6 via the 
activation of ATF3. In its anti-bacterial role, itaconate was shown to inhibit the isocitrate lyase (ICL) of some bacteria, leading 
to an inhibition of the bacterial growth, in a glyoxylate shunt-dependent manner.    





One of the most physiological routes of infection to study Brucella infection in a mouse model 
is the intranasal infection. This route of infection confronts Brucella with the mucosal immune 
system. Brucella must escape from it to be able to reach the lymph nodes and the spleen. The 
immune effector mechanisms controlling Brucella in lungs remain still largely unknown. At 5 
and 12 days post infection, comparison of wild type and genetically deficient mice demonstrates 
that IL-17-dependent TH17 and IFN-γ-dependent TH1 responses, respectively, are 
indispensable to control infection. However, due to the stealth feature of Brucella, inflammation 
is weakly induced, which makes the analysis of the earlier immune response complicated. 
Following Brucella inoculation, alveolar macrophages are the main infected cells in lungs 
during the first 48 hours of infection. It is why we wanted to use a without a priori approach 
(RNA-sequencing) in order to identify upregulated genes in alveolar macrophages following 
Brucella intranasal infection of mice. This approach should allow us to identify candidate genes 
participating in the early control of Brucella growth in alveolar macrophages. 
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Brucellosis is one of the most widespread bacterial zoonoses worldwide. Here, our aim 
was to identify the effector mechanisms controlling the early stages of intranasal infection by 
Brucella in C57BL/6 mice. During the first 48 hours of infection, alveolar macrophages (AMs) 
are the main infected cells in the lungs. Using RNA sequencing, we identified the aconitate 
decarboxylase 1 gene (Acod1; also known as Immune responsive gene 1, Irg1), as one of the 
most upregulated genes in murine AMs in response to B. melitensis infection at 24h post-
infection. Upregulation of Acod1was confirmed by RT-qPCR in lungs infected by B. melitensis 
and B. abortus. We observed that Acod1-/- C57BL/6 mice display a higher bacterial load in their 
lungs than wild type (wt) mice following B. melitensis or B. abortus infection, demonstrating 
that Acod1 participates to the early control of pulmonary Brucella infection. The ACOD1 
enzyme is mostly produced in mitochondria of macrophages, and converts cis-aconitate, a 
metabolite from the Krebs cycle, into itaconate. Dimethyl-itaconate (DMI), a chemically 
modified membrane permeable form of itaconate, has a dose-dependent inhibitory effect on 
B. melitensis and B. abortus growth in vitro. Interestingly, DMI does not inhibit multiplication 
of the isocitrate lyase deletion mutant ∆aceA B. abortus in vitro. Finally, we observed that, 
unlike the wild type strain, ∆aceA B. abortus strain multiplies similarly in wt and Acod1-/- 







Brucellae are facultative intracellular Gram-negative coccobacilli that infect mammals 
and cause brucellosis (reviewed in (1)(2)(3)(4)). Human brucellosis is a zoonotic infection that 
is mainly transmitted through ingestion of food contaminated with Brucella. Aerosols 
contamination is also common during abortions or in butcher’s shops. Without prolonged 
antibiotics treatment, brucellosis causes a severe and debilitating chronic disease (1)(5).  
The mouse is the experimental animal model the most commonly used to study Brucella 
infection (6). Following intranasal infection, B. melitensis multiplies in the lungs for several days 
before spreading to draining lymph nodes and then to the spleen where they persist for months 
(7). Chronically B. melitensis infected mice develop a protective memory response able to 
efficiently control a secondary Brucella infection (8). However, this response is not able to 
eliminate bacteria that has settled in CD11c+ splenic reservoir cells during primary infection (9), 
suggesting that splenic reservoir cells constitute a niche that hides Brucella from IFN-γ 
mediated protective immune response (10)(11). Thus, in order to develop new therapeutic 
strategies against brucellosis, it would be very useful to identify the early-acting mechanisms 
against Brucella in the lungs before it has established its niche in the spleen. 
Over the course of evolution, Brucella has acquired specific stealth strategies that allow 
it to reduce or interfere with its recognition by the immune system and neutralize immune 
effector mechanisms (reviewed in (3)(12)). Consequently, the inflammatory response against 
Brucella is particularly weak and difficult to detect. We previously showed that TCR-d, TAP1, 
and IL-17RA deficiencies affect the early control of B. melitensis in the lungs (5 days post 
infection) (8). At high dose of infection, IL-1R and inflammasomes appear involved in early 
immune protective mechanisms against respiratory B. abortus infection (7 days post infection) 
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(13). However, the precise effector immune mechanisms involved in early control of Brucella 
remain largely unknown. 
Alveolar macrophages (AMs) are well-known to act as first line pulmonary immune 
sentinels and constitute the dominant immune cells in lungs at the steady state (14). In the first 
days of intranasal infection, CD11c+ F4/80+ AMs constitute the main pulmonary cells infected 
by Brucella (15)(7). Their elimination increases the spread of B. abortus to the draining lymph 
nodes (15), suggesting that they display an ability to partially control Brucella multiplication. 
AMs perform a critical homeostatic role by clearing inhaled material from the airways and by 
recycling pulmonary surfactant (14). Due to these steady-state functions, AMs express unique 
transcriptional and epigenetic profiles that are highly distinct from those of other tissue-
resident macrophages (16). It is therefore not surprising that Brucella was shown to induce in 
vitro weak IL-1β, IL-6, and TNF-α production in lungs alveolar macrophages compared with 
peritoneal macrophages (17). 
In the present study, to identify the mechanisms involved in Brucella control by AMs, 
we have chosen to use an unbiased approach by RNA sequencing (RNAseq) on whole lungs and 
purified AMs samples from mice infected by the intranasal route with B. melitensis. We 
observed that Acod1/Irg1 gene, coding for a cis-aconitate decarboxylase (18), is among the 
most overexpressed genes in response to infection and we demonstrate that Acod1 






Acod1 is one of the most upregulated gene in alveolar macrophages from B. melitensis 
infected mice. 
In order to identify the immune effector mechanisms controlling the early multiplication 
of Brucella in the lung, we compared gene expression in the lungs of Brucella-infected and PBS-
treated wild type C57BL/6 mice. Mice were infected with 107 CFU of B. melitensis and sacrificed 
24 hours later. Lungs were harvested and analyzed by RNA sequencing. The results of this 
analysis are presented Figure S1. A volcano plot representation of these data shows that only 
a very low number of genes is significantly upregulated by infection (Figure S2). Among them, 
Lipocalin-2 (Lcn2) is involved in innate immune response against bacteria by sequestering iron 
(19). Klf2 (Krüppel-like Factor 2), Irx1 (Iroquois homeobox 1) and Cebpd (CCAAT enhancer 
binding protein delta) are transcription factors. This contrasts sharply with the increase in the 
expression of 1526 genes observed in the lungs of wild type C57BL/6 mice after intranasal 
infection of 106 CFU of Legionella pneumophilia (20). However, the very weak immune response 
induced by Brucella in lung is not really surprising given the well-known Brucella's stealth 
strategy (12). 
We hypothesize that the early immune response against Brucella is not systemic in lung 
and should be sought at the cellular level, in the first cells infected with Brucella. Following 
intranasal infection, alveolar macrophages (AMs) constitute the main pulmonary cells infected 
by Brucella between 2 and 24 hours (15)(7). In order to confirm this in our experimental model, 
we intranasally infected wild type C57BL/6 mice with 107 CFU of mCherry-B. melitensis stained 
with the fluorescent tracer eFluor670. The latter makes it possible to visualize by flow 
cytometry the cells infected with Brucella (7). We confirm that the main infected cells at 24 
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hours post infection express the CD11c and Siglec-F markers (89.9 % of total infected cells) and 
are therefore indeed AMs (Figure S3). Then, we purified under biosafety condition 3 the low-
density lung cells expressing the CD11c marker in mice infected for 24 hours with 107 CFU of 
eFluor670 stained mCherry-B. melitensis. This cell fraction is highly enriched in infected cells of 
the AM type and contains 73 % of CD11c+ eFluor+ cells (Figure S3.B). 
We compared gene expression in AMs enriched fraction purified from the lungs of 
Brucella-infected and PBS-treated wild type C57BL/6 mice. The results of this analysis are 
presented Figure S4. A volcano plot representation of these data shown that 466 genes (R1 
genes) are significantly upregulated in infected mice (Figure 1.A). We used the Metascape 
platform to perform a pathway enrichment analyze of these genes. The first signature identified 
is the response to interferon-beta (Figure 1.B). The genes associated with this signature (R2 
genes) were represented on a heatmap to see the expression of each gene of this pathway 
(Figure 1.C). Among them, some genes are described to play an effector role in the innate 
immune response against intracellular pathogen. Igtp (IFN-gamma-inducible GTP-binding 
protein) participate to disruption of Toxoplasma gondii vacuoles (21). Gbp3 and Gbp6 regulate 
the cell-autonomous immunity in macrophages by coordinating a potent oxidative and 
vesicular trafficking program to protect the host from intracellular bacteria (22). The 
implication of Gbp proteins in the STING-dependent type I interferon response against B. 
abortus has already been described (23). A very interesting candidate is the Acod1/Irg1 gene 
which has been described to play a role of direct effector against intracellular bacteria but also 
a role of regulator of the inflammatory response (reviewed in (24)). The involvement of this 





Figure 1. Acod1 is one of the most upregulated gene in alveolar macrophages from B. melitensis infected mice. 
Wild type C57BL/6 mice were intranasally infected with 107 CFU of wild type B. melitensis 16M. Lung were 
harvested at 24 hours post infection, alveolar macrophages purified and the RNA extracted and sequenced. Naïve 
mice receiving intranasally PBS were used as control. (A) Volcano plot of RNA-seq data from naïve versus infected 
alveolar macrophages shows the adjusted P-value (false discovery rate, FDR -log10) versus fold change (log2). The 
466 genes with a FDR < 0,05 and FC > 1,5 are shown in the R1 green square. Acod1 is the 178th most upregulated 
gene. (B) The R1 genes have been copy-paste in Metascape (https://metascape.org) to perform a pathway 
enrichment analyze. (C) The R2 genes from the first pathway coming out from Metascape analyze were 
represented on a heatmap to see the expression of each gene of this pathway. The color scale indicates the Z 




Acod1 deficiency induces a lack of Brucella control in lungs.  
To formally determine whether Acod1 participates to the control of Brucella infection 
or not, we compared the CFU count of bacteria in lungs and spleen from wild type and Acod1-
/- C57BL/6 mice intranasally infected with 107 CFU of wild type B. melitensis or B. abortus (Figure 
2.A). We observed that Acod1-/- mice infected with B. melitensis displayed significantly 
enhanced CFU only at 9 days post infection in lungs, when compared to wild type mice. In 
contrast, CFU count are significantly enhanced at 2, 5- and 9-days post infection in Acod1-/- mice 
infected with B. abortus. This difference may be the consequence of the lower induction of 
Acod1 in response to infection with B. melitensis (Figure 2.B). In agreement, Acod1 deficiency 
has only minimal impact on the course of B. melitensis and B. abortus in spleen where no Acod1 




Figure 2.  Acod1 gene expression is correlated to Brucella control in lungs. (A) wild type and Acod1-/- C57BL/6 
mice were intranasally infected with 107 CFU of wild type B. melitensis 16M or B. abortus 2308, as indicated. At 2, 
5, 9- and 28-days post infection, lungs and spleen were harvested and CFU were counted.  Each point represents 
one mouse. n= number of mice used. Grey bar represents the mean. Significant differences between the indicated 
groups are marked with asterisks: *p < 0.1, **p < 0.01. ns= non-significant. Data are representative of at least 3 
independent experiments. (B) wild type C57BL/6 wt mice were intranasally infected with 107 CFU of wild type B. 
melitensis 16M or B. abortus 2308, as indicated. At 2, 5- and 9-days post infection, lungs and spleen were harvested 
and RNA was extracted. After reverse-transcription into cDNA, qRT-PCR were done with Acod1 primers. At least 6 
mice were pooled for each condition. The data are representative of 3 independent experiments. The fold change 
number is indicated on the bars.  
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Enhanced susceptibility of Brucella infected Acod1-/- mice is not associated to higher 
inflammation in lungs. 
Acod1 deficiency has been associated to a lack of inflammatory control in several model 
of viral (25) and bacterial (26) infection in mice. For example, Acod1-/- but not wild type C57BL/6 
mice, intranasally infected with Mycobacterium tuberculosis, succumbed rapidly, and mortality 
was associated with increased infection, neutrophilia and production of inflammatory 
cytokines (26). Depletion of neutrophils enhances survival of M. tuberculosis-infected Acod1−/− 
mice. 
In order to determine whether Acod1 tempers Brucella-induced inflammation in our 
experimental model or not, we analyzed the cellular recruitment induced by B. abortus in the 
lungs of infected mice. Wild type and Acod1-/- C57BL/6 mice were infected with 107 CFU of B. 
abortus and sacrificed 9 days post infection. The lungs were removed and analyzed by flow 
cytometry and fluorescence microscopy. The cytometric analysis shows that the infection 
induces an increase in the total number of cells in the lungs, with a significant increase in the 
number of neutrophils and B and T lymphocytes (Figure 3.A). However, this increase is not 
significantly different between wild type and Acod1-/- mice. Histological analysis shows no 
clusters of neutrophils (GR1+ cells) around cells infected with Brucella in the lungs. (Figure 3.B). 
Finally, a measurement of the expression of the proinflammatory cytokines TNF-a, IL-1b and 
IL-6 in these mice by RT-qPCR shows that these cytokines are indeed induced by the infection 
but are not significantly more expressed in the Acod1-/- mice than in wild type mice (Figure 4). 
On the whole, our data show that Acod1 deficiency does not lead to a detectable increase in 





Figure 3. Enhanced susceptibility of B. abortus infected Acod1-/- mice is not associated to higher cell recruitment 
in lungs. Wild type and Acod1-/- C57BL/6 mice were intranasally infected with 107 CFU of wild type mCherry 
expressing B. abortus 2308. At 9 days post-infection, mice were sacrificed and lung harvested. (A) Lungs cells were 
isolated and then analyzed by flow cytometry for FSC and the expression of CD3, F4/80, and B220 markers. 
Uninfected mice served as control. Significant differences between the indicated groups are marked with asterisks:  
*p < 0.1, ***p < 0.001. ns= non-significant. The cells were counted from the total cell number by organ. Data 
represent the number of total cells, neutrophils (F4/80neg Ly6G+), B cells (CD3neg B220+) and T cells (CD3+ B220neg) 
per lung from individual mice. 3 and 6 mice have been used for the control or the infected condition, respectively. 
These data are representative of at least 2 independent experiments. (B). Lungs were fixed, embedded. Slides of 
5 µm were made with a cryostat. Slides were stained and analyzed by fluorescent microscopy for the expression 
of DAPI, phalloidin, mCherry and GR1 marker. These images are representative of at least 2 independent 





Figure 4. Enhanced susceptibility of B. abortus infected Acod1-/- mice is not associated to higher pro-
inflammatory cytokines expression in lung. Wild type (red) and Acod1-/- (blue) C57BL/6 mice were intranasally 
infected with 107 CFU of wild type mCherry expressing B. abortus 2308. At 9 days post infection, mice were 
sacrificed, lungs collected, RNA extracted and qRT-PCR performed. TNF-α, IL-1β, and IL-6 expression levels were 
analyzed. Tbp gene was used as negative control, and RNA from naïve mice was used as standard condition. Data 
shown the fold increase of RNA expression for indicated cytokine from infected mice compared to control mice. 
At least 6 mice were pooled for each condition. The data are representative of 3 independent experiments. 
ns=non-significant. 
 
In neutral pH condition, dimethyl-itaconate and 4-octyl-itaconate, but not itaconate, inhibit 
Brucella growth in culture. 
Acod1 gene codes for a cis-aconitate decarboxylase that converts the cis-aconitate into 
itaconate (18). Itaconate concentration reached 5 mM in mouse Bone Marrow-Derived 
Macrophages after LPS stimulation (27). It has been reported that itaconate could directly 
inhibit the in vitro multiplication of numerous bacteria such as S. enterica, M. tuberculosis (18), 
L. pneumophila, S. aureus and A. baumannii (20). As expected, we found that physiologically 
relevant concentrations of itaconate (8-12 mM) completely inhibits the in vitro growth of B. 
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melitensis and B. abortus in rich acidic medium (2YT, pH~3.5) (Figure S5.A). Surprisingly, at 
neutral pH in 2YT, itaconate does not seem to have any significant effect on Brucella 
multiplication in vitro, regardless of the species (Figure S5.B). This could be due to the inability 
of the itaconate to cross the bacterial membrane because of its charged nature. In vivo, after 
phagocytosis, Brucella is supposedly being at acid pH in the phagolysosome of the host cell, 
increasing the possibility of an increased membrane permeability. Thus, itaconate might be 
able to enter in Brucella in physiological in vivo conditions and exert its potentially inhibitory 
effect. To validate this hypothesis, we tested in vitro at neutral pH the impact of different 
concentrations of dimethyl-itaconate (DMI) (28), a membrane-permeable non-ionic form of 
itaconate, on the multiplication of B. melitensis and B. abortus. We observed that DMI inhibits, 
in a concentration-dependent manner, the growth of both Brucella species in rich medium 
(2YT) (Figure 5.A), suggesting that itaconate is able to specifically affect Brucella when it can 
cross its membrane. Similar results were obtained with 4-octyl-itaconate (27), another 
membrane-permeable non-ionic form of itaconate (Figure S6). 
B. abortus bacteria incubated for 24 hours in the presence of 10 mM of DMI in 2YT, 
washed and then cultured again in the absence of DMI show 100 times less CFU than control 
bacteria, not treated with DMI (data not shown), which demonstrates that the DMI is 
bactericidal for Brucella.  
 
Inhibition of Brucella growth in culture by dimethyl-itaconate is isocitrate lyase-dependent. 
Itaconate has been described to bind the bacterial enzyme isocitrate lyase (ICL) (18) 
which is part of the glyoxylate shunt that is exclusively found in prokaryotes, lower eukaryotes, 




Figure 5. The multiplication of Brucella in vitro is inhibited by dimethyl-itaconate via an isocitrate lyase-
dependent mechanism. (A) Comparison of the impact of different concentrations of dimethyl-itaconate (DMI) on 
the growth of wild type B. melitensis (left panel) or B. abortus (right panel) in rich medium (2YT). (B) Comparison 
of the impact of 1 mM of DMI on the growth of wild type, ∆aceA and ∆aceA-complemented B. abortus in poor 
medium (Plommet-Erythritol). (C) Dimethyl-fumarate (DMF) has been used as control, in the same conditions than 
(B). The bacteria grew during 72h at 37 °C, the OD was measured every 30 min in a Bioscreen system. The standard 




encountered by bacteria in phagolysosomes (29). We compared the effect of DMI on the 
growth of a wild-type strain and an ICL deficient strain (DaceA) of B abortus in a defined minimal 
medium for Brucella, the Plommet-erythrytol medium (30). We observed that the growth of 
the DaceA strain was much less affected by DMI than the growth of the wild type strain (Figure 
5.B). Complementation of the DaceA mutant with a plasmid encoding the isocitrate lyase 
renders it sensitive to DMI, which demonstrates that itaconate acts via ICL to inhibit the 
multiplication of Brucella under our experimental conditions. In contrast, dimethyl-fumarate 
(DMF), that is described to inhibit the growth of E. coli (31), reduce similarly the growth of wild 
type and DaceA B. abortus (Figure 5.C), suggesting that DMI is specifically responsible for the 
ICL-dependent inhibition of B. abortus growth. 
DMI treatment induces significant morphological changes in Brucella. Transmission 
electron microscopy (TEM) analysis shows that wild type B. abortus treated for 24 hours with 
1 mM DMI present significant thickening of the envelope (Figure S7). However, these 
alterations are also observed with DMI-treated DaceA B. abortus, demonstrating that these 
envelope defects do not correlate with the growth inhibition effect of DMI. 
 
Acod1 deficiency does not affect the growth of DaceA B. abortus in vivo.  
Finally, to determine whether Acod1-dependent control of Brucella infection in vivo is 
acting via bacterial ICL, wild type and Acod1-/- C57BL/6 mice we intranasally infected with 107 
CFU of wild type or DaceA B. abortus and sacrificed 9 days post infection. In striking contrast 
with wild type strain of B. abortus, CFU analysis of lungs from infected mice showed that growth 
of DaceA strain is not affected by Acod1 deficiency (Figure 6), demonstrating that Acod1-
independent control of Brucella in lungs is well dependent on the expression of ICL by Brucella. 
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In addition, the fact that the CFU of Acod1-/- mice infected with wild type and DaceA B. abortus 
are comparable is consistent with the proposal that ICL is the main target of Acod1. 
 
 
Figure 6. Acod1 deficiency does not affect the growth of DaceA B. abortus in vivo. Wild type and Acod1-/- C57BL/6 
wt mice were intranasally infected with 107 CFU of wild type or DaceA mCherry expressing B. abortus 2308, as 
indicated. At 9 days post infection, mice were sacrificed, lungs harvested and CFU counted. Each point represents 
one mouse, n = number of mice used for each condition. Grey bar represents the mean. Significant differences 
between the indicated groups are marked with asterisks: **p < 0.01. ns= non-significant. The data are 





Mucosal surfaces are portals of entry for the vast majority of pathogens. In the case of 
brucellosis, natural infections take place mainly via the intestinal (32) and respiratory tracts 
(33). Despite this, little is known about the immune mechanisms controlling Brucella at mucosal 
level. We have previously shown that the early multiplication of B. melitensis in the lungs of 
infected mice is controlled by the immune system. The comparison of mice genetically deficient 
for key elements of the innate and adaptive immune response demonstrated that gd T 
lymphocytes, CD8 T lymphocytes as well as pathways dependent on the IL-17RA receptor were 
involved (34). However, the precise mechanisms directly controlling the proliferation of 
Brucella in the lungs remain largely unknown. In order to identify them, we used a without a 
priori approach by performing RNA sequencing of the whole lungs as well as the main cells 
infected by Brucella, the alveolar macrophages. 
 Intranasal B. melitensis infection does not appear to induce any detectable systemic 
response in the lungs at 24 hours post infection, even at a dose of 107 CFU, which fits well with 
its stealth pathogen profile (3)(35). In striking contrast, analysis of the RNA profile of purified 
alveolar macrophages allowed us to identify 466 genes whose expression is significantly 
increased compared to uninfected controls. Clustering analysis carried out using Metascape led 
us to select several genes involved in the anti-bacterial immune responses induced by type 1 
interferon, such as Igtp, Gbp3, Gbp6 and Acod1. Among these, Acod1 is described to play dual 
roles in immunity and diseases (for a review see (24)) and has never been associated with the 
control of Brucella infection. We therefore chose to explore its role in the pulmonary immune 
response against Brucella. 
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Acod1 gene  was originally identified in 1995 as a 2.3-kb cDNA from a library synthesized 
from mRNA isolated from a murine macrophage cell line after LPS stimulation (36). It is 
markedly upregulated in response to pathogen associated molecular patterns, such as LPS and 
CpG and inflammatory cytokines, such as type I interferon and tumor necrosis factor. ACOD1 
enzyme catalyzes itaconate metabolite production by cis-aconitate decarboxylation and is 
mainly found in mitochondria of myeloid cells. 
Itaconate is well described to downregulate pro-inflammatory cytokine and reactive 
oxygen species productions by multiple mechanisms (24). It has been reported that Acod1 
expression tempers inflammation and prevent immunopathology during Mycobacterium 
tuberculosis (26) and Respiratory Syncytial Virus (25) infections in mice. In striking contrast, in 
our Brucella infection model, we showed that the absence of Acod1 does not significantly 
increase proinflammatory cytokines production or neutrophil recruitments in lungs from 
infected mice, despite a significant increase in the bacterial load in the lungs. Again, this must 
be the consequence of the stealth pathogen profile of Brucella. 
Itaconate is also known for its ability to inhibit the multiplication of several bacteria in 
vitro (18) and in vivo (20). We have shown that two membrane-permeable forms of itaconate, 
DMI and 4OI, fully inhibit Brucella multiplication in vitro. B. melitensis and B. abortus display 
the same sensitivity to DMI and 4OI. However, in mice, Acod1 deficiency increases susceptibility 
to B. abortus much more than to B. melitensis. This difference can be correlated to the earlier 
and stronger induction of Acod1 expression in the lungs by B. abortus than by B. melitensis 
following intranasal infection. This could be explained by the higher CFU level of B. abortus, 
comparatively to B. melitensis, in the lungs of wild type mice.  
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Itaconate inhibits bacteria multiplication via isocitrate lyase (ICL), the key enzyme of the 
glyoxylate shunt, a two-step metabolic pathway that serves as an alternative shunt to the 
tricarboxylic acid cycle and is essential for bacterial growth under specific conditions. In 
Mycobacterium tuberculosis, ICL also exhibits additional methyl-isocitrate lyase activity. This 
later is required for the detoxification of propionyl-CoA through the 2-methylcitrate cycle (18). 
No attenuation of ICL deficient B. abortus strain, DaceA, was reported in BALB/c mice (37). We 
showed that DaceA B. abortus is more resistant to itaconate inhibition in vitro than wild type 
bacterial strain and displays similar multiplication in wild type and Acod1-/- mice. On the whole, 
our results support a model in which ACOD1 enzyme restricts Brucella replication in murine 
alveolar macrophages through a bacterial ICL dependent mechanism. However, aceA 
deficiency does not prevent or reduce Brucella multiplication in lungs, demonstrating that ICL 
is not essential to Brucella multiplication in this condition. This suggests that Acod1-mediated 
ICL-dependent inhibition of Brucella multiplication in our murine infection model is not 
explained by a simple blockage of the glyoxylate shunt or by the toxic accumulation of 
propionyl-CoA. The precise mechanism of Brucella growth inhibition by itaconate therefore 
remains to be elucidated. It is interesting to remark that DMI induced also, independently of 
ICL, a massive disorganization of the bacterial envelope. One possible mechanism for this effect 
could be the inhibition of several L,D-transpeptidases, which are enzymes crosslinking peptide 
stems of the peptidoglycan. Indeed, these enzymes have a cysteine in their active site and 
itaconate is known to alkylate this residue. 
Our results demonstrate that Acod1 plays very different roles depending on the 
bacterial species. Its ability to regulate inflammation does not seem to be exercised against 
stealthy bacteria such as Brucella, although it is essential for the control of neutrophil-mediated 
immunopathology during M. tuberculosis infection (26). The capacity of itaconate to inhibit 
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bacterial multiplication can occur through a variety of pathways, which might be reflective of 
metabolic differences between bacteria species. 
In summary, our study provides for the first-time evidences showing a role of Acod1 cis-
aconitate decarboxylase enzyme producing itaconate in pulmonary control of Brucella infection 
in mouse model. We also demonstrate that this control is exerted at a cellular level, in alveolar 
macrophages, and acts via the bacterial enzyme isocitrate lyase. However, due to the moderate 
effect of Acod1 deficiency on Brucella multiplication in vivo, we hypothesize that ACOD1 acts 
in concert with other antibacterial factors, such as GBP proteins whose expression is also found 
increased in Brucella infected alveolar macrophages and which have been described as 
participating in the control of Brucella in vitro and in vivo (23). As mouse ACOD1 enzyme is 
∼80% identical in amino acid sequence to human ACOD1 with all five predicted cis-aconitate 
decarboxylase domains fully conserved (18), the development of pharmacological agents that 
enhance ACOD1 function or promote itaconate production might help to control early stages 




MATERIAL AND METHODS 
Ethics statement 
The procedures used in this study and the handling of the mice complied with current 
European legislation (Directive 86/609/EEC). The Animal Welfare Committee of the Université 
de Namur (UNamur, Belgium) reviewed and approved the complete protocol for Brucella 
melitensis and B. abortus infection (Permit Number: UN-LE-18/309). 
Mice, bacterial strains and reagent  
Wild type C57BL/6 mice were acquired from Harlan (Bicester, UK). Acod1-/- C57BL/6 
mice (49) were acquired from Dr Eik Hoffmann (University of Lille, France). All wild type and 
deficient mice used in this study were bred in the animal facility of the Gosselies campus of the 
Université Libre de Bruxelles (ULB, Belgium). 
The wild type B. melitensis 16M strain used here is a B. melitensis 16M stably expressing 
a rapidly maturing variant of the red fluorescent protein DsRed (55), the mCherry protein, 
under the control of the strong Brucella spp. promoter, psojA. The construction of the mCherry-
producing Brucella strain has been described previously in details (38). We also used mCherry-
wild type B. abortus 2308 (39) and mCherry-∆aceA (isocitrate lyase) B. abortus (37) and the 
complemented strain. Brucella abortus 2308 ∆aceA was complemented with the pMR10ΩaceA 
plasmid. Briefly, the aceA gene and its promoter was amplified with the Q5 High-Fidelity DNA 
polymerase (New England Biolabs) with the following forward and reverse primers 5’-CGC 
GGATCC ATT TCC ACC AGT TCC TGA TC -3’ and 5’-AAAA CTGCAG GGA TTG TTC TTC TGC TCT 
TTC-3’. PCR products were purified (Macherey-Nagel Clean-up kit) and cloned into the EcoRV 
site of the pGemT in E. coli DH10B. The aceA gene was then subcloned into the pMR10 plasmid 
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(a kind gift from C.D. Mohr and R.C. Roberts, Stanford University) with the restriction enzymes 
BamHI and PstI. The resulting plasmid was introduced into E. coli S17.1 strain (40) and into B. 
abortus 2308 ∆aceA by mating. Brucella strains were always handled under BSL-3 containment 
according to Council Directive 98/81/EC of 26 October 1998 and a law of the Walloon 
government of 4 July 2002. 
Itaconate (Sigma-Aldrich) as well as dimethyl itaconate (DMI) (Sigma-Aldrich) were 
diluted in bidistilled water, whereas 4-octyl-itaconate (4OI) (Sigma-Aldrich) was diluted in 
DMSO. After filtration, the solutions were stored at 4 °C. 
Intranasal Brucella infection 
Brucella cultures were grown overnight with shaking at 37°C in 2YT liquid medium 
(Luria-Bertani broth with double quantity of yeast extract) and were washed twice in RPMI 1640 
(Gibco Laboratories) (2000xg, 10 min) before inoculation of the mice.  
Mice were anesthetized with a cocktail of Xylasine (9 mg/kg) and Ketamine (36 mg/kg) 
in PBS before being inoculated by intranasal injection of the indicated dose of Brucella in 30 µl 
of RPMI. Control animals were inoculated with the same volume of RPMI. The infectious doses 
were validated by plating serial dilutions of the inoculums. At the selected time after infection, 
mice were sacrificed by cervical dislocation. Immediately after sacrifice, lungs and spleen were 
collected for bacterial count, flow cytometry, qRT-PCR, MAs purification and/or microscopic 
analyses.  
Bacterial counting  
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Organs were homogenized into PBS/0.1% X-100 Triton (Sigma-Aldrich). We performed 
successive serial dilutions in PBS to obtain the most accurate bacterial count and plated them 
on 2YT medium. The CFU were counted after 4 days of incubation at 37°C. 
RNA extraction 
RNA from whole lungs and spleen was extract with the Tripure/Chloroform method. 
Briefly, lungs and spleen were harvested from mice, cut in small piece and homogenized in 1 
mL of Tripure (Tripure Isolation Reagent – Roche). After 5 min of incubation at RT, 200 µL of 
chloroform was added, and the tube was mixed vigorously during 15 seconds, then incubated 
10 min at RT. After a centrifugation of 15 min (12,000xg at 4 °C), the aqueous phase was 
collected and placed in a new tube. 500 µL of isopropanol was added. The tube was mixed by 
inversion and centrifuged for 10 min (12,000xg at 4 °C). The pellet was washed twice with 75 % 
ethanol (7,500xg for 5 mi at 4 °C), suspended in 50 µL of water, and incubated for 10 min at 55 
°C to completely resuspend the RNA pellet. RNA from purified AMs was extracted with the 
RNeasy Mini kit (Qiagen).  
RNA sequencing and analyze 
After DNAse I, RNAse-free treatment (Thermo Scientific), the RNA samples were then 
transform into cDNA, and the library was prepared. The Novaseq 6000 Trueseq SBS reagents 
(25 millions reads paired-end) and Trueseq stranded RNA library preparation were used for the 
Illumina sequencing. 
Genes with no raw read count were filtered out with an R script. Raw read counts were 
normalized and a differential expression analysis was performed with DESeq2 by applying an 




RNA was treated with the DNAse I- RNAse-free kit (Thermo Scientific). Briefly, 2 µg of 
RNA was treated 30 min with DNAse I at 37 °C followed by DNAse I inactivation with 50 mM of 
EDTA for 10 min at 65 °C. The RNA was then reverse transcribed with Superscript II reverse 
transcriptase (Invitrogen) with hexamer random primers as described by the manufacturer. A 
condition without reverse transcriptase was also conducted in parallel as a negative control. 
cDNA was then mixed with SybrGreen mix (FastStart universal SYBR Green Master (Rox); Roche) 
and the appropriate primers sets and subjected to qRT-PCR in a LightCtcle96 (Roche). The 
forward and reverse primers used were 5’-GGC ACA GAA GTG TTC CAT AAA GT-3’ and 5’-GAG 
GCA GGG CTT CCG ATA G-3’ for Acod1, 5’-GCG AAC AAA GCC AGA TGC AA-3’ and 5’-CCC CTT 
TCC TCC CAA ACC AA-3’ for TNF, 5’-CGC ATG TTC CTG GGG AGA TT-3’ and 5’-TGG GAT GCA ACA 
TGG CTC TT-3’ for IL-1, 5’-GGC TTG CCC CAC TAC TTA GG-3’ and 5’-GCG AAC AAA GCC AGA TGC 
AA-3’ for IL-6. TATA binding protein (Tbp, forward 5’-GTT GGG GTG GCA TTT TCT GTG-3’, 
reverse 5’-GGC CTC TGC ATG TGT TCT CAT-3’) mRNA was used as the reference housekeeping 
gene for normalization. A total of 45 three-step cycles were performed as follows: 95 °C for 10 
sec, 60 °C for 10 sec, and 92 °C for 10 sec. Melting curves were then performed to assess primer 
specificity. Target mRNA fold change was calculated based on the 2-∆∆Ct formula, where Tbp 
gene was used as the reference gene, and RNA from naïve mice was used as standard condition. 
At least 6 biological replicates and 3 technical replicates were performed for each tested gene. 
Bioscreen analysis 
Overnight cultures were prepared in 2YT rich medium the day before in order to obtain an 
OD600 nm between 0.2 – 0.5 the day after. Cultures were washed twice in PBS (2000xg during 10 
min at RT), and there suspended in 2 YT rich medium or Plommet-Erythritol defined minimal 
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medium (30) in order to obtain an OD600 nm = 0.05 in a final volume of 700 µL. We used the 
Bioscreen system (Thermo Fisher) to measure the growth of Brucella at 37 °C during 72 hours. 
Brucella melitensis staining with eFluor670 
 For some histological and flow cytometry experiments, we stained B. melitensis with 
eFluor670 labelling. Cultures (10 ml) were grown overnight as indicated above, bacteria of 1 ml 
of culture were centrifuged (2 min, 7500xg, RT) and the pellets washed 3 times with 1 ml of 
PBS, then the bacteria were incubated for 20 min at RT in the dark with eFluor670 dye at the 
final concentration of 10 µM in 1 mL of PBS. After incubation, the bacteria were washed three 
times in 1 mL of PBS and once diluted in PBS in order to obtain the precise infectious dose 
before inoculation of the mice. 
Cytofluorometric analysis 
The lungs were harvested and cut into small pieces and incubated for 1 hour at 37°C 
with a mix of 100 μg/ml of DNAse I fraction IX (Sigma-Aldrich) and 1.6 mg/ml of collagenase 
(400 Mandl U/ml), as described previously (6). The cells were then washed, filtered and 
incubated with saturating doses of purified 2.4G2 (anti-mouse Fc receptor, ATCC) in 200 μl PBS, 
0.2% BSA, 0.02% NaN3 (FACS buffer) for 20 min at 4°C to prevent antibody (Ab) binding to the 
Fc receptor. 
3–5x106 cells were stained on ice with various fluorescent mAb combinations in FACS 
buffer. We acquired the following mAbs and reagents from BD Biosciences: BV421-coupled 
E50-2440 (anti-Siglec-F), BV421-coupled 1A8 (anti-Ly-6G), fluorescein (FITC)-coupled HL3 (anti-
CD11c), FITC-coupled 145-2C11 (anti CD3e), Alexa Fluor 647-coupled T45-2342 (anti-F4/80), 
APC-coupled RA3-6B2 (anti-CD45R/B220). The cells were analyzed on a BD FacsVerse flow 
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cytometer. Dead cells and debris were eliminated from the analysis according to size and 
scatter. 
Immunofluorescence microscopy of lung 
Lungs were fixed for 20 minutes at RT in 2% paraformaldehyde (PFA). Then, lungs, still 
in 2% PFA, were placed under a vacuum until no air was present in the lungs for 2 hours. After 
PFA fixation and two washes in PBS, lungs were incubated overnight at 4°C in a 20% PBS-sucrose 
solution. Tissues were then embedded in Tissue-Tek OCT compound (Sakura), frozen in liquid 
nitrogen, and cryostat sections (5 µm) were prepared. For staining, tissue sections were 
rehydrated in PBS and incubated in a PBS solution containing 1 % blocking reagent (Boeringer) 
(PBS-BR 1%) for 20 min before incubation overnight in PBS-BR 1% containing the following: 
DAPI nucleic acid stain Alexa Fluor 350, 488 phalloidin (Molecular Probes) and Alexa Fluor 647–
coupled RB6-8C5 anti-Ly6G/Ly6C (Gr1) (Biolegend). Slides were mounted in Fluoro-Gel medium 
(Electron Microscopy Sciences, Hatfield, PA). Labelled tissue sections were visualized with an 
Axiovert M200 inverted microscope (Zeiss, Iena, Germany) equipped with a high-resolution 
monochrome camera (AxioCam HR, Zeiss). Images (1384x1036 pixels, 0.16 μm/pixel) were 
acquired sequentially for each fluorochrome with A-Plan 10x/0.25 N.A. and LD-Plan-NeoFluar 
63x/0.75 N.A. dry objectives and recorded as eight-bit grey-level *.zvi files. At least 3 slides 
were analyzed per organ from 3 different animals and the results are representative of 2 
independent experiments.   
Purification and transmission electron microcopy analysis of alveolar macrophage. 
Pulmonary alveolar macrophages were obtained by homogenization and filtration of 
lungs, density gradient centrifugation (5 ml of 1.085 g/cm3 nycodenz were mixed to the cells, 
then 5 mL of cold RPMI was delicately added above the nycodenz, and the tube was 
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centrifuged, 1700xg during 30 min, with minimum braking). A CD11c specific Magnetic 
associated cell sorting (MACS) was performed on the collected low-density cells at the interface 
between nycodenz and RPMI by using MiniMACS, MS column and CD11c+ magnetic beads 
(Miltenyl Biotec). 
Purified alveolar macrophages were fixed 2 hours in 2,5% glutaraldehyde in cacodylate 
buffer 0,1 M at 4 °C, wash 3 times (4000xg, 5 min) with cacodylate buffer 0,2 M then postfixed 
in 2% osmium tetroxide in cacodylate buffer 0,1 M during 1 hour at RT. After 3 washes, samples 
were serially dehydrated in ethanol (EtOH 30 % first 5min, followed by 10 min – the same for 
EtOH 50 %, 70 %, 85 %, 100%). Propylene oxide was then added 4x5 min at RT and the pellet 
was progressively embedded in epoxy resin (Agar 100 resin; Agar Scientific, United Kingdom) 
(75:25, 50:50 and then 25:75 % of propylene oxide/resin). Ultrathin 50-nm sections were 
obtained, mounted on copper-Formvar-carbon grids (EMS, United Kingdom), and stained with 
uranyl acetate and lead citrate by standard procedures. Observations were made on a Tecnai 
10 electron microscope (FEI, Eindhoven, The Netherlands), and images were captured with a 
Veleta charge-coupled-device (CCD) camera and processed using the AnalySIS and Adobe 
Photoshop software programs. 
Statistical analysis 
We used a (Wilcoxon-)Mann-Whitney test provided by the GraphPad Prism software to 
statistically analyze our results. Each group of deficient mice was compared to the wild type 
mice. We also compared each group with the other groups and displayed the results when 
required. Values of p < 0.05 were considered to represent a significant difference. *, ** denote 
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Suppl Figure 1. RNAseq data of whole lungs from infected versus naïve mice. Wild type C57BL/6 mice intranasally 
infected with 107 CFU of wild type B. melitensis (n=3), or receiving the same volume of PBS (naïve group) (n=3), 
have been sacrificed at 24 h post infection. Lungs were harvested and RNA extracted. RNAseq was performed with 
Illumina system and Deseq2 analyze as described in material and methods. Data represent the list of genes 
associated to their fold change (FC) (Log2) and adjusted P value - log10 (false discovery rate, FDR). Data are 






Suppl. Figure 2. Few genes are upregulated following intranasal B. melitensis infection in whole lungs. Wild type 
C57BL/6 mice were intranasally infected with 107 CFU of wild type B. melitensis 16M. Lungs were harvested at 24 
hours post infection and the RNA was extracted and sequenced. Naïve mice receiving intranasally PBS were used 
as control. Volcano plot of RNA-seq data from naïve versus infected lung shows the adjusted P-value (false 
discovery rate, FDR -log10) versus fold change (FC) (log2). The four genes with an FDR < 0.05 and FC > 1.5 are 
shown in the R1 green square. RNAseq was performed at least two times and each sample was generated from a 






Suppl. Figure 3. Alveolar macrophages are the main B. melitensis infected cells in lung. Wild type C57BL/6 wt 
mice (n = 5) received intranasally PBS (control mice) or 5x106 CFU of mCherry-expressing B. melitensis labelled 
with eFluor670. Mice were sacrificed at 24 hours post infection. The lungs were harvested, and the cells were 
isolated and then analyzed by flow cytometry for the FSC and the expression of eFluor670, mCherry, CD11c, and 
Siglec-F as indicated. (A) Gating strategy. Numbers indicate the percentage of eFluor670+ cells among total cells 
(high panels) and the percentage of eFluor670+ cells that are also positive for CD11c and Siglec-F markers (low 
panels) in naïve mice (left panels) or infected mice (right panels). B. Same strategies of gating, but with previously 







Suppl Figure 4.  RNAseq data of alveolar macrophages from infected versus naïve mice. Wild type C57BL/6 mice 
intranasally infected with 107 CFU of wild type B. melitensis (n=3), or receiving the same volume of PBS (naïve 
group) (n=3), were sacrificed at 24 h post infection. Lungs were harvested, alveolar macrophages purified and RNA 
extracted. RNAseq was performed with Illumina system and Deseq2 analysis as described in material and methods. 
Data represent the list of genes associated to their fold change (FC) (Log2) and adjusted P value - log10 (false 






Suppl. figure 5. At neutral pH, itaconate does not inhibit Brucella growth in vitro. Comparison of the impact of 
different concentrations of itaconate on the growth of wild type B. melitensis (left panel) or B. abortus (right panel) 
in rich medium (2YT). A acidic itaconate (pH ≃	3.6). B. neutralized itaconate solution (pH = 7.0). The bacteria grown 
during 72h at 37 °C, the OD was measured every 30 min in a Bioscreen system. The standard deviation was 






Suppl. figure 6. 4-octyl-itaconate inhibit Brucella growth in vitro. Comparison of the impact of different 
concentrations of 4-octyl-itaconate on the growth of wild type B. melitensis or B. abortus in rich medium (2YT). 
The bacteria grown during 72h at 37 °C, the OD was measured every 30 min in a Bioscreen system. The standard 






Suppl. figure 7. Dimethyl-itaconate impacts wild type and DaceA B. abortus morphology in vitro. Transmission 
electronic microscopy images were performed as described in materials and methods section on wild type and 
DaceA B. abortus, cultured in poor medium (Plommet-Erythritol) overnight supplemented or not with 1 mM of 
dimethyl-itaconate. Red arrows indicate membrane alterations. 
  




 Discussion and perspectives 
The immune response in mice after an intranasal B. melitensis infection has been previously 
characterized in our group (Hanot Mambres, Machelart et al. 2016). We showed that CD8 αβ 
T cells, γδ T cells and IL-17RA are indispensable in the control of primary infection in lungs at 
5 days post infection and that IFN-γ secreting by CD4 αβ T cells is indispensable at 12, 28 and 
50 days post infection (Hanot Mambres, Machelart et al. 2016). However, the earlier immune 
response (before 5 days) has never been characterized. After i.n. infection, alveolar 
macrophages (AMs) are the main infected cells (> 90 %) the first 48 hours p.i (Potemberg, 
Demars, in submission). We used RNA-seq, a without a priori high throughput technique, to 
identify upregulated genes in infected AMs. After a first selection based on the false discovery 
rate (FDR) and fold change (FC) (FDR < 0.05, and FC > 1.5), few (466) genes appear 
significantly upregulated at 24 hours p.i., probably due to the Brucella stealth. We used meta-
analysis resource, Metascape, available freely online, to order these genes in different pathways. 
The “response to IFN-β” is the pathway the most represented.  
 
 The type I IFN response in bacterial infections 
Even if IFN-β responses are often associated to viral responses and to a tissue damage control 
(Lee and Ashkar 2018), there are more and more studies about the role of type I IFN in bacterial 
diseases. The effect of type I IFN signaling upon bacterial infection can be protective as well 
as detrimental for the host (Perry, Chen et al. 2005, Boxx and Cheng 2016, Kovarik, Castiglia 
et al. 2016). In one hand, type I IFN induces a host susceptibility by promoting apoptosis of 
immune cells such as macrophages or lymphocytes, by inhibiting the expression of IL-17A by 
γδ T cells, or by leading to the inhibition of neutrophils recruitment. For examples, it has been 
demonstrated that IL-1 and TH1 responses are inhibited after lungs infection with M. 
tuberculosis in mice, leading to an immunosuppression (Mayer-Barber, Andrade et al. 2011). 
Another example is the inhibition of IL-17A in an i.n. infection model with Francisella 
tularensis (Henry, Brotcke et al. 2007). The deleterious impact of type I IFN can also coming 
from an exacerbated immune response, defined by an over production of inflammatory 
cytokines and immune cells recruitment, as demonstrated after an i.n. infection with 
Staphylococcus aureus (Parker, Planet et al. 2014). In the other hand, type I IFN can protect 
against bacterial infections by promoting hosts defenses by inducing interferon-stimulated 




genes such as Acod1 in Legionella pneumophilia model (Naujoks, Tabeling et al. 2016), but 
also by inducing CXCL10 in Helicobacter pylori model (Watanabe, Asano et al. 2010) for 
examples. In those models, IFN-β-deficient mice are more susceptible to the infection than wild 
type mice. Those contrasted responses triggered by IFN-β are not yet understood but suggest 
an incontestable role of type I IFN in some bacterial infections. Among the genes from 
“response to IFN-β” in our Brucella model, aconitate decarboxylase 1 (Acod1) (also called 
Immune responsive gene 1, irg1) is one of the most upregulated gene in AMs at 24 hours post 
intranasal infection with 107 bacteria, with a fold change of 1.92 in comparison to AMs from 
uninfected mice. We decided to work with this gene as Acod1-deficient C57BL/6 mice are 
available, and as more and more publications about the role of Acod1 in bacterial infections 
emerged since 2016 (Lampropoulou, Sergushichev et al. 2016, Naujoks, Tabeling et al. 2016, 
Mills, Ryan et al. 2018, Nair, Huynh et al. 2018). We identified this gene only in AM at 24 
hours p.i., not in total lung cells. As Acod1 is a gene mainly expressed in mitochondria of 
myeloid cells, it is not surprising to do not detect it in RNA-seq performed on entire lungs. Of 
course, even if we detected Acod1 by RNAseq, and that we confirmed the expression of Acod1 
mRNA by qRT-PCR, we did not check the production of ACOD1 at the protein level. However, 
as the inhibition of bacterial growth seems dependent on ICL, we could speculate that ACOD1 
is produced, at least at a low level. 
 
 Acod1 and inflammation 
One of the well described role of Acod1 gene (and of its product itaconate) is an anti-
inflammatory role by decreasing pro-inflammatory cytokines production such as IL-1β or IL-
6. In in vitro and in vivo infectious models with Legionella or Mycobacterium, it has been shown 
that the absence of Acod1 leads to a loss of the infection control (Michelucci, Cordes et al. 2013, 
Nair, Huynh et al. 2018). In our model, we showed that the absence of Acod1 in Brucella 
infected mice leads to an increase in CFU (of 0.5 - 1 log) compared to wt mice, but this increase 
was not due to a lack of inflammation. Indeed, we did not observe a different recruitment of 
neutrophils, a difference of pro-inflammatory cytokines expression, or a difference in total 
recruited cells in lungs of Acod1-KO mice. 
One thing which seems quite obvious in this study is the difference of impact of the Acod1 
deficiency with B. melitensis or B. abortus in lungs after i.n. infection. Indeed, Acod1-KO mice 




showed higher susceptibility to B. abortus infection than Acod1-KO mice infected with B. 
melitensis. However, in vitro, itaconate, the product of ACOD1 action, inhibits the growth of 
both bacteria species in a similar manner at 4 mM and 6 mM in rich medium, suggesting that 
both species are equally sensitive to itaconate. Hence, the difference observed in vivo could be 
due to the fact that B. abortus is present at higher levels and persists longer in lungs of infected 
wt mice, probably due to a more inflammatory character than B. melitensis. In the literature, 
high levels of Acod1 expression are associated to highly pro-inflammatory bacteria such as 
Mycobacterium tuberculosis, Legionella pneumonae or Acinetobacter baumannii, suggesting 
that the trigger of inflammation is necessary for the expression of Acod1 (Naujoks, Tabeling et 
al. 2016, Nair, Huynh et al. 2018). A possible hypothesis could be that once highly 
inflammatory bacteria are detected by the immune system, the induced inflammation allows the 
induction of Acod1 expression allowing itaconate to play its anti-inflammatory role. Indeed, a 
too high inflammatory environment can be deleterious for the host. However, in the case of 
bacteria more stealth but enough inflammatory to induce Acod1 expression, itaconate could 
play its anti-bacterial role to try to eliminate bacteria. It would be the case for Brucella, known 
for its stealth (see introduction) and being a model where no inflammation impacts have been 
observed (no difference in cytokines expression, in recruited cells, etc.). Even if it is also 
realistic to imagine that highly inflammatory bacteria actively induce Acod1 gene to take 
advantage of the anti-inflammatory role of itaconate, this second hypothesis would not explain 
the expression of Acod1 in infections with less inflammatory bacteria. In addition, as the Acod1-
KO mice infected with Mycobacterium tuberculosis died at 21 d. p.i. of an important 
neutrophilia, the first hypothesis seems the most probable. This could explain why the impact 
of Acod1 on the control of Brucella is weaker than another more inflammatory bacteria. The 
fact that DMI completely inhibits the growth of B. melitensis and B. abortus in vitro, where 
inflammation is absent, also suggests that the inflammatory environment seems important for 
the expression of Acod1 and the itaconate role. In order to test this hypothesis, it would be 
interesting to infect wt and Acod1-KO mice with a more virulent mutant of Brucella. It is the 
case for example of the ∆fliC, a mutant for flagellin which presents CFU 2 logs higher than wt 
strain at 12 and 21 days post i.p. infection in spleen (Terwagne, Ferooz et al. 2013). Wild type 
B. microti could also be tested as this Brucella species is hyper-virulent in mice (Jiménez de 
Bagüés, Ouahrani‐Bettache et al. 2010). Another experiment that we could test is to decrease 
the infectious dose (to 105 bacteria for example) and infect intranasally wt and Acod1-deficient 
mice in order to evaluate the bacterial level in kinetic in lungs. Indeed, it would be interesting 




to test whether the immune system is not “saturated” by 107 bacteria as infectious dose. In 
addition, whether the hypothesis that inflammation is required to express Acod1 is correct, this 
lower dose should decrease the difference of CFU between both mice groups.  
Finally, lungs have been mainly studied as we did not observe expression of Acod1 in spleen 
and no difference of CFU between wt and Acod1-KO mice after an intranasal infection. What 
we should try is to infect wt and Acod1-KO mice by intraperitoneal injection to better confirm 
the absence of Acod1 expression in spleen. It would be also interesting to harvest the lungs after 
an i.p. and to study the infected cells in this organ to check if the route of infection impacts 
somehow the expression of Acod1 in lungs. 
 
 Itaconate and its alkylation power 
Itaconate is able to alkylate cystein residues of protein thanks to its electrophilic α,β-unsaturated 
carboxylic acid. The reaction is a Michael addition, forming a 2,3-dicarboxypropyl adduct 
between itaconate and the targeted protein. For example, itaconate alkylates KEAP1 protein on 
cysteine residues 151, 257, 288, 273 and 297 (Mills, Ryan et al. 2018). As shown in 
supplementary data, itaconate is able to modify the morphology of wild type and ∆aceA 
(deficient for ICL) Brucella in a same way, suggesting a non-specific and general action of 
itaconate on these bacteria. It is not really surprising as cysteine residues are abundant at the 
protein level. However, we showed that itaconate inhibits the growth of Brucella in an ICL-
dependent mechanism, in vitro (dose-dependent) but also in vivo as the level of CFU between 
Acod1-KO mice infected with B. abortus wt or B. abortus ∆aceA are the same. To go further 
in the study of the possible link between itaconate and ICL, it would be interesting to incubate 
itaconate with purified ICL, and to perform mass spectrometry in order to identify the presence 
of a modification on cysteine residues by itaconate, but also to mutate the cysteine residues of 
ICL to observe if the inhibition of the Brucella growth in these conditions is still present.   
 
 aceA gene, towards a new potential role? 
As ∆aceA B. abortus grows almost as well as the wt strain in poor medium, suggesting this 
gene to be non-essential, it seems that the link between itaconate and ICL does not lead to the 
inhibition of ICL activity but rather lead to consequences ICL-dependent. Therefore, the known 




impacts such as the glyoxylate shunt inhibition, or the propionyl-CoA detoxification linked to 
the ICL inhibition do not seem involved in our conditions. It could suggest another role of ICL, 
or the existence of a homologous gene.  One thing that seems obvious is the potential link 
between Acod1 expression induced by inflammation and the effect of itaconate on metabolism.  
 
 Role of Acod1 and itaconate at the cellular level 
We found Acod1 as being one of the most interesting upregulated gene in AMs at 24 hours post 
intranasal infection with B. melitensis, but its expression was absent in whole lungs in the same 
conditions. Even if this could suggest an expression of Acod1 mainly in those AMs, it would 
be interesting to compare the CFU level in infected “classical” Acod1-KO mice and Acod1-KO 
mice where the gene is KO only in myeloid cells (Nair, Huynh et al. 2018). It could be possible 
also to study the level of expression of Acod1 overtime, in vitro in BMDM infected with B. 
abortus and to link this expression with the virulence of Brucella in those cells. To be closer of 
the in vivo model, we purified AMs as described in material and methods and we tried to culture 
these cells in plates (data not shown) and to infect them in vitro. Unfortunately, we did not 
succeed to infect AMs in vitro in our conditions. What we did not try is to purify AMs from 
already infected mice. However, the addition of physiological itaconate and DMI on infected 
RAW 264.7 macrophages in vitro shows an impact on the morphology of RAW macrophages 
(data not shown), leading to a complicated interpretation about the Brucella control by DMI in 
vitro. 
 ACOD1 and its localization 
We know that itaconate, the product of ACOD1 action, is mainly produced in mitochondria of 
macrophages. A recent study (Naujoks, Tabeling et al. 2016) showed that mitochondria and 
Legionella-containing vacuoles were in close associations, hypothesizing that either Legionella 
recruits mitochondria to take advantage of its nutritional and energetic resources, or 
mitochondria are recruited via a TLR-depending mechanism to phagosomes to bring the 
defense strategies closer to bacteria (Naujoks, Tabeling et al. 2016). Even if we observed 
sometimes close associations between mitochondria and BCV in our transmission electronic 
microscopy images, the number of these observations was extremely weak and probably 
random. However, we could quantify this in vivo by comparing the number of associations in 
samples from infected wt mice to infected Acod1-KO mice. Always in the idea to localize 




ACOD1 in cells, we could also use ACOD1-antibody (in addition to other markers) to label 
histology slides of infected lungs.  
The major difference between in vivo and in vitro conditions in terms of localization is the 
presence of Brucella in a phagosome in in vivo condition. It is hypothesized that physiological 
itaconate does not impact Brucella in vitro as it does not cross the bacterial membrane. But in 
vivo, Brucella could be already a bit weakened before to be in contact with itaconate, giving to 
the endogenous itaconate the possibility to enter into phagocytosed bacteria. To confirm this 
hypothesis, it would be interesting to weakly permeabilized bacteria before addition of itaconate 
for kinetic in vitro studies. Another idea would be to use a mutant of Brucella with a defect in 
its cell wall, such as ∆per-Brucella (a rough strain), to see if this strain is more susceptible to 
itaconate. If the growth of this mutant is attenuated by itaconate, that would suggest that the 
non-inhibition of Brucella by itaconate in neutral condition is due to an inability of itaconate to 
penetrate inside Brucella. 
It is also possible that transporters for itaconate are only induced in in vivo conditions, allowing 
itaconate to penetrate Brucella. We could imagine that those transporters are not specific for 
itaconate, but that the molecule could be able to use them in certain conditions. These 
transporters could be completely absent or inactive in in vitro conditions, leading to a non-
penetration of physiological itaconate in vitro. It would be interesting to incubate Brucella in 
vitro with other acidic molecules such as citric acid or acetic acid in order to study if the 
inhibition of Brucella growth in acidic condition is due to acidity it-self or to itaconate 
molecule.  
 Dimethyl-itaconate, a good substitute? 
In our study, we used in vitro a modified permeable form of itaconate, the dimethyl-itaconate 
(DMI). We observed that DMI inhibits, in a dose-dependent manner, the growth of B. abortus 
in an isocitrate lyase-dependent way. Before to test this experiment, we tried to use the 
physiological itaconate. The solution of this suspend molecule has an acid pH, and completely 
inhibits the growth of Brucella (B. melitensis and B. abortus) at 10 mM, independently of 
isocitrate lyase, as B. abortus ∆aceA was inhibited in the same way with the same 
concentrations. To be sure that itaconate effect was not due to its acidity, we tried the same 
experiments but with neutralization of itaconate pH. In this case, no inhibition, in any 
conditions, was observed, suggesting that the impact previously observed was due to acidity 




itself. In literature, when physiological itaconate is used and is shown to be a good inhibitor of 
bacterial growth, the neutralization of pH is never mentioned, letting the doubt about the real 
impact of itaconate molecule itself, in vitro. However, using the modified DMI, we observed 
an inhibition of B. abortus growth, depending on isocitrate lyase, in neutral pH conditions. To 
be sure that the addition of methyl groups does not impact the action of itaconate, we used the 
dimethyl-fumarate as control molecule, and we confirmed that the methyl groups themselves 
do not impact specifically ICL. In addition, the fact that we found that ICL is also the target in 
vivo suggest that DMI is able to mimic what happen in vivo. This was not the case using 
physiological itaconate, in neutral or acid conditions, probably because the neutral 
physiological itaconate was not able to cross the bacterial membrane, or the acid itaconate had 
a non-specific impact on bacteria, respectively.  




IV. General conclusion 
 
Our work highlights different elements that are very important to take into account when we 
are working on infection process. Of course, the real study subject should be the natural host, 
taken in its environmental conditions, with its immunologic past context, and using the natural 
routes of infection or vaccination. However, this is almost impossible to use those natural hosts 
for numerous practical and economic reasons. This is why a reductionist approach using animal 
and in vitro models has been developed and used for decade in order to study biological 
questions. But the choice of this experimental model is very important and our work 
demonstrates how it can affect the results. Indeed, in a context of selection of potential vaccine 
candidates or host-pathogen relationship study in a mouse model, we highlight the importance 
of the choice of this infection route. As the experimental model is already different from the 
natural host, we thought that the route of infection, at least, should the same than the natural 
route of vaccination. We hypothesized that working with different routes of infection could bias 
the results. 
We used Brucella, an intracellular bacterium causing brucellosis mainly in mammals such as 
bovine and ovine but also in human, to test this hypothesis in three different mouse models of 
infection: intraperitoneal, intranasal and intradermic infection routes. We observed from our 
study that the dissemination of bacteria, the nature of the infected cells or of the infected organs 
as well as the nature of protective immune response are different depending on the route of 
infection, suggesting a different control of bacteria depending on the primary site of infection 
and the passage through the blood, mainly. We concluded that it is important to use a route of 
infection as close as the natural route of vaccination to decrease the failure rate when a vaccine 
candidate experimented in mouse is finally tested in the natural host. 
From this study, we also concluded that the mucosal model, with intranasal infection, is one of 
the most physiological model that we studied. But this route of infection leads to more questions 
about the early effector mechanisms in the local site of infection. To answer this question, we 
used a RNA sequencing approach and identified Acod1 gene which is known to be expressed 
exclusively in myeloid cells such as macrophages. In lungs of intranasally infected mice, Acod1 
plays a role in the early control of Brucella multiplication in alveolar macrophages. However, 




even if various types of macrophages, such as red pulp macrophages and marginal zone 
macrophages, are also infected in the spleens, we did not detect the expression of Acod1 or an 
impact of Acod1 deficiency in this organ, suggesting a specific role of Acod1 in the control of 
Brucella in mucosal environment only. This also suggests that some effectors could be 
discovered using a specific route of infection but not another one, confirming the importance 
of the choice of the experimental model. 
In conclusion, the use of an appropriate route of infection is a first prerequisite towards a better 
discovery of candidate vaccines or effectors. However, independently of the choice of the more 
appropriate experimental model, another major and unsolved problem to study biological 
systems is the redundant and the complementary genes/proteins that frequently hide the impact 
of inactivating a single target. This could explain the weak impact that we observed when we 
compared the course of Brucella infection in wild type and Acod1-deficient mice. Our results 
demonstrate that ACOD1 (via itaconate) is one of the effectors controlling Brucella infection 
in lungs, but ACOD1 certainly acts with other effectors such as Guanylate Binding Proteins 
(GBP), Nitric Oxide (NO), etc. In addition, Brucella is a stealthy bacterium. Consequently, it 
is still more complicated to find new potential effectors in this infectious model because, by 
using a physiological route of infection such as i.n., almost none change is detected in terms of 
cells recruitment, inflammation, cytokines production, etc. 
At this point, we must conclude that years of research will be still necessary to completely 
understand Brucella infection and eradicate brucellosis. However, this work constitutes a first 
step in understanding of the complex world of host-pathogen relationship, from which some 
conclusions are transposable to other infection models. 
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All the procedures and the mice handling complied with current European legislation (directive 
86/609/EEC) and the corresponding Belgian law: Royal Decree on the protection of 
experimental animals of April 6, 2010. The Animal Welfare Committee of the Université de 
Namur (UNamur, Belgium) has reviewed and approved the protocols (Permit Numbers: 13-195 
for the intradermal infection, 05-058 for the intraperitoneal infection and 18-309 for the 
intranasal infection and Acod1-KO mice).   
Mouse strains 
Wild-type C56BL/6 mice were acquired from Harlan (Biester, UK). TCR- δ-/-, CD3ε-/-, TCR-β-
/-, MuMT-/-, CCR2-/-, and CCR7-/- C57BL/6 were all purchased from The Jackson Laboratory 
(Bar Harbor, ME). IFN-γR-/- and IL-12p35-/- C57BL/6 mice were acquired from Dr. B. Ryffel 
(University of Orleans, France). IL17RA-/- C57BL/6 mice were acquired from Dr. K. Huygen 
(Belgian Scientific Institute for Public Health, Brussels, Belgium). TNFR1-/- C57BL/6 were 
acquired from Dr. C. De Trez (Université Libre de Bruxelles, Belgique). TAP1-/- C57BL/6 mice 
and MHCII-/- C57BL/6 mice were acquired from Jörg Reimann (University of Ulm, Germany). 
Acod1-/- C57BL/6 mice were acquired from Dr. E. Hoffmann (Institute Pasteur of Lille, France).  
All the mice were bred in the animal facility of the Gosselies campus (Université Libre de 
Bruxelles, Belgique).  
Mouse infection 
Preparation of the infectious dose 
- Cultivate the strains 5 days before the infection in 2 YT rich medium agar plates 
- Prepare an overnight (ON) liquid culture the day before in 10 mL of 2 YT rich medium 
(in a Falcon 50 mL) to obtain an optical density (OD600 nm) between 0.7-0.9 (end of the 
exponential phase) 




- The morning of the infection, wash the bacteria: centrifuge the Falcon at 3,500 g during 
10 min at 20 °C, through the supernatant away, and add 10 mL of PBS 
- Repeat this last step once to wash bacteria again 
- Measure the OD to calculate and prepare the infectious dose (3x109 bacteria / mL at OD 
= 1) 








- Do serial dilutions as control of the infectious dose, and then plate them to obtain a 
countable number of CFU 
 Naïve animals were injected with the same volume (see the different infection below) of PBS. 
Intraperitoneal infection 
For i.p. injection, 500 µL of infectious dose was administrated by mouse. 2x104 bacteria / mouse 
(105 bacteria / mL) were prepared in RPMI.  
Intradermal infection 
The infectious dose was administrated in the footpad of mice, after a brief anesthesia with 
Isoflurane. Around 20 µL of infectious dose was administrated in the footpad. So, 2x106 
bacteria / mL was prepared in order to obtain around 2x104 bacteria / mouse.  
Intranasal infection 
Even if the type of anesthesia is still debated, it has been published that lungs are more 
efficiently infected by bacteria (Miller, Stabenow et al. 2012) or other products (Southam, 
Dolovich et al. 2002) when instillation is performed under anesthesia. Therefore, animals were 
anesthetized by intraperitoneal injection of Ketamine (36 mg/ kg) / Xylazine (9 mg/ kg) in PBS 
before the infection and were then infected with 30 µL of infectious dose (4x104 bacteria / mL, 
3.33x108 bacteria / mL or 3.33x109 bacteria / mL). 




Bacterial strains and media 
 
Growth conditions 
The different strains of Brucella were grown in 2 Yeast-Extract rich medium (composed of 
Luria-Bertani (LB) mix (20 g/ L), yeast extract (5 g / L), peptone (6 g / L) and agar (13 g / L) 
when it was necessary) or in Plommet Erythritol minimal medium (composed of K2HPO4 (7 g 
/ L), KH2PO4 (3 g / L), NaCl (5 g / L), Na2S2O3 (0.1 g / L), Biotine (0.0001 mg / L), Nicotinate 
(0.2mg / L), Thiamine (0.2 mg / L), Pantothenate (0.04 mg / L), (NH4)2SO4 (0.5 g / L), Erythritol 
(2 g / L), Tyrosine (0.25 g / L), MgSO4 (10 mg / L), MnSO4 (0.1 mg / L), FeSO4 (0.1 mg / L).  
Nalidixic acid (Nal) (25 ug / mL) was added in the agar medium when Brucella WT (naturally 
resistant to Nal) was used, and Kanamycin (Kan) (10 ug / mL) was added for all the other 
modified strains of Brucella.  
Escherichia coli was grown in LB rich medium, composed of peptone (10 g / L), yeast extract 
(5 g / L), NaCl (5 g / L) (and agar 15 g / L when necessary). Kanamycin was added in the agar 
medium as the plasmids used are KanR.  
Bacterial strains 
Different strains of bacteria were used in the experiments: 
- Brucella melitensis 16M WT (NalR) 
- Brucella melitensis 16M mCherry was performed to constitutively expressed the 
mCherry gene under a strong translocase (SecE) promotor (NalR, KanR). The 
construction protocol was published in (Copin, Vitry et al. 2012)  
- Brucella abortus 2308 mCherry (NalR, KanR ) was performed following the same 
protocol that was described in Copin et al., 2012 (Barbier, Machelart et al. 2017)  
- Brucella abortus 2308 ∆aceA, for which the construction was described in (Zúñiga-
Ripa 2014) 
- Brucella abortus 2308 ∆aceA was complemented with the pMR10 plasmid. Briefly, the 
aceA gene and its promoter was amplified with the Q5 High-Fidelity DNA polymerase 
(New England Biolabs). PCR products were purified (Macherey-Nagel Clean-up kit) 
and cloned into the EcoRV site of the pGemT in E. coli DH10B. This plasmid allows 




the white/blue screening in E. coli DH10B strain (thermofisher / Invitrogen). White 
clones were PCR screened and sequenced with the universal M13 primers. aceA gene 
was then subcloned into the pMR10 plasmid (a kind gift from C.D. Mohr and R.C. 
Roberts, Stanford University) with the restriction enzymes BamHI and PstI. The 
resulting plasmid was introduced into E. coli S17.1 strain and into B. abortus 2308 
∆aceA by conjugation 
- Brucella melitensis ∆virB strain was constructed in the B. melitensis mCherry strain as 
described in (Nijskens, Copin et al. 2008)  
- The complemented strain of B. melitensis ∆virB was done using the plasmid pBBR-
pvirBvirB containing the complete virB operon, under the control of its own promoter 
(Nijskens, Copin et al. 2008) 
 
Brucella staining with eFluor670 
For some experiments, eFluor670 staining was used to stain the primary amines of the outer 
membrane of Brucella. Because Brucella has an unipolar growth and because primary amines 
(and so the eFluor670) do not move in the membrane, the staining allows to distinguish between 
the mother bacteria and the daughter bacteria.  
Protocol: 
- Calculate the infectious dose as describe above. Make sure that initial volume ~ 1 mL to 
put this volume in an Eppendorf 
- Wash the bacteria in 1 mL of PBS: centrifuge (7,000 g, 2 min 30 at 20 °C), throw away 
the supernatant, add 1 mL of PBS, suspend the bacteria 
- Centrifuge again and then incubate the bacteria in eFluor670 diluted in 1 mL of PBS 
(1/500) 20 min in the dark on a wheel. 
The stocks of eFluor670 have a final concentration of 5 mM and are stocked at - 20 °C 
- Wash 4 times the bacteria: centrifuge (7,000 g, 2 min 30 at 20 °C), throw away the 
supernatant, add 1 mL of PBS, suspend the bacteria (x4) 
- Make a last wash after which the bacteria are suspended in RPMI and put at the final 
volume with RPMI (depending on the infectious dose calculation) 
- Infect the mice (see the protocol above) 




Brucella growth curve and CFU  
Growth curve (bioscreen) 
The measurement of OD 600 nm in a well containing Brucella allows to monitor the 
multiplication rate of these bacteria overtime. WT Brucella usually reach the stationary phase 
(OD600 nm = 2) after 72 h. Based on that, measurements were done every 30 min during 72 h in 
a Bioscreen C (Oy Growth Curves). 
Protocol:  
- Prepare an overnight culture in 2 YT rich medium the day before in order to reach OD600 
nm between 0.2 and 0.5 (exponential phase) the day after  
- Wash 2 times the bacteria with PBS (centrifuge the Falcon at 3,500 g during 10 min at 
20 °C) 
- Measure the OD600 nm again 
- Dilute bacteria to obtain OD600 nm = 0.05 and resuspend them in a final volume of 700 
µL of fresh medium (2 YT or minimal medium, depending on the experiment) 
- Add 200 µL of the culture / well in the specific plate for bioscreen 
- Add 5 mL of PBS in the edge of the plate to avoid the evaporation of the liquid in the 
wells what will modify the OD 
 
Colonies forming units (CFU) – in vivo 
The evaluation of the colonies forming units allow to know the number of bacteria from an 
organ (in our case) still living and able to divide (by opposition with the PCR technique for 
example). Each colony is the consequence of one isolated bacterium that divided to form the 
colony. 
Protocol:  
- Once the mice are killed, harvest the organ, weight it and place it in a Falcon 15 mL 
containing 1 mL of Triton-X100 0.01 % / PBS.  
- Homogenized with an Ultraturax (X120 from CAT-Ing).  
- Plate 100 µL of this lysat on 2 YT agar plates 




- Incubated for 4-5 days at 37 °C.  
Serial dilutions were done when necessary to obtain a countable number of CFUs. 
Fluorescent microscopy on mice tissues 
The immunohistofluorescence techniques allow to stain a specific protein present in the cell 
using antibodies and fluorochromes via emission of fluorescence. Not very quantitative, this 
method mostly allows a qualitative study, locating the proteins present within a cell. 
  
- Once the mice are killed, harvest the lungs and fixe it with paraformaldehyde 2 % (pH 
7.4) for 30 min at RT  
- Evacuate the organs to be sure that paraformaldehyde fixed correctly the entire lungs. 
After that, lungs were still fixed for 1h30 more at RT  
- Wash 2 times with PBS 
- Incubate the organs in 20 % sucrose / PBS solution overnight at 4°C  
- Embedded them in Tissue-Tek OCT compound (Sakura) 
- Froze them in liquid nitrogen and stocked them at -20 °C  
 
- Prepare slides of 5 µM of thickness with a microtome (Leica CM1850 Cryostat) and 
stock the slide at -20 °C  
 
- Before staining, rehydrate the slide in PBS for 5 min 
- Draw a hydrophobic circle around the organs and incubate them in Blocking reagent 1 
% / PBS solution (BR) (Boeringer) for 20 min at RT  
- Draw a hydrophobic circle around the organs to maintain and incubate the slide in the 
antibodies (mAbs) or reagents diluted in BR solution overnight at 4 °C  
In this thesis, we used the following antibodies or reagents: DAPI nucleic acid stain 
Alexa Fluor 350 (1/1000), 488 phalloidin (MolecµLar Probes) (1/100), APC-coupled 
BM8 (anti-F4/80, Abcam) (1/200), Alexa Fluor 647-coupled M5/114.15.2 (anti-I-A/I-E, 
MHCII, BioLegend) (1/200), AlexaFluor 647-coupled HL3 (anti-CD11c, BD 
Biosciences) (1/200), biotin-coupled 1A8 (anti-Ly6G, BioLegend) (1/200), biotin-
coupled APA5 (anti-CD140a/ PDGFRA, eBioscience) (1/200).  
- Wash the slide by diving it several times in a bath of PBS 




- Draw a hydrophobic circle around the organs 
 
- If a secondary staining is necessary, incubate the slide with the secondary antibody for 
2 h at 4°C and, then wash 2 times 
In our experiment, we used the biotin-coupled Abs were incubated with streptavidin-coupled 
APC (1/400) for 2 h.  
- Wash in PBS as described above 
- Mount the slides in Fluoro-Gel medium (Electron Microscopy Sciences, Hatfield, PA) 
- Visualize the labeled tissue sections with a microscope 
For our experiments, we used an Axiovert M200 inverted microscope (Zeiss, Iena, Germany) 
equipped with a high-resolution monochrome camera (AxioCamHR, Zeiss). Images 
(1,384×1,036 pixels, 0.16μm/pixel) were acquired sequentially for each fluorochrome with A-
Plan 10x/0.25 N.A. and LD-Plan-NeoFluar 63x/0.75 N.A. dry objectives and recorded as eight-
bit gray-level∗.zvi files.  
At least 3 slides were analyzed per organ from 3 different animals and the results are 
representative of 2 independent experiments. 
Confocal microscopy 
The confocal microscopy, as the fluorescence microscopy, is an optical imaging technique 
using antibodies and fluorochromes to detect light from labelled proteins in a sample. The 
confocal microscopy has the advantage to have a laser that concentrate the light in one point 
and a pinhole in front of the detector to eliminate the out-of-focus light. This system allows to 
increase the resolution and the contrast of images. 
Protocol: 
- The tissue sections were prepared as described above  
- Visualize the labeled tissue sections with a microscope 
Confocal analyses were performed using a LSM780 confocal system fitted on an Observer Z 1 
inverted microscope equipped with an alpha Plan Apochromat 63x/1.46 NA oil immersion 
objective (Zeiss, Iena, Germany). DAPI was excited using a 405 nm blue diode, and emission 




was detected using a band-pass filter (410–480 nm). The 488 nm excitation wave length of the 
Argon/2 laser was used in combination with a band-pass emission filter (BP500-535 nm) to 
detect Alexa Fluor 488 phalloidin. The 543 nm excitation wave length of the HeNe1 laser and 
a band-pass emission filter (BP580–640 nm) were used for the red fluorochrome mCherry. The 
633 excitation wave length of the HeNe2 laser and a band-pass emission filter (BP660–695 
nm) were used for far-red fluorochromes such as APC. To ensure optimal separation of the 
fluorochromes, blue & red signals were acquired simultaneously in one track and green & far 
red signals were acquired in a second track. The electronic zoom factor and stack depth were 
adjusted to the region of interest while keeping image scaling constant (x-y: 0.066 micron, z: 
0.287micron). A line average of 4 was used and datasets were stored as 8-bit proprietary∗.czi 
files. The images were displayed using Zen2012 software (Zeiss) with linear manual contrast 
adjustment and exported as 8-bit uncompressed∗.TIF images. The figures, representing single 
optical sections across the region of interest, were prepared using the Canvas program. 
Flow cytometry analyses 
Flow cytometry is a technique used to measure different properties of a cell population (as the 
size and granularity) as well as the presence of proteins by using anti-proteins antibodies. By 
contrast with microscopic analyses, this one is well more quantitative as flow cytometry is able 
to analyze billions of cells in few seconds. The flow of labelled single cells passes in front of a 
laser that excites the fluorochromes. The emitted fluorescences are concentrated, detected and 
converted in numeric values.  
Protocol: 
- Kill the mice and harvest the lungs 
- Place them in a 6-wells plate (one lung / well) with droplets of cold RPMI 
- Homogenized with scissors, flush, and filtered through 72 µM filter on a Falcon 15 mL  
- Wash the cells: centrifuge them at 500 g during 7 min at 4 °C and resuspend them in 
cold FACS buffer (0.2 % BSA, 0.02 % NaN3 in PBS)  
- Incubate the cells in saturating doses of purified 2.4G2 (anti-mouse Fc receptor, ATCC) 
(1/200) diluted in for 20 min at 4 °C to prevent antibody (Abs) binding to the Fc 
receptor.  
- Wash (once) the cells as describe above 
- Incubate the cells were in the different Abs diluted in FACS buffer for 30 min at 4°C 

















- Take a proportion of the sample (of the filtrate of 
lungs, after 24G2 incubation in the flow cytometry 
analyses in our case) 
- Add 10 µL of this sample in the chamber of the cell  
- Count the number of cells in the 16 big squares in the 
center of the chamber 
 Figure 17: Image of a Neubauer cell
In our experiments, we used: BV421-coupled E50-2440 (anti-SiglecF, BD Biosciences) (1/200),
BV421-coupled T45-2342  (anti-F4/80,  BD Bioscences)  (1/200),  BV421-coupled M1/70  (anti-
CD11b,  BD  Bioscences)  (1/200),  fluorescein  (FITC)-coupled  145-2C11  (anti-CD3ε,  BD 
Bioscences)  (1/200),  FITC-coupled  30-F11  (anti-CD45n  BD  Biosciences)  (1/200),  FITC-
coupled M1/70  (anti-CD11b,  BD Biosciences)  (1/200),  FITC-coupled  HL3  (anti-CD11c,  BD 
Biosciences) (1/200),  phycoerythrin (PE)-coupled HL3 (anti-CD11c, BD Biosciences) (1/200),
PE-coupled 1A8 (anti-Ly6G, BD Biosciences) (1/200),  allophycocyanin (APC)-coupled BM8 
(anti-F4/80,  BD  Bioscences)  (1/200),  biotin-coupled  2G9  (anti-MHCII,  I-A/I-E,  BD
Biosciences) (1/200). Biotin-coupled APA5 (anti-CD140a/ PDGFRA, eBiosciences) (1/400).
- Wash the cells 2 times as described above
- If a secondary staining is necessary, incubate the cells with the secondary antibody for
30 min at 4°C and, then wash 2 times
- Fix the cell by incubating them in PFA 2 % for 30 min at RT
- Wash the cells 2 times
- Incubate the cells in FACS Buffer, at 4 °C and in the dark until the analyze
- Analyze the cells on a flow cytometer
We  used  the  BD  FacsVerse  flow  cytometer.  Dead  cells  and  debris  were eliminated  from  the 
analysis according to size and scatter.
Cells numeration
To calculate the absolute number of cells present in a sample, the Neubauer cell (Figure 17)
can be  used.  This  cell  is  composed  of  9  big  squares  (number1  on  Figure  17),  each  of  1 mm².  
The central  square  is  itself  composed  of  16  smaller  squares  (number  3  on  Figure  17) of  0.4  
mm², squares that we used for the cells numeration in this project.




- Multiply the mean of counted cells by the dilution factor (depending on the proportion 
taken at the beginning) and by 250,000 (conversion factor of the small squares5) to 
obtain the number of cells / mL. 
 
Detection of Brucella specific antibodies by Enzyme-Linked 
ImmunoSorbent Assay (ELISA) 
The enzyme-linked immunosorbent assay technique is used to detect the presence of proteins 
in a sample by using antibodies. The antigen-antibody complex is revealed by the detection of 
color produced by the reaction between a substrate and an enzyme conjugated to an antibody. 
It exists different ELISA tests: the direct one, the indirect one, the “sandwich” one, and the 
competitive one. Even if in clinical research the sandwich one is the most use, in research the 
most common used ELISA test is the indirect one which is the one described below. 
Protocol: 
- Coat the polystyrene plate (269620 Nunc) with 50 µL / well of the antigen (109 bacteria 
of heat-killed B. melitensis / mL diluted to obtain 107 bacteria / mL in each well) and 
incubate the plate overnight at 4 °C with parafilm to avoid evaporation. Tap the edge of 
the plate before incubation to be sure that no air bubbles are present  
- Flip the plate to eliminate all the liquid of the wells 
- Block the non-specific sites with 200 µL of casein 3.35 % / PBS for 2 h at RT.  
- Flip the plate 
- Incubate the plate with 50 µL of plasma/ well in serial dilutions in casein 3.65 % / PBS 
during 1 h at RT.  
 
5 the superficy of counted squares is: 0.2 mm x 0.2 mm = 0.4 mm² = 0.0004 cm². The deeper of the cell is = 0.1 m 
= 0.01 cm. the volume of one square (nb 3) = 0.0004 cm² x 0.01 cm = 0.00004 cm³ = 0.00004 mL. The conversion 
factor to calculate the number of cells / mL is so equal to 250,000. 




▪ 6 dilutions of 3 in 3 (starting with a 
dilution 30x): take 4 µL of plasma, add 
116 µL of casein 3.35 % / PBS; add 
these 120 µL in the first well. Add 80 µL 
of casein 3.35 % / PBS in the 5 other 
wells. Take 40 µL of the first well and 
dilute it in the second well. Start again 
from the second to the third well, with 
40 µL and for the other wells 
▪ The dilutions were prepared in another 96-wells plate and then transferred in 
the Nunc plate 
▪ In our experiences, 12B12 (monoclonal antibody anti-smooth LPS of 
Brucella) and naïve mouse plasma were used as positive and negative 
controls, respectively  
- Wash 4 times with PBS and flip between each wash 
- Add 50 µL / well of antibody conjugated to an enzyme (ex. Horseradish Peroxidase - 
HRP) diluted in casein 3.35 % / PBS were added for 1h at RT. 
We used isotype-specific to Brucella IgM, IgG1, IgG 2c, IgG3 (see the table below)  
- Wash 4 times the plate and flip between each wash 
- Add 100 µL / well of 3,3′,5,5′-Tetramethylbenzidine (TMB6) (the substrate of the 
enzyme HRP) and incubate the plate for 15 min in the dark at RT; a blue color appeared 
- Stop the reaction by addition of 25 µL / well of H2SO4 2N; the blue color has to switch 
in yellow 
- Measure the OD of each well at 450 nm with a spectrophotometer 




6 Kit BD OptEiA ref 555214. 2 solutions to mix together at equal volume just before ue. Take the reagents out of 
the frigde 30 min before use 
 
 
Figure 18:  Example  of  the  organization  of  
a plate for ELISA




Antibody Reference Dilution used 
Anti-Mouse IgG Peroxydase 
antibody 
A2554, Sigma-Aldrich 1/4000 
Anti-Mouse IgM Peroxydase 
antibody 
18786, Sigma-Aldrich 1/4000 
Ant-mouse IgG1- 
Peroxydase 
LO MG1-13 1/2000 
Anti-mouse IgG2b - 
Peroxydase 
LO MG2b-2 1/2000 
Anti-mouse IgG2a et 2c)- 
Peroxydase 
LO MG2a-9 1/2000 





Immune memory study in vivo 
As explained in the introduction, an immune memory developed after a first infection with a 
pathogenic agent, that will lead to a better and faster immune response during a second infection 
with the same pathogenic agent. To mimic this and evaluate the efficiency of a secondary 
infection, mice are first vaccinated then challenged with Brucella, and CFU are compared to 
those from mice infected only one time. 
Protocol:  
- Immunized C57BL/6 WT mice with Brucella melitensis WT (2x104 bacteria / mouse) 
during 1 month 




- Give a double-antibiotics treatment (Streptomycin 450 mg/kg and Rifampycin 12 
mg/kg) in water drink in order to eliminate Brucella from the first infection during 2 
weeks 
- Give 2 weeks of rest to in order to eliminate antibiotics from their organism (stop the 
antibiotics treatment by giving fresh water drink to mice) 
- Challenge mice (by the same route of infection) with a dose of 2x104 B. melitensis 
mCherry / mouse    
The two different strains of bacteria that we used allowed us to control that no bacteria from 
the first infection were still present. 
- Kill the mice and harvest the organs 








Purification of lung alveolar macrophages (AM) 
As we needed at least 106 AM for the transmission electronic microscopy (TEM – see below), 
the broncho-alveolar lavages (BAL) were not possible. To bypass this, we based our 
purification of alveolar macrophages (AM) on a protocol of dendritic cells purification from a 
spleen of rat.  
Protocol: 
- Sacrifice the mice 
- Harvest the lungs 
- Place the lung in a 6-wells plate (on ice) with 2, 3 drops of cold RPMI – 5 mM of EDTA) 
- Homogenize the lungs with scissors 
  Figure 19: plan of the experiment to study the immune memory




- Scratch the homogenate with the piston of a 1 mL syringe 
- Add 4-5 mL of cold RPMI – 5 mM EDTA 
- Filter the cells through a filter of 72 µM placed on a Falcon 15 mL 
- Add 10 mL of cold complete medium7 to wash the cells 
- Centrifuge the cells at 1,400 g during 7 min at 4 °C 
- Through the supernatant away and resuspend the cells in cold complete medium with 5 
mM of EDTA + 24G2 (1/200) to block the non-specific site  
- Incubate the cells 20 min at 4 °C 
- Add 10 mL of cold complete medium to wash the cells 
- Centrifuge the cells at 1400 g during 7 min at 4 °C 
- Thought the supernatant away 
-  Add CD11c-coupled magnetic beads (Milteny) to the cells (in the liquid staying from 
the wash) 
o Fix the cells (if infected with Brucella) 
o Count the cells (with the Neubauer cells – see above) 
o Add 100 µL of beads for 108 cells 
- Resuspend the cells and incubate in the dark during 15 min at 4 °C 
- Place the MACS column (MS size) on the magnetic field 
- Place a collector tube under the column to collect liquid 
- Wet the MACS column: add 1 mL of cold complete medium and wait for the liquid is 
completely out of the column 
- Add the cells into the column and wait for all liquid is completely out of the column 
- Wash 3 times the column by adding 1 mL of cold complete medium with 5 mM of 
EDTA (between each wash, wait for all the liquid is completely out of the column 
- Change your collector tube (Falcon 15) 
- Remove the column of the magnetic field, and rapidly flush with the provided piston 
- Add 10 mL of cold complete medium 
- Centrifuge the cells at 1,400 g during 7 min at 4 °C 
- Through the supernatant away 
- Resuspend the cells in a medium depending on the next experiment 
 
7 Complete medium: 500 mL of RPMI + 50 mL of Fœtal Bovin Serum (FBS) + 5 mL of non-essential amino 
acids + 5 mL of L-Glutamate + 5 mL of pyruvate 





RNA extraction, RNA-sequencing and qRT-PCR 
RNA extraction and isolation 
RNA was extracted with 2 different protocols depending on the samples: Trizol purification for 
entire lungs, and with a kit (RNeasy Mini kit (Qiagen8)) for purified alveolar macrophages. 
Trizol purification (total lung cells) 
- Kill the mice and harvest the lungs (small piece, 50-100 mg, is sufficient) and place it 
in a Falcon 15 mL 
- Add 1 mL of Tripure9  
- Homogenized by using Ultraturax 
- Transfer in Eppendorf 
- Incubate 5 min at RT  
- Add 0.2 mL of chloroform  
- Mix vigorously during 15 sec 
- Incubate 2 to 15 min at RT 
- Centrifuge at 12,000 g fir 15 mon at 4 °C 
- Transfer the aqueous phase in a new Eppendorf 
- Add 500 µL of isopropanol to precipitate RNA 
- Mix by inversion 
- Incubate 5 to 10 min at RT 
- Centrifuge at 12,000 d for 10 min at 4 °C 
- Through the supernatant away 
- Wash 2 times the pellet with 75 % ethanol 
- Centrifuge at 7,500 g for 5 mon at 4 °C 
- Through the supernatant away 
- Quick spin and through the rest of ethanol away 
- Resuspend in 30 µL of RNAse-free water 
 
8 Qiagen Online (Cat No./ID: 74104) 
9 TriPure Isolation Reagent (ref: 11667157001) from Merck 




- Incubate for 10-15 min a 55-60 °C to completely resuspend RNA 
After this technique, a DNAse I, RNase-free10 treatment was done. 
Protocol: 
- In a new RNAse free Eppendorf, mix 1 µg of RNA with 1 µL of 10X reaction buffer 
(with MgCl2) and 1 µL (1U) of DNAse I, RNA-free, and fill up to 10 µL with DEPC 
water 
- Incubate at 37 °C during 30 min 
- Add 1 µL of 50 mM EDTA 
- Incubate at 65 °C during 10 min 
RNeasy Mini kit 
- Purify the AMs (see protocol above), pellet the cells in an Eppendorf (in complete 
medium) 
- Add 600 µL of Buffer RLT11 and vortex 
- Add 600 µL of 70 % ethanol and mix by pipetting 
- Transfer 600 µL of the sample to a RNeasy Mini spin column placed on a 2 mL 
collection tube. Close the lid and centrifuge for 15 s at 8,000 g 
- Discard the flow-through 
- Do the same two previous steps in order to transfer all the sample in a column 
- Add 700 µL of Buffer RW112 to the RNeasy spin column. Close the lid and centrifuge 
for 15 sec at 8,000 g 
- Discard the flow-through 
- Add 500 µL of Buffer RPE13 to the RNeasy spin column, close the lid and centrifuge 
for 15 sec at 8,000 g 
 
10 Ref M0303S from New Englands BioLabs 
11 As we purified the RNA from tissues, we added 10 µL of β-mercaptoethanol to 1 mL of Buffer RLT. Buffer 
RLT contains guanidine isothiocycanate, which allows the binding of RNA to the silica membrane of the spin 
column. 
12 The Buffer RW1 contains a guanidine salt and ethanol. It is used to wash and remove biomolecules 
(carbohydrates, proteins, fatty acids etc.,) that are non-specifically bound to the silica membrane.  
13 The Buffer RPE contains ethanol. This washing buffer is used to remove the salts from the previous buffers. 




- Discard the flow-through 
- Add 500 µL of Buffer RPE to the RNeasy spin column, close the lid and centrifuge for 
2 min at 8,000 g 
- Place the RNeasy spin column in a new 2 mL collection tube and centrifuge at full 
speed for 1 min to dry the membrane 
- Place the RNeasy spin column in a new 1.5 mL collection tube 
- Add 30 µL of RNase-free water to elute RNA 
Here, no DNAse I, RNAse-free treatment was done as the kit already process to a DNA 
elimination.  
RNAsequencing 
The RNAsequencing technique uses the next-generation sequencing in order to sequence the 
whole genome of an organism in order to quantify the RNAs present at one given moment. 
Different methods can be used to do RNA-Seq. one of the most common is the targeting of 
mRNA (poly-adenylated)14 thanks to a poly-T queue binded to magnetic beads. The RNAs are 
then translated into cDNA, then fragmented and a library is prepared in function of the machine 
that will be use for the sequencing.  
For this project, we did by ourself the RNA extraction (see protocol above), the DNAse I, 
RNAse-free treatment. The RNA samples were then send to the NGS service of ULB (F. Libert) 
where they transform the RNA into cDNA, prepared the library and did the Illumina RNA 
sequencing. They used the Novaseq 6000 Trueseq SBS reagents (25 millions reads paired-end) 
and Trueseq stranded RNA library preparation for the Illumina sequencing. 
 
Analyse of the RNAsequencing 
For the analyse, we collaborated with S. Goriely and A. Azouz (µLB). Briefly, genes with no 
raw read count were filtered out with an R script. Raw read counts were normalized and a 
 
14These RNA are more stable and are often translated to proteins. The poly-T selection allows also to eliminate 
the ribosomal RNA, and the bacterial RNA (even if some bacteria possess poly-T tail) 




differential expression analysis was performed with DESeq2 by applying an adjusted p-value 
< 0.05 and absolute log2-ratio larger than 0.5849. 
Quantitative real-time polymerase chain reaction (qRT-PCR) 
This technique provides quantitative information about the abundance of genes in a sample, in 
comparison to a reference gene, here called the housekeeping gene (HKG, TBP for TATA 
binding protein in our case). Briefly, a fluorescent dye – Takyon No ROX Syber 2x MasterMix 
blue dTTP15 - (in our case) interlaces in any double-strand DNA formed during a polymerase 
chain reaction (in real-time). More DNA is present (correlated to RNA amount), more 
fluorescent signal is rapidly detected. Usually, the quantification DNA relies on a plotting of 
fluorescence depending on the number of cycle of PCR, on a logarithmic scale. A threshold is 
delimited by the background noise of fluorescence. Once the number of cycle at which the 
fluorescent signal exceeds this threshold, the threshold cycle (Ct) is reached and that 
corresponds to the value used to calculate the gene expression level. At each step of 
amplification during the PCR, the amount of DNA doubles. In our case, we use the relative 
quantification, based on a reference condition, which was naive mice cDNA. 
Transformation of RNA into cDNA 
One RNA extracted from lung (see protocol above) and treated with DNAse I RNAse-free 
treatment (see protocol above), RNA is transform into cDNA before doing qRT-PCR for 
different reasons: 1) RNAse are ubiquitous in nature, it is more preferable to work with cDNA, 
2) RNA is chemically unstable due to their nucleophilic 2´ hydroxyl groups.  3) Amplification 
phase during PCR only work with DNA as material, and 4) most of sequencing protocol are 
designed to use DNA and not RNA (using DNA polymerase). The kit that we used is High 
capacity cDNA Reverse Transciprtion kit from Applied BioSystems). 
Protocol: 
 
15 Ref UF-NSMT-B0101 from Eurogentec 
 
 




- For the RT+ (with reverse transcriptase enzyme), add to a new RNAse-free Eppendorf 
15 µL of treated RNA, 3 µL of Hexamer Random primer 10x, and 6.3 µL of RNase-
free water  
- Incubate 10 min at 65 °C 
- Put on ice for 1 min 
- Add 3 µL of RT Buffer 10x, 1.2 µL of dNTPs 25x, and 1.5 µL of Reverse Transcriptase 
- Vortex for some seconds 
- Quick spin 
- Incubate for 10 min at 25 °C 
- Incubate for 120 min at 37 °C 
- Incubate for 5 min at 85 °C 
- Dilute 10 times with RNAse-free water and freeze the cDNA until use 
For the negative control (without Reverse Transcriptase – RT-), mix 5 µL of treated RNA, 1 
µL of Hexamer Random Primer 10x, 2.1 µL of RNAse-free water. Follow the same incubation 
steps. The, add 1 µL of RT Buffer 10x, 0.4 µL of dNTPs 25x, and follow the same incubation 
steps. 
qRT-PCR 
- To calculate the efficacy of the PCR, we diluted the cDNA (3 in 3) 
- Make duplicate for each condition 
- Make a master mix; 5 µL of Takyon dye, 1 µL of reverse primer and 1 µL of forward 
primer 
- Add 7 µL of this master mix in each well 
- Add 3 µL of cDNA 
- Cover the plate with the plastic sheet provided 
- Centrifuge the plate at 200 rpm for 1 min  
- Analyze is done on Roche machine16 with the program provided with 
For the analyze, mean of duplicates has been calculated. Then, the slope, R², and the efficiency 
have been calculated on excel via the formulas “PENTE” for the slope, 
 
16 LightCycler® 96 System 




“COEFFICIENT.DETERMINATION” for the R² and “=(10^(-1/slope)-1)*100” for the 
efficiency. Only the Ct with an efficiency included between 90 and 100 % were taken in count. 
These Ct were then transformed to have an efficiency of 100 %. At least 6 mice for each group 
have been tested. The mean of the Ct of each group has been calculated.  
For the calculation of the expression, we used the classical 2-ddCt, with the Ct normalized to 100 
%: 
1) dCt= Mean of Ct100% (Unknown gene – Acod1) – Mean of Ct100% (Housekeeping gene – tbp) 
2) ddCt= mean of Ct100 % (infected mice) – mean of Ct100 % (naïve mice) 
3) 2-ddCt 
Transmission electronic microscopy (TEM) 
The transmission electronic microscopy has the great advantage to have a resolution (0,2 nm) 
much higher than the fluorescent microscopy. This technique allows to observe very small and 
detailed structures thanks to electrons as source of illumination; more the wavelength is 
reduced, more the resolution is high. The source of electrons, in the case of the microscope 
Tecnai 10 (Philips) of UNamur, is emitted from an electron gun fitted with a tungsten filament. 
The electron beam is focused by 2 condenser lenses to one small spot. Then the electron beam 
passes through pairs of deflection coils and a final lens aperture. The spot of electron is deflected 
by this late lens and reaches the sample. The interaction between the sample and the electron 
beam results in an electrons exchange between the sample and the electron beam. The new 
secondary electrons produced can be detected by the secondary electron detector. Moreover, 
the energy absorbed by the sample can also be detected and used to create an image of the 
sample thanks to emitted signals from the samples and X-Ray detector. 
This protocol was used for purified AMs (see protocol above), RAW macrophages (see protocol 
above), and bacteria from liquid culture. In this last case, 2 mL of liquid culture were used. 
We work with a final volume of 400 µL for each steps. 
- Suspend your cells in 50/50 Glutaraldehyde 4 % / Cacodylate buffer 0.2 M for 2 hours 
at RT or ON at 4 °C 




- Transfer all the cells in a specific Eppendorf for TEM (ask to the TEM service from 
UNamur) 
- Wash 3 times (centrifugation for cells: 1,000 g 2 min and for bacteria: 4,000 g for 5 
min) with cacodylate 0.2 M 
- Add 50/50 Osmium 4 % / Cacodylate 0.2 M during 1 h at RT 
- Wash 1 time with sterile dH2O and centrifuge 
- Wash 2 times with cacodylate 0.2 M and centrifuge  
- Add EtOH 30 % and mix by inversing 
- Incubate for 5 min, then centrifuge and through the supernatant away 
- Add EtOH 30 % and mix by inversing 
- Incubate for 10 min, then centrifuge and through the supernatant away 
- Repeat the same steps for EtOH 50, 70 and 85 % 
- Add EtOH 100 % and mix by inversing 
- Incubate for 10 min 
- Repeat the same step 2 more times 
- Take the resin out of the freezer and let it at RT 
- Add propylene oxide for 5 min and centrifuge 
- Repeat this step 3 more times 
- Add 75 % of propylene oxide / 25 % of resin and let your sample under agitation during 
15 min 
- Centrifuge and add 50 % of propylene oxide / 50 % of resin and let your sample under 
agitation during 20 min 
- Centrifuge and add 25 % of propylene oxide / 75 % and let your sample under agitation 
during 20 min 
- Centrifuge and add pure resin 
- Place the sample at 37 °C for 1 day, then at 45 °C for 1 day and finally at 60 °C for 3 
days. Let the cap open 
The pellet has been cut and contrasted by the Service of electronic microscopy from UNamur). 
For the contrast, use small grids special for electronic microscopy. Place the bright side (with 
cells) on a drop (100 µL) of uranium acid and let them for 20 min. Rinse the grids with water 
and absorb water with a Tork paper. Do the same on a drop of lead citrate for 10 min. Rinse the 
grids with water and absorb water with a Tork paper.  






We used a (Wilcoxon-)Mann-Whitney test provided by the GraphPad Prism software to 
statistically analyze our results. Each group of deficient mice was compared to the wild-type 
mice. We also compared each group with the other groups and displayed the results when 
required. Values of p<0.05 were considered to represent a significant difference. ∗, ∗∗, ∗∗∗ 
denote p<0.05, p<0.01, p<0.001, respectively.  
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